

SHAREHOPE MEDICINE CO.,LTD.

ShareHope


盛弘醫藥股份有限公司
ShareHope Medicine Co.,Ltd.

8403.TWO

2024 ANNUAL REPORT

ASIA'S LEADING HEALTHCARE ECOSYSTEM

敏盛醫療體系
精準大健康生態系
Health Ecosystem



PUBLISHED ON APRIL 21, 2025

SEARCH THE URL OF THE ANNUAL REPORT:

[HTTPS://MOPS.TWSE.COM.TW/](https://mops.twse.com.tw/)

COMPANY WEBSITE : [HTTPS://WWW.SHARE-HOPE.COM/](https://www.share-hope.com/)

SHAREHOPE MEDICINE CO ., LTD.

2024 Annual Report

1. Name, title, contact number, and email address of the company spokesperson and acting spokesperson

1. Company Spokesperson

Name: He Weiguang

Job Title: Deputy General Manager

Tel: (03)346-5760 Ext 553

E-mail: vincent.ho@share-hope.com

2. Company Spokesperson

Name: Li Peichen

Job title: Associate

Tel: (02)3322-1589 Ext 210

E-mail: jinlee@share-hope.com

2. Address and telephone number of the head office, branch office, and factory

1. General Administration Office

Address: 19F , No. 168, Jingguo Road, Taoyuan District , Taoyuan City Tel : (03) 346-9595

3. Name, address, website and telephone number of the stock transfer agency

Name: Qunyi Jinding Securities Co., Ltd. Stock Agency Department

Address: B2, No. 97, Section 2, Dunhua South Road, Da'an District , Taipei City

Website: <https://agency.capital.com.tw>

Tel: (02) 2702-3999

4. Name, firm name, address, website and phone number of the accountant who certified the financial report for the most recent year

Accountant's Name: Kou Huizhi, Guo Xinyi CPA

Firm Name: A&H CPA LLP

Address: 68F , No. 7, Section 5, Xinyi Road, Xinyi District, Taipei City

Website: <https://home.kpmg/tw/>

Tel: (02) 8101-6666

5. Name of the trading venue where overseas securities are listed for trading and methods for inquiring about the information of such overseas securities

This company does not apply

6. Company website : <http://www.share-hope.com>

Directory

1. Report to Shareholders	1
1.1 Business results for 2024	1
1.2 Overview of the 2025 Business Plan	3
1.3 Impact of external competition, regulatory environment and overall business environment	7
2. Corporate Governance Report	9
2.1. Information on directors , supervisors , general manager, deputy general manager, assistant manager, and heads of departments and branches	9
2.2 Corporate Governance Operation	41
2.3 Information on public fees for accountants	130
2.4 Information on change of accountant	130
2.5 The company's chairman, general manager, or manager in charge of financial or accounting affairs who has worked for the firm to which the certifying CPA belongs or its affiliated companies within the past year	130
2.6 Changes in equity transfers and equity pledges by directors, supervisors, managers, and shareholders holding more than 10% of the shares in the most recent year and up to the date of publication of the annual report	131
2.7 Information on whether the top ten shareholders in terms of shareholding ratio are related persons or spouses or relatives within the second degree of kinship.	134
2.8 The number of shares held by the company, its directors, supervisors, managers and enterprises directly or indirectly controlled by the company in the same invested enterprise, and the calculation of the comprehensive shareholding ratio	136
3. Participation and Fund Raising	138
3.1 Capital and Shares	138
3.2 Corporate bond handling status	145
3.3 Special shares handling situation	145
3.4 Overseas depository receipts	145
3.5 Employee stock option certificates	145
3.6 Issuance of new shares in the event of a merger or acquisition or transfer of shares of another company	145
3.7 Fund utilization plan and implementation status	145
4. Operation Overview	146
4.1 Business Content	146
4.2 Market and Production and Sales Overview	171
4.3 Information about employees	183
4.4 Environmental Protection Expenditure Information	188
4.5 Labor-Capital Relations	189

4.6 Information and communication security management	197
4.7 Important Contracts.....	200
5. Review and Analysis of Financial Status and Financial Performance and Risk Issues.....	203
5.1 Financial Status.....	203
5.2 Operating Results	205
5.3 Cash Flow	206
5.4 Impact of major capital expenditures on financial operations in the most recent year	207
5.5 Recent investment policies, major reasons for profit or loss, improvement plans, and investment plans for the coming year.....	207
5.6 Risks	209
5.7 Other important matters	212
6. Special matters to be recorded	213
6.1 Relevant information of related enterprises in the most recent year	213
6.2 Status of private placement of securities in the most recent year and up to the publication date of the annual report.....	219
6.3 Other necessary supplementary explanations	219
7. In the most recent year and as of the date of publication of the annual report, whether any of the matters specified in Article 36 of the Securities and Exchange Act has occurredthreeMatters stipulated in the second paragraph of this item that have a significant impact on shareholders' equity or securities prices.....	220

1. Report to Shareholders

1.1 Business results for 2024

(1) Results of business plan implementation

The company's consolidated revenue for fiscal year 2024 was NT\$4,325,831,000, net profit after tax was NT\$200,097,000, and earnings per share was NT\$1.53. Both revenue and profit increased compared to the previous year.

Judging from the operating results in 2024, the company's development will continue to review and consolidate businesses with insufficient synergy. The operating performance of each subsidiary and investment as well as the synergy of cooperation among various business units are the company's future business focus.

The operating results are summarized as follows:

➤ Consolidated Financial Statements (Unit: Thousand Yuan)

	2024	2023
operating income	4,325,831	3,873,384
operating costs	3,611,427	3,147,007
Operating profit	714,404	726,377
operating expenses	750,297	712,564
Other income and expenses, net	214,382	105,286
operating profit	178,489	119,099
Operating incomeIncome and expenditure	(4,579)	(10,115)
Net profit before tax	173,910	108,984
income tax expense	51,512	53,719
Net profit for this period	122,398	55,265
Net profit for this period is attributable to:		
parent company owner	200,097	124,557
non-controlling interest	(77,699)	(69,292)

➤Summary of individual financial statements

	2024	2023
Net profit for the year (thousand yuan)	200,097	124,557
Earnings per share: basic (yuan)	1.53	0.95
Diluted earnings per share (yuan)	1.52	0.95

(Note) 2023's EPS is retrospectively adjusted.

(2) Financial income and expenditure and profitability analysis

1. Financial income and expenditure

Unit: NT\$ thousand

project	2024	illustrate
Cash and cash equivalents at the beginning of the year	1,383,022	
Net cash inflow from operating activities	266,675	
Net cash outflow from investing activities	35,108	Mainly involves disposal of real estate and collection of dividends.
Net cash outflow from financing activities	(227,215)	It mainly includes repayment of loans, repayment of lease principal and payment of cash dividends.
Effect of exchange rate changes on cash and cash equivalents	2,045	
Cash and cash equivalents at year end	1,459,635	

2. Profitability Analysis

project	2024	2023
Return on assets (%)	2.25	1.11
Return on equity (%)	3.08	1.37
Operating profit to paid-in capital ratio (%)	13.62	9.45
Ratio of pre-tax net profit to paid-in capital	13.27	8.65
Net profit rate (%)	2.83	1.43
after tax (RMB)	1.53	0.95

(3) Research and development status

Our company provides medical logistics services, with its main focus on business and channel expansion. It is not a manufacturing company and does not have a research and development department.

Mincheng, a subsidiary of the Company, upholds the spirit of technological innovation, strengthens its core meltblown technology, applies it to products in the people's livelihood, industry, and medical and biotech industries, and develops related processes and products. We continue to invest in R&D resources, whether it is equipment, funds, or the recruitment of R&D talents with a master's degree or above. Our main goal is to accelerate the development of new products and processes and shorten the R&D schedule from both hardware and software strengths. The R&D team is also constantly trying to develop products in new application areas required by different industries, including feasibility assessment of new polymer materials in meltblown processes, and the gradual development of special non-woven fabric composite processes.

1.2 Overview of the 2025 Business Plan

(1) Business Policy

Pharmaceutical distribution business :

- Joint procurement platform for pharmaceutical products : including medicines, health materials, home care products, etc.
- Warehousing and logistics management of pharmaceutical and medical materials.
- Professional information consultation and services for pharmaceuticals and health materials.
- Distribution and agency of medicines, health foods and cosmeceuticals.

Specialist service business :

- Medical equipment leasing: including the sale, purchase and leasing of medical equipment, engineering and surgical instruments, information hardware and software and other specific equipment.
- Subsequent services for leased medical equipment: including maintenance (original or aftermarket) , repair and related maintenance consultation, and assistance in handling second-hand equipment.
- Project leasing: We tailor-make our products and services to meet the needs of our customers and provide them with complete and appropriate leasing projects.
- Professional consulting: Provide evaluation related to the establishment, procurement and updating of medical equipment, software and hardware consulting related to the establishment of medical institutions, establishment and cooperation consulting of large medical equipment; floor planning, engineering design and cooperation consulting of medical specialties.
- Specialized management: Cooperate with medical specialists in medical institutions to provide high-end medical equipment for specialized management,

combine medical expertise with the equipment supply chain, provide more advanced and professional medical services to the medical public, and assist with suggestions on space and engineering design planning.

Health Management Career:

- Medical health examination management consulting and entrusted operation services.
- Medical testing laboratory management consulting and entrusted operation services.
- Integrated marketing of medical testing related instruments, reagents and consumables.
- Medical manpower planning and dispatch services.
- Planning and setting up of medical office.
- Workplace health management consulting services.

Dialysis Services

- Provide logistical support to the dialysis center, including equipment rental, supply of medicines and medical supplies.

Smart Medical City Division

- "Smart Medical Residence" is a complex apartment hotel located in the Taoyuan City Station Business District, with a superior geographical location, convenient transportation, and complete living functions. Combined with smart medical services, it is committed to creating a service experience with "healthy life" as the core, so that every traveler can enjoy a beautiful and healthy accommodation experience.
- In addition to cooperating with businesses in the Taoyuan area to provide catering services to residents of Smart Medical Residence, the catering business is also actively developing the "Minsheng Healthy Kitchen" to provide meals for hospital patients and employees, and is committed to promoting healthy, balanced and diversified dietary choices.

(2) Expected sales volume and basis

1. Medical supply services

The Medical Distribution Department has been working on the drug and medical material supply platform for a long time, and has excellent supply chain operations management and procurement cost advantages, forming sufficient conditions for integrated joint procurement, and then striving for preferential conditions through collective bargaining to reduce the procurement costs of drugs and medical materials.

We continue to invest in Leap Lion Health Co., Ltd. and have established a

number of pharmacies across Taiwan, targeting the chronic prescription and over-the-counter drug markets. In recent years, due to the widespread chronic diseases in Taiwan's medical market, long-term prescriptions and self-paid drugs have increased year by year, driving the gradual growth of Taiwan's pharmacy market.

2. Specialized service business

The equipment leasing business and medical institution service management have continued to grow steadily and dynamically as the company's overall business has expanded.

In addition, the Specialty Services Department will focus more on the cooperative operation of medical specialties, and implement a mutually beneficial development model that combines specialty operations with equipment leasing and medical management. It will cooperate with the development and layout of the group's various business units, continue to deepen the depth and breadth of its business, and explore new growth momentum.

3. Health management services

After experiencing the impact of the epidemic, people's awareness of health has increased, and they pay more attention to personal health. Therefore, legal physical examinations and personal health examinations have set historical records in terms of the number of people examined and the operating income of the units affiliated to the Health Management Department. There has also been a significant increase in the number of migrant workers undergoing health examinations, with the main factors being the impact of domestic labor shortages and adjustments in operating strategies by peer hospitals. In 2024, we will continue to expand the health check service team and strengthen cost control to continuously improve service quality and satisfaction, establish customer loyalty and company brand image. In addition to fully expanding the business to achieve the budget target, we will expand the scope of operations in accordance with the company's mid- and long-term strategic direction and establish health checkup service bases throughout Taiwan.

With the changes in the medical environment and the instability of health insurance policies, many medical institutions have switched to single-supplier services for medical testing laboratories in order to improve their operations. In addition to being able to quickly acquire professional skills and resources, continuously improve quality, and enhance customer satisfaction, hospitals can also reduce operating costs to achieve a win-win situation. The company's health

management department has developed mature medical testing technology and professional management methods based on its rich experience. At the same time, it has professional planning of equipment rental services and integration with external testing reagent manufacturers, which gives it a strong competitive advantage in undertaking related businesses. In addition, in response to the inclusion of Next Generation Sequencing (NGS) in national health insurance benefits in the second quarter of 2024, and the Ministry of Health and Welfare's 2021 amendments to the "Regulations on the Implementation or Use of Specific Medical Technology Inspection and Testing Medical Equipment" (referred to as the "Special Management Law"), which positively lists and manages genetic testing projects developed by laboratories themselves, we have also established a complete evaluation and application process to assist in the evaluation and selection of appropriate inspection agencies and provide necessary inspection services when clinical diagnosis and treatment are needed.

In terms of health management and medical personnel support, with the medical personnel of the medical group as a strong backing, we provide occupational safety and health management related services, including on-site medical personnel services, workplace health management planning, and remote care . In addition to a rich and comprehensive talent pool, we continuously improve the quality of talents through professional training, and develop an "on-site health service information system" to provide clients with the most appropriate and highest quality health management care and medical professional personnel dispatch and management services through objective data analysis, identification of service demand points, and medical personnel management .

4. Dialysis Division

In conjunction with the company's business units, we continue to expand logistical support for each dialysis center , including equipment rental, and the supply of medicines and medical supplies.

5. Smart Medical City Division

Smart Medical Residence currently has 192 guest rooms, including elegant rooms, deluxe rooms and family rooms, to meet the needs of diverse travelers. In addition to providing high-quality accommodation services, it also combines smart pharmacies, professional health examinations and customized medical beauty and other medical resources to create an integrated service model of "medical care × accommodation", so that travelers can take care of their health during their travels

and practice a full-scale experience of combining medical care and travel.

The catering business adheres to the concept of health, provides diversified and nutritionally balanced catering services, and combines medical and nursing accommodation as the main axis to further enhance the overall quality of the hotel and the value of medical and tourism services.

(3) Future company development strategy

The company's four major development guidelines for 2025 are:

1. Expand and consolidate core business .
2. Develop new businesses .
3. Build a specialized brand .
4. Shape a culture of discipline .

1.3 Impact of external competition, regulatory environment and overall business environment

With the rise of preventive medicine, the health check-up market has become the hottest industry. It is estimated that the domestic health examination market is nearly 20 billion yuan a year. In terms of the regulatory environment, in recent years, due to the government's emphasis on workplace working environment, labor safety, occupational medicine, and the concept of continuous quality improvement driven by medical certification, the competent authority has revised the "Occupational Safety and Health Law" to protect the safety of workers in the workplace, and established "Labor Health Protection Rules" and "Medical Institution Approval and Management Measures for Physical and Health Examinations of Workers" to ensure the quality of labor physical examinations. The first to be affected are the labor physical examination business and factory medical manpower dispatch business, which will be greatly affected, and relatively speaking, it will also provide the company with new opportunities for this business. Therefore, it is imperative to improve internal management performance, increase internal operational efficiency and reduce costs, so as to effectively improve service quality and do a good job of perfect customer relationship management, so that the automated mass production business model can be replicated in large quantities to establish economies of scale and become the world's largest health management platform.

In terms of pharmaceutical supply services, due to the impact of the national health insurance quota policy , medical institutions and national health insurance pharmacies are facing multiple pressures such as limited growth in national health insurance income, point-value accounting and cost reduction , and must reduce operating costs through joint procurement . Therefore, we are moving towards a new business model of obtaining pharmaceutical outsourcing and pharmaceutical procurement authorization for medical institutions , and continuing to vertically integrate and manage the supply chain to effectively open up sales channels in order to achieve horizontal integration synergy.

Shenghong has invested in Yueshi Pharmacy and Yueshi Health to establish chain pharmacies across Taiwan . There are now nearly 100 pharmacies , becoming an important base for deepening community medical services . Among them, the franchised pharmacies in Taoyuan have combined the resources of the Minsheng medical system nearby to develop long-term care institution medication evaluation business and home care medicine services, so that patients with chronic diseases and those who need health consultation can receive complete and professional services in the community. This will also help expand the pharmaceutical distribution business and receive support and feedback from end consumers.

In terms of equipment leasing, in response to the sluggish environment and the post-epidemic medical and capital utilization needs , equipment leasing owners have requested to reduce rents and interest rates or extend the use period, and the company's profits have been relatively reduced; in addition to the coordinated medical and engineering services and medical service management and engineering suggestions as the added value of equipment leasing, the company also responds to market demand and strives for greater profits. The direction is to merge agents or obtain the agency rights of important medical equipment and special materials, and provide cooperative institutions with the establishment of an instrument-centered medical specialty cooperative management service model, and conduct upstream and downstream integration in terms of product sales, leasing, management, maintenance and resale of second-hand equipment, and consider the layout of AI smart medical care, in order to develop more comprehensive and professional medical leasing and specialty services.

In the dialysis business, we actively integrate the dialysis business of the system hospitals and external parties, continuously improve the functions of the department within the system medical ecosystem, and combine the inherent advantages of medical services, pharmaceuticals, health materials, equipment rental, etc. in the system medical ecosystem to provide comprehensive logistical support for dialysis centers.

This year, the company will focus on developing the medical business ecosystem and strive for sustainable growth. At the same time, it will focus on six major axes as operational development priorities, namely: e- medical services , physical pharmacy channels , expansion of medical service locations, expansion into the upstream field of medical materials, and operation and management of smart medical and health examination businesses . It is expected that with the active introduction of innovative models and the synergy of the group's resource integration, the full-year operation will have the opportunity to reach a new peak.

Chairman Hung-jen Yang



2. Corporate Governance Report

2.1. Information on directors , supervisors , general manager, deputy general manager, assistant manager, and heads of departments and branches

(1) Information of directors and supervisors

April 15 , 2025

Professional title (Note1)	Nationality or place of registration	Name	gender (Note2)	choose(At once)appointment date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relationship	
Chairman	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2003.09.10	36,298,290	28.80%	37,750,221	28.80%	-	-	-	-	1. Department of Medicine, National Taiwan University 2. Master of Public Health, Harvard University, USA 3. Peter. Drucker School of Management MBA Program 4. John. Master of Health Sciences, Johns Hopkins 5. Visiting Scholar at Stanford University 6. PhD, Institute of Sports Science, National Taiwan Sport University 7. CEO of Minsheng Medical System 8. Director of Beijing Smile Angel Children's Hospital	1. CEO of Minsheng Medical System 2. Chairman of the United Medical Foundation 3. Director of China BenQ Hospital Holdings 4. Chairman of Harvard Health 5. Chairman of Hengxin Investment Co., Ltd. 6. Chairman of Honghan Health Enterprise Co., Ltd. 7. Chairman of Born Management Consulting Co., Ltd. 8. Chairman of Shengyou Rehabilitation Technology Co., Ltd. 9. Chairman of Anzhun Technology Co., Ltd. 10. Supervisor of Shengyu Health Technology Co., Ltd.	none	none	none	He also serves as the CEO. In order to strengthen the independence of the board of directors, the company

Professional title (Note1)	Nationality or place of registration	Name	gender age (Note2)	choose(At once)appointment date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relationship	
	China Republic of China	Representative Yang Hongren	male 51-60	2024.06.24	3 years	2003.09.10	924,480	0.74%	967,930	0.74%	-	-	-	-	9. Director of Minsheng General Hospital	11. Director of Shengshi Digital Health Co., Ltd. 12. Chairman of Shengyun Pharmaceutical Co., Ltd. 13. Chairman of Yueshi Health Co., Ltd. 14. Chairman of Mincheng Health Technology Co., Ltd. 15. Chairman of Medical Electronics Digital Transformation Co., Ltd. 16. Director of Universal Biotech Multimedia Corporation 17. Director of One-Da International Hospital Management Consultants Co., Ltd. 18. Chairman of SanGu Co., Ltd. 19. Chairman of Precision Health Co., Ltd. 20. Director of Minsheng Asset Management Co., Ltd. 21. Director of Fondix Information Co., Ltd. 22. Supervisor of China Development Biomedical Venture Capital Co., Ltd. 23. Supervisor of Yue De Enterprise Co., Ltd. 24. Supervisor of Bozhi Cultural and Creative Co., Ltd. 25. Chairman of Minsheng Medical Control Co., Ltd.	director	Yang Chen Caibi	Mother and Child	has added one independent director in 2013 to enhance the board's functions and strengthen its supervisory function.
Vice Chairman	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2003.09.10	36,298,290	28.80%	37,750,221	28.80%	-	-	-	-	1.Department of Economics, National Taiwan University 2. University of Texas at Dallas, Master of Business Administration 3. Foreign banks are responsible for the overall Taiwan market business		none	none	none	-
	China Republic of China	Representative Xu Shengxin	male 61-70	2024.06.24	3 years	2003.09.10 (Note 6)	-	-	-	-	-	-	-	4. Served as a professional senior manager in several listed companies in the electronics industry in Taiwan		none	none	none		
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2010.09.01	36,298,290	28.80%	37,750,221	28.80%	-	-	-	-	1. Yuan Ze School of Management EMBA 2. Department of Medical Technology, Taipei Medical College 3. Senior Vice President of Minsheng General Hospital	1. Chairman of Zhongyuan Medical Management Co., Ltd. 2. Vice Chairman of Shengyun Pharmaceutical Co., Ltd. 3. Director of Mincheng Health Technology Co., Ltd. 4. Director of the United Medical Foundation 5. Director of Harvard Health Corporation 6. Director of Fondix Information Co., Ltd. 7. Supervisor of Yueshi Health Co., Ltd.	none	none	none	-
	China Republic of China	Representative Liu Qingwen	male 61-70	2024.06.24	3 years	2010.09.01 (Note 7)	56,847	0.05%	59,120	0.05%	-	-	-	-	4. Deputy Director of Administration, Minsheng General Hospital 5. Chairman of Shengyun Pharmaceutical Co., Ltd.		none	none	none	

Professional title (Note 1)	Nationality or place of registration	Name	gender age (Note 2)	choose(At once) appointment date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relationship	
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2009.08.01	36,298,290	28.80%	37,750,221	28.80%	-	-	-	-	1. PhD, School of Management, University of Cambridge, UK 2. Master of Economics, National Taiwan University 3. Bachelor of Economics, National Taipei University (College of Law and Business, National Chung Hsing University)	1. President of Taiwan Economic Research Society and Director of Sustainable Development Policy Research Center 2. Director of the Intellectual Property Evaluation Service Center of the Taiwan Institute of Economics 3. Director of Biotechnology Industry Research Center, Taiwan Institute of Economics 4. Editor-in-Chief of "Agricultural Biotechnology Industry Quarterly"	none	none	none	-
	China Republic of China	Representative Sun Zhili	female 51-60	2024.06.24	3 years	2009.08.01 (Note 8)	-	-	-	-	-	-	-	-			none	none	none	
director	China Republic of China	Minsheng Medical Control Co., Ltd. Limited Company		2024.06.24	3 years	2023.06.30	36,298,290	28.80%	37,750,221	28.80%	-	-	-	-	1. Doctor of Medicine, Institute of Clinical Medicine, National Taiwan University 2. Bachelor of Medicine, National Taiwan University 3. Professor of Internal Medicine and Emergency Medicine, National Taiwan University College of Medicine 4. Director of the Cardiovascular Center, National Taiwan University Hospital 5. Director of Cardiology Department, National Taiwan University Hospital 6. Director of the Department of Emergency Medicine, National Taiwan University Medical School 7. Director of the Department of Emergency Medicine, National Taiwan University Hospital 8. Director of Taoyuan Hospital, Ministry of Health and Welfare, Executive Yuan 9. Director of Hsinchu Hospital, Ministry of Health and Welfare, Executive Yuan 10. Director of Luodong Boai Hospital	1. Chief Director of Hospital Division 2. Director of the Roche Foundation, a medical foundation 3. Honorary Professor, National Taiwan University College of Medicine 4. Chief Director of Minsheng General Hospital	none	none	none	-
	China Republic of China	Representative Chen Wenzhong	male 61 - 70	2024.06.24	3 years	2023.06.30	-	-	-	-	-	-	-	-			none	none	none	-
director	China Republic of China	Rongyang Management Consultants Limited Company		2024.06.24	3 years	2018.06.27	133,928	0.11%	139,285	0.11%	-	-	-	-	1.Master of Public Administration, University of Southern California (USC) 2. Deputy Director of Administration of Minsheng Jingguo General Hospital 3. Vice President of Minsheng Medical System 4. Deputy CEO of Asia Pacific Health Corporation 5. The 5th and 6th Council Member of the Regional Hospital Association of the Republic of China	1. Chairman of Rongyang Management Consulting Co., Ltd. 2. Chairman and General Manager of Minsheng Asset Management Co., Ltd. Vice Chairman of Bisheng Construction Co., Ltd. 4. Director of Mincheng Health Technology Co., Ltd. 5. Director of Shengyun Pharmaceutical Co., Ltd.	none	none	none	-
	China Republic of China	Representative Zhang Changrong	male 51-60	2024.06.24	3 years	2003.09.10	-	-	-	-	-	-	-	-			none	none	none	

Professional title (Note 1)	Nationality or place of registration	Name	gender age (Note 2)	choose (At once) appointment date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relationship	
															6. Deputy Captain of Taoyuan County Patrol Team					
director	China Republic of China	Yang Chen Cai	female 81-90	2024.06.24	3 years	2003.09.10 (Note 9)	1,416,771	1.12%	1,473,441	1.12%	1,261	0 %	-	-	1. Department of Physics, Normal University 2. Teaching assistant and lecturer at Taipei Medical College 3. President of Xinsheng Medical School 4. Chairman of Jiuyu Co., Ltd. 5. Chairman of Minsheng Asset Management Co., Ltd.	1. Chairman of Jiabei Industrial Co., Ltd. 2. Chairman of Yang Zheng Investment Co., Ltd. 3. Director of Ariel Aesthetics Co., Ltd. 4. Director of Yue De Enterprise Co., Ltd.	Chairman	Yang Hongren	Mother and Child	-
Independent Director	China Republic of China	Wu Genzai	male 61-70	2024.06.24	3 years	2018.6.27	-	-	-	-	-	-	-	-	1. Department of Accounting, National Taiwan University 2. Auditor and audit team leader of Deloitte Touche Tohmatsu CPA Ltd. 3. CFO and Director of Management Department in Manufacturing Industry 4. Partner Accountant of Chengxin United Accounting Firm 5. Special lecturer at the Small and Medium Enterprises Division of the Ministry of Economic Affairs and the Business Management Consulting Company 6. Passed the 1991 Higher Accountant Examination	1. Partner Accountant of Zhanyu United Certified Public Accountants 2. Director of Zhan Yu Development Industrial Co., Ltd.	none	none	none	-
Independent Director	China Republic of China	Li Shuxing	male 61-70	2024.06.24	3 years	2019.6.27	-	-	-	-	-	-	-	-	1. PhD in Accounting, New York University 2. Bachelor of Business Administration, National Chengchi University 3. Dean of School of Management, Tunghai University 4. Acting Dean of the School of Management, Tunghai University 5. Vice President for Finance, National Taiwan University 6. Dean of College of Management, National Taiwan University 7. Dean of the Department of Accounting, National Taiwan University 8. Editor-in-chief of Asia-Pacific Journal of Accounting and Economics 9. Editor-in-Chief of NTU Management Series 10. AACSB Visiting Committee Member 11. Member of AACSB Asia Pacific Advisory Committee	1. Dean of the College of Management, Chang Gung University / Professor of the Department of Digital Finance 2. Independent Director of Fubon Financial Holdings Co., Ltd. 3. Independent Director of Kanglian Biomedical Technology Co., Ltd. 4. Independent Director of Alphabet Inc.	none	none	none	-

Professional title (Note 1)	Nationality or place of registration	Name	gender age (Note 2)	choose (At once) appointment date	term of office	first election date (Note 3)	When elected hold shares		now Number of shares held		Spouse and minor children currently hold shares		Hold shares in someone else's name		Main academic qualifications (Note 4)	Currently holding positions in the company and other companies	Other managers, directors or supervisors who are related by spouse or within the second degree of affinity			Remarks (Note 5)
							Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio	Number of shares	shareholding ratio			job title	Name	relationship	
															12. Chairman of the Chinese Accounting Education Association					
Independent Director	China Republic of China	Chen Houming	male 61-70	2024.06.24	3 years	2021.07.30	-	-	-	-	-	-	-	-	1. PhD, Graduate School of Business, National Taiwan University 2. Master of Applied Statistics, University of Iowa, USA 3. Master of Management Science, Tamkang University 4. Chairman of the Chinese Negotiation Management Society 5. Member of the National Development Fund Management Committee, Executive Yuan 6. Convener of Management Department of the Ministry of Science and Technology, Executive Yuan 7. President of the Business Development Research Institute 8. Dean of the College of Social Sciences and Management, Director of the Institute of Business Administration, and Director and Director of the Department of Business Administration, National Chung Hsing University 9. Professor of International Business Department, National Chi Nan University 10. Associate Researcher, Chinese Institute for Economic Research	1. Distinguished Professor of the Department and Graduate Institute of International Business, National Taiwan University 2. Chairman of the Chinese Business Education Development Association 3. Honorary Chairman of Taiwan Marketing Science Society 4. Independent Director of Xinbang Electronics Co., Ltd. 5. Independent Director of Fuchiao Industrial Co., Ltd. 6. Independent Director of Creative Electronics Co., Ltd.	none	none	none	-
Independent Director	China Republic of China	Yao Xiubi	female 41-50	2024.06.24	1 year	2023.06.30	-	-	-	-	-	-	-	-	1. Master of Business Administration, University of Missouri-Columbia 2. Tunghai University Super EPOST 3. Department of Finance, National Chung Cheng University 4. Ginko International Co., LTD Acting Spokesperson 5. Director of the Chairman's Office of Yongsheng Optical Co., Ltd.	1. Manager of Strategic Investment Department of Yongsheng Optical Co., Ltd. 2. Director of Formosa Optical Technology Co., Ltd. 3. Director of Haichang Biochemical Technology Co., Ltd. 4. Director of Yujia Sheng Co., Ltd. 5. Supervisor of Shangjingcheng Co., Ltd. 6. Director of Xiamen Weimeng Environmental Protection Materials Co., Ltd.	none	none	none	-

Note1: Legal person shareholders should list the names and representatives of the legal person shareholders respectively (if they are representatives of legal person shareholders, the name of the legal person shareholder should be indicated), and the following table 1 should be filled out.

Note2: The actual age should be listed and expressed in an interval format.

Note 3: Fill in the time when you first served as a director or supervisor of the company. If there is any interruption, please note the explanation.

Note 4: For experience related to the current position, if you have worked in a certification accounting firm or related company during the preceding period, your job title and responsible position should be stated.

Note 5: If the chairman of the company and the general manager or a person with a similar position (top manager) are the same person, each other's spouse or first-degree relative, the reasons, rationality, necessity and countermeasures (such as adding independent director seats) should be explained , and there should be relevant information that more than half of the directors do not concurrently serve as employees or managers, etc.).

Note6 : Mr. Xu Shengxin 2018/9 to 2020/10 Not during the period of serving as a director.

Note7: Mr. Liu Qingwen 2011/8 to 2018/6 and 2020/11 to 2021/7 are not the period of serving as a director.

Note 8: Ms. Sun Zhili 2003/8 to 2018/6 During the period of serving as an independent director; 2018/7 to 2018/8 Not during the period of serving as a director.

Note 9: Ms. Yang Chen Caibi 2021/3 to 2021/7 For the period of serving as supervisor; 2015/8 to 2017/10 Not during the period of serving as a director.

Major shareholder of a legal person shareholder

April 15 , 2025

Name of legal person shareholder (Note 1)	Major shareholder of a legal person shareholder (Note 2)
Minsheng Medical Control Co., Ltd.	Yang Zheng Investment Co., Ltd. 11.88%, Minsheng Asset Management Co., Ltd. 11.87%, Taoyuan City Yiren Charity Foundation 11.33%, Ruian Pharmaceutical Co., Ltd. 5.40%, Yang Minsheng 3.33%, Xindong Biotech Co., Ltd. 3.31%, Fulin Investment Co., Ltd. 2.99%, Yang Chen Caibi 2.36%, Yung Sin Pharmaceutical Industry Co., Ltd. 2.18%, and Shengli Management Consulting Co., Ltd. 1.79%.
Rong Yang Management Consultants Limited	Zhang Changrong (99.96%), Yang Yizhen (0.04%)

Note 1: If the director or supervisor is a legal person shareholder representative, the name of the legal person shareholder should be filled in.

Note 2 : Fill in the name of the major shareholder of the legal person shareholder (whose shareholding ratio is the top ten) and their shareholding ratio. If the major shareholder is a legal person, the following Table 2 should be filled in.

Note 3 : For corporate shareholders who are not corporate organizations, the names of shareholders and shareholding ratios that should be disclosed above are the names of investors or donors (please refer to the Judicial Yuan announcement for inquiries) and their investment or donation ratios. If the donor is deceased, the word "deceased" shall be noted.

If the major shareholder is a legal person, the major shareholder

April 15, 2025

Name of legal person (Note 1)	Major shareholder of a legal person (Note 2)
Yang Zheng Investment Co., Ltd.	Yang Minsheng 58.58% , Yang Chen Caibi 31.18% , Yang Yizhen 5.12% , and Yang Yisan 5.12% .
Minsheng Asset Management Co., Ltd.	Minsheng Medical Control Co., Ltd. 14.62%, Yang Zheng Investment Co., Ltd. 8.47%, Yang Chen Caibi 7.71%, Ruian Pharmaceutical Co., Ltd. 5.29%, Yang Minsheng 4.77%, Yang Hongren 3.77%, Mincheng Health Technology Co., Ltd. 3.38%, Xindong Biotech Co., Ltd. 3.27%, Fulin Investment Co., Ltd. 2.93%, and Yongxin Pharmaceutical Industry Co., Ltd. 2.13%.
Taoyuan City Foundation Yiren Charity Foundation	Minsheng General Hospital 66.31%, Longtan Minsheng Hospital 4.42%, Huang Mingan 3.68%, MiG International Co., Ltd. 3.68%, Nanshan Life Charity Foundation 3.32%, Dayuan Minsheng Hospital 2.21%, Huang Ruyu 1.99%, Wang Xiaofen 1.84%, Zhao Guoqing 1.84%, Luzhu Xuanji Temple 1.84% (2024 annual donation ratio).
Ruian Pharmaceutical Co., Ltd.	Jianqiao Xinyuan Pharmaceutical Biotechnology Co., Ltd. holds 94.51%.
Xindong Biotech Co., Ltd.	Youyuan Co., Ltd. holds 14.07%, Taiwan Venture Capital Co., Ltd. holds 11.25%, Yongyou Industrial Co., Ltd. holds 10.93%, National Development Fund Management Committee, Executive Yuan holds 6.77%, Jingshentang Investment Co., Ltd. holds 0.64%, Xu Shengxiong holds 0.09%, and Dingji Industrial Co., Ltd. holds 0.08%.
Fulin Investment Co., Ltd.	Fulin Engineering Co., Ltd. holds 17.95%, Sun Xinhui holds 14.54%, Sun Minling holds 6.59%, and Sun Guanyu holds 20.95%.
Yongxin Pharmaceutical Industry Co., Ltd.	Yongxin International Investment Holding Co. , Ltd. 100 % .
Shengli Management Consultants Co., Ltd.	Tavia Yeung 50% , Tavia Yeung 50% .

Note 1: If the major shareholder in Table 1 above is a legal person, the name of the legal person should be filled in.

Note 2: Fill in the name of the legal person's major shareholder (whose shareholding ratio is the top ten) and their shareholding ratio .

Note 3: If the legal person shareholder is not a company organization, the shareholder name and shareholding ratio that should be disclosed above are the names of investors or donors (refer to the Judicial Yuan announcement for inquiries) and their

Contribution or donation ratio. If the donor is deceased, please add "deceased" .

(2) The professional knowledge and independence of directors or supervisors:

1. Disclosure of professional qualifications of directors and supervisors and independence of independent directors :

condition Name	Professional qualifications and experience (Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Representative of Minsheng Medical Control Co., Ltd. Chairman Yang Hongren	Major: Department of Medicine, National Taiwan University; has work experience in the medical field and possesses the operational judgment, international market perspective, and decision-making abilities required by the company. Experience: Director of Corning Hospital/Director of Beijing Smiley Angel Children's Hospital/Person in charge of Minsheng General Hospital.	Yang Hongren is the representative of the Company's corporate directors and serves as the Company's Chairman and CEO and a director of its subsidiaries . He is also one of the top ten natural person shareholders of the Company (0.74%) and is not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission . She is the mother and son of Director Yang Chen Caibi, and has a kinship relationship within the second degree of spouse .	0
Representative of Minsheng Medical Control Co., Ltd. Xu Shengxin, Vice Chairman	Major: Department of Economics, National Taiwan University; has work experience in investment marketing management and operations management, and possesses the business, industry knowledge and crisis management capabilities required by the company. Experience: Foreign banks are responsible for the overall Taiwan market business/ Served as a professional senior manager in several listed companies in the electronics industry in Taiwan.	Xu Shengxin is the representative of the Company's corporate directors and a director of subsidiaries, but not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission .	0
Representative of Minsheng Medical Control Co., Ltd. Liu Qingwen Director	Major: EMBA from Yuan Ze School of Management; Experience in medical institution management and operations management, as well as industry knowledge, accounting and financial analysis skills required by the company. Experience: Deputy Medical Director of Minsheng General Hospital/Chairman of Shenghong Pharmaceutical Co., Ltd.	Director Liu Qingwen is the representative of the Company's corporate directors and serves as the Company's general manager and a director of its subsidiaries . He is not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission .	0
Representative of Minsheng Medical Control Co., Ltd. Sun Zhili Director	Major: PhD from Cambridge University School of Management; possesses academic and professional experience required for the company's business and possesses the business and industry knowledge required by the company. Experience: Director of the Biotechnology Industry Research Center and Intellectual Property Evaluation Service Center of the Taiwan Institute of Economics / Adjunct Associate Professor of the Institute of Biotechnology, National Taiwan University / Adjunct Associate Professor of the Institute of Technology Management, National Tsing Hua University	Sun Zhili is the representative of the Company's corporate directors and is not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission .	0

condition Name	Professional qualifications and experience (Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Representative of Minsheng Medical Control Co., Ltd. Director	Major: Department of Medicine, National Taiwan University; Experience in the medical field and possess the industry knowledge, crisis management and decision-making abilities required by the company. Experience: Doctor of Medicine, National Taiwan University Institute of Clinical Medicine / Bachelor of Medicine, National Taiwan University / Professor of Internal Medicine and Emergency Medicine, National Taiwan University College of Medicine / Director of the Cardiovascular Center, National Taiwan University Hospital / Director of the Department of Cardiology, National Taiwan University Hospital / Director of the Department of Emergency Medicine, National Taiwan University College of Medicine / Director of the Department of Emergency Medicine, National Taiwan University Hospital	Director Chen Wen Zhong is the representative of the Company's corporate directors and is not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission .	0
Representative of Rongyang Management Consultants Co., Ltd. Director	Major: Master of Public Administration from the University of Southern California (USC); Experience in medical institution management and asset management and leadership skills required by the company: Deputy Director of Administration of Minsheng Jingguo Hospital/Deputy CEO of Asia Pacific Health Corporation/Fifth and Sixth Council Member of the Regional Hospital Association of the Republic of China/Deputy Captain of the Taoyuan County Patrol Team	Chang Chang-jung is the representative of the Company's corporate directors and is not an independent director. The rest of the independence conditions are in accordance with Article 3 , Paragraph 1 of the "Regulations on the Establishment and Compliance of Independent Directors of Public Companies" promulgated by the Financial Supervisory Commission .	0
Director Yang Chen Caibi	Major: Physics Department of Normal University; possesses professional experience in academics, investment management and the business of the company. Experience: Teaching assistant and lecturer at Taipei Medical College/Principal of Xinsheng Medical School/Chairman of Jiuyu Co., Ltd./Chairman of Minsheng Asset Management Co., Ltd.	Director Yang Chen Caibi currently serves as a natural person director and is also one of the top ten natural person shareholders of the Company (1.12%) . However, she also meets the independence requirements of the competent authority. In the two years before her election and during her term of office, she met the independence conditions listed in Article 3 of the "Regulations on the Establishment and Compliance of Independent Directors of Publicly Issued Companies" promulgated by the Financial Supervisory Commission . During her tenure as a director, she has been granted the right to fully participate in decision-making and express opinions in accordance with Article 14-3 of the Securities and Exchange Act, and has independently exercised relevant powers accordingly. She is the mother and son of Chairman Yang Hongren, and has a kinship relationship within the second degree of spouse.	0

condition Name	Professional qualifications and experience (Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Wu Genzai Independent Director	<ol style="list-style-type: none"> 1. Major: Graduated from National Taiwan University with a Bachelor of Accounting (passed the 1991 CPA Examination); possesses working experience in accounting, finance and other areas required for the Company's business. 2. Experience: Auditor/audit team leader at Deloitte Touche Tohmatsu CPA LLP, CFO of manufacturing industry, director of management department, partner accountant at Chengxin CPA LLP, special lecturer at the Small and Medium Enterprises Department of the Ministry of Economic Affairs, and corporate management consulting company. 3. Mr. Wu Du has extensive experience in accounting practice. Through his expertise, he can provide insightful guidance in all aspects of data review and can offer appropriate suggestions. 	<p>The following four independent directors do not fall under any of the circumstances specified in Article 30 of the Company Act , are not elected by the government, legal persons or their representatives in accordance with Article 27 of the Company Act, and do not have a spouse or second degree of kinship relationship with other directors. In the two years prior to their election, they did not fall under any of the following circumstances :</p> <ol style="list-style-type: none"> 1. An employee of the company or its affiliated enterprises. 2. Being a director or supervisor of the company or its affiliated enterprises (however, this does not apply to those who concurrently hold the position of independent director of the company and its parent company, subsidiary, or subsidiary of the same parent company in accordance with this Act or the laws of the local country) . 3. The individual and his/her spouse, minor children or any other person who holds 1% or more of the total issued shares of the company or is one of the top ten natural person shareholders. 4. The spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship of the manager in Item 1 or the persons listed in Items 2 and 3 . 5. A director, supervisor or employee of a corporate shareholder who directly holds 5% or more of the total issued shares of the company, or who is one of the top five shareholders or a corporate shareholder who has appointed a representative to serve as a director or supervisor of the company in accordance with Article 27, Paragraph 1 or 2 of the Company Act (but this does not apply to independent directors of the company and its parent company, subsidiary, or subsidiary of the same parent company who are appointed in accordance with this Act or local laws and regulations) . 6. More than half of the board seats or voting shares of the Company and another company are controlled by the same person, who is a director, supervisor or employee of the 	0
Li Shuxing Independent Director	<ol style="list-style-type: none"> 1. Current position: Dean of the College of Management, Chang Gung University / Professor of the Department of Digital Finance 2. Major: PhD in Accounting from New York University; Lecturer at public or private colleges and universities with relevant majors required by our company's business: Professional experience in business, finance, accounting and other areas required by our company's business. 3. Experience: Vice President of Finance/Dean of College of Management/Head of Department of Accounting, National Taiwan University; Acting Dean of College of Management/Chair Professor of Department of Accounting, Tunghai University; Chairman of Chinese Accounting Education Association 4. Independent Director Li has a background in accounting and has many years of experience as an independent director in other industries. He is able to share the company's experience in operating multiple industries and provide management decision-making advice in industry integration analysis, risk management, etc. 	<ol style="list-style-type: none"> 4. The spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship of the manager in Item 1 or the persons listed in Items 2 and 3 . 5. A director, supervisor or employee of a corporate shareholder who directly holds 5% or more of the total issued shares of the company, or who is one of the top five shareholders or a corporate shareholder who has appointed a representative to serve as a director or supervisor of the company in accordance with Article 27, Paragraph 1 or 2 of the Company Act (but this does not apply to independent directors of the company and its parent company, subsidiary, or subsidiary of the same parent company who are appointed in accordance with this Act or local laws and regulations) . 6. More than half of the board seats or voting shares of the Company and another company are controlled by the same person, who is a director, supervisor or employee of the 	3

condition Name	Professional qualifications and experience (Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
Chen Houming Independent Director	<ol style="list-style-type: none"> Current position: Distinguished Professor, Department of International Business and Graduate Institute, National Taiwan University Major: PhD in Marketing from the Graduate School of Business at National Taiwan University; Lecturer at public or private colleges and universities with majors related to our company's business; Professional experience in business and our company's business. Experience: Dean of the Business Development Research Institute, Dean of the College of Social Sciences and Management at National Chung Hsing University. Independent Director Chen has management expertise and experience as an independent director in other industries. He can provide diverse suggestions on operations and management in a timely manner and give clear guidance on practical operations. 	<p>other company (but this does not apply if the independent directors of the Company and its parent company, subsidiary or subsidiary of the same parent company are appointed in accordance with this Act or local laws and regulations) .</p> <p>7. The chairman, general manager or person of equivalent position of the company and another company or institution is the same person or spouse, and is a director (council member), supervisor (auditor) or employee of the other company or institution (but this does not apply if the independent directors of the company and the parent company, subsidiary or subsidiary of the same parent company are appointed in accordance with this Act or the laws of the local country) .</p> <p>8. Serving as a director (council member), supervisor (supervisor), manager or shareholder holding 5% or more of the shares of any of the following (1) to (4) specific companies or institutions that have financial or business dealings with the Company.</p>	3
Yao Xiubi Independent Director	<ol style="list-style-type: none"> Current position: Manager of Strategic Investment Department of Yongsheng Optics Co., Ltd. Major: Master of Business Administration from the University of Missouri-Columbia; professional experience in applying financial analysis, evaluating industry mergers and acquisitions , and the company's business. Experience: Tunghai University Super EPOST/National Chung Cheng University Department of Finance/Ginko International Co., LTD Acting Spokesperson/Director of the Chairman's Office of Yongsheng Optical Co., Ltd. Independent Director Yao has management expertise and experience as a director in other industries. He can provide the company with advice on diversified business operations and provide management decision-making advice in analyzing financial statements and evaluating industrial mergers and acquisitions. 	<p>(1) Holding more than 20% but less than 50% of the total issued shares of the company.</p> <p>(2) The other company and its directors, supervisors and shareholders holding more than 10% of the total number of shares hold a total of more than 30% of the total number of issued shares of the company, and the two parties have a record of financial or business dealings. The stocks held by the aforementioned persons include their spouses, minor children and those who hold the stocks in the names of other persons.</p> <p>(3) The company's operating income comes from other companies and their group companies for more than 30%.</p> <p>(4) The quantity or total purchase value of the company's main product raw materials (referring to those that account for more than 30% of the total purchase value and are key raw materials that are indispensable for the manufacture of products) or main commodities (referring to those that account for more than 30% of the total operating income) comes from other companies and their group companies for more than 50%.</p> <p>9. Professionals, sole proprietors, partnerships, owners, partners, directors, supervisors, managers and their spouses of companies or institutions that provide audit services to the company or its affiliated companies, or business, legal, financial, accounting and other related services with a cumulative remuneration of more than NT\$500,000 in the</p>	0

condition Name	Professional qualifications and experience (Note 1)	Independence situation (Note 2)	Number of independent directors of other publicly listed companies
		past two years. However, this restriction does not apply to members of the Compensation Committee, the Public Takeover Review Committee, or the Merger and Acquisition Special Committee who perform their duties pursuant to this Act or relevant laws and regulations of the Corporate Merger and Acquisition Act.	

Note 1: Upon investigation, all directors of the Company have not committed any of the violations specified in Article 30 of the Company Law .

2. Diversity and independence of the board of directors:

The Company has established the "Director Election Rules", which state that the election of directors (including independent directors) of the Company should take into account the overall configuration, the composition of members should take into account diversity, and formulate appropriate diversity guidelines based on its own operations, operating patterns and development needs, which should include but not be limited to the following two aspects :

1. Basic conditions and values: gender, age, nationality and culture, etc.

2. Professional knowledge and skills: professional background (such as law, accounting, industry, finance, marketing or technology), professional skills and industry experience, etc.

The Company's current Board of Directors consists of 11 directors, including 4 independent directors, with extensive experience and expertise in the fields of medicine, finance, business and management. At the same time, in accordance with the board diversity policy, the company also attaches great importance to gender equality in the composition of the board of directors. When electing directors in 2023, a female director was added, making the current board of directors include three female directors. When the shareholders' meeting re-elected the current board of directors in 2024, three female directors were maintained, with a ratio of 27.3%, which was in compliance with the relevant laws and regulations at the time of the election. However, the company has 11 board seats, but less than one-third of them are female directors, which is due to the characteristics of the industry. The Company intends to seek talent recommendations from various channels such as industry and academia when the Board of Directors is re-elected upon expiration of its term, in order to improve corporate governance effectiveness and implement a policy of diversity in board members.

The current board of directors of our company has elected 11 directors, of which 4 are independent directors, accounting for 36.3 % . During the election, the company evaluated them and issued an independent director qualification checklist. When taking office, the independent directors signed an independent director declaration, confirming that none of the independent directors are subject to the provisions of Article 26-3, Paragraphs 3 and 4 of the Securities and Exchange Act , and exercised their independence. In addition, except for Director Yang Chen Caibi and Director Yang Hongren, who are mother and son, the other directors of this board of directors are not spouses or relatives within the second degree of kinship.

Diversity of board members:

Diversity of Board members		Basic composition							Industry Experience				Professional capabilities			
Diversified core projects	Country of Citizenship	gender	concurrently serves as the company staff	age				Independent Director Term of Office	Medical profession	Medical institution management	educate	Investment Management	law	Accounting and Finance	Marketing Management	Information Technology
				41 to 5 0	51 to 60	61 to 70	71 above	Within 3 sessions								
Yang Hongren	Republic of China	male	V		V				V	V	V	V			V	V
Xu Shengxin	Republic of China	male				V			V	V		V		V	V	V
Liu Qingwen	Republic of China	male	V			V			V	V		V		V	V	V
Sun Zhili	Republic of China	female			V						V	V			V	V
Chen Wenzhong	Republic of China	male	V			V			V	V	V	V		V	V	V
Zhang Changrong	Republic of China	male	V		V					V				V	V	V
Yang Chen Caibi	Republic of China	female					V			V	V	V				
Wu Genzai	Republic of China	male				V		V						V		
Li Shuxing	Republic of China	male				V		V			V	V		V		V
Chen Houming	Republic of China	male				V		V			V	V		V	V	V
Yao Xiubi	Republic of China	female		V				V			V			V	V	V

The overall capabilities of the board members are:

Diversified core projects	gender	Operational judgment ability	Accounting and financial analysis skills	Business management capabilities	Crisis handling ability	Industry knowledge	International Market Outlook	Leadership	Decision-making ability
Name of Director									
Yang Hongren	male	V	V	V	V	V	V	V	V
Xu Shengxin	male	V	V	V	V	V	V	V	V
Liu Qingwen	male	V	V	V	V	V	V	V	V
Sun Zhili	female	V	V	V	V	V	V	V	V
Chen Wenzhong	male	V	V	V	V	V	V	V	V
Zhang Changrong	male	V	V	V	V	V	V	V	V
Yang Chen Caibi	female	V	V			V			V
Wu Genzai	male	V	V	V	V	V		V	V
Li Shuxing	male	V	V	V	V	V	V	V	V
Chen Houming	male	V	V	V	V	V	V	V	V
Yao Xiubi	female	V	V	V	V	V	V	V	V

(3) General Manager, Deputy General Managers, Assistant Managers and Heads of Departments and Branches

April 15 , 2025

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
Chief Executive Officer	Republic of China	Yang Hongren (Note 1)	2020/01/31	967,930	0.74%	0	0	0	0	1. Department of Medicine, National Taiwan University 2. Master of Public Health, Harvard University, USA 3. Peter. Drucker School of Management MBA 4. John. Master of Health Sciences, Johns Hopkins 5. PhD, Institute of Sports Science, National Taiwan Sport University 6. Visiting Scholar at Stanford University 7. CEO of Minsheng Medical System 8. Director of Beijing Smile Angel Children's Hospital 9. Physician in charge of Minsheng General Hospital	1. CEO of Minsheng Medical System 2. Chairman of the United Medical Foundation 3. Director of China BenQ Hospital Holdings 4. Chairman of Harvard Health 5. Chairman of Hengxin Investment Co., Ltd. 6. Chairman of Honghan Health Enterprise Co., Ltd. 7. Chairman of Born Management Consulting Co., Ltd. 8. Chairman of Shengyou Rehabilitation Technology Co., Ltd. 9. Chairman of Anzhun Technology Co., Ltd. 10. Supervisor of Shengyu Health Technology Co., Ltd. 11. Director of Shengshi Digital Health Co., Ltd. 12. Chairman of Shengyun Pharmaceutical Co., Ltd. 13. Chairman of Yueshi Health Co., Ltd. 14. Chairman of Mincheng Health Technology Co., Ltd. 15. Chairman of Medical Electronics Digital Transformation Co., Ltd. 16. Director of Universal Biotech Multimedia Corporation 17. Supervisor of One-Da International Hospital Management Consultants Co., Ltd.	Dong thing	Yang List color Bi	mother son	Chairman and CEO

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
											18. Chairman of SanGu Co., Ltd. 19. Chairman of Precision Health Co., Ltd. 20. Director of Minsheng Asset Management Co., Ltd. 21. Director of Fondix Information Co., Ltd. 22. Supervisor of China Development Biomedical Venture Capital Co., Ltd. 23. Supervisor of Yue De Enterprise Co., Ltd. 24. Supervisor of Bozhi Cultural and Creative Co., Ltd. 25. Chairman of Minsheng Medical Control Co., Ltd.				
President	Republic of China	Liu Qingwen	2005/6/1	59,120	0.05 %	0	0	0	0	1. Department of Medical Technology, Taipei Medical College 2. Yuan Ze School of Management EMBA 3. Senior Vice President of Minsheng General Hospital 4. Deputy Director of Administration, Minsheng General Hospital 5. Chairman of Shengyun Pharmaceutical Co., Ltd.	1. Chairman of Zhongyuan Medical Management Co., Ltd. 2. Vice Chairman of Shengyun Pharmaceutical Co., Ltd. 3. Director of Mincheng Health Technology Co., Ltd. 4. Director of the United Medical Foundation 5. Director of Harvard Health Corporation 6. Director of Fondix Information Co., Ltd. 7. Supervisor of Yueshi Health Co., Ltd.	none	none	none	
Deputy General Manager	Republic of China	Fu Lanying (Note 2)	2016/9/29	376	0%	0	0	0	0	1. Department of Industrial Management Technology, National Taiwan Institute of Technology 2. International Internal Auditor 3. International Internal Control Self-Assessor 4. Enterprise Appraiser of China Intangible Assets and	1. Supervisor of Honghan Health Enterprise Co., Ltd. 2. Supervisor of Shengyun Pharmaceutical Co., Ltd. 3. Supervisor of Harvard Health Corporation	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
										Enterprise Appraisal Association 5. Senior Medical Manager of Taiwan Medical Management Association 6. Senior Engineer, General Manager's Office, Audit Office Manager, Shenghong Pharmaceutical Co., Ltd. 7. Director of the Audit Office and Director of the Accounting Office of Minsheng General Hospital 8. Senior Executive of Minsheng Medical System Operation Department and President's Office					
Deputy General Manager	Republic of China	Chen Pengxuan (Note 3)	2019/08/16	153	0%	0	0	0	0	1. Graduated from Chang Gung University Graduate School of Medical Administration 2. Intelligent Medical Technology Company/Senior Vice President 3. Makolon Co., Ltd./General Manager 4. Shenghong Pharmaceutical Co., Ltd./Deputy CEO of Long-term Care Division 5. Minsheng Medical System/Administrative Director 6. Minsheng Medical System/Nursing Supervisor	1. Legal representative of Minsheng (Tianjin) Investment Management Co., Ltd. 2. Vice Chairman of Yueshi Health Co., Ltd. 3. Director of Fondix Information Co., Ltd.	none	none	none	
Deputy General Manager	Republic of China	Ke Weixin	2023/06/01	187	0%	0	0	0	0	1. Department of Pharmacy, Taipei Medical College 2. Institute of Pharmacy, Kaohsiung Medical University 3. Yuan Ze University Graduate School of Management 4. Director of Pharmacy Department, Minsheng	Supervisor of Super Biotech Co., Ltd.	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
										General Hospital 5. Senior Manager of Pharmaceutical Distribution Department, Shenghong Pharmaceutical Co., Ltd.					
Deputy General Manager	Republic of China	Wu Mingxun	2008/1/1	264,863	0.20%	34,488	0.03%	0	0	1. Master of Life Science Institute, National Chung Hsing University 2. Master of Management, Yuan Ze University	1. General Manager of Zhongyuan Medical Management Co., Ltd. 2. Director of Medical Technology Department, Minsheng General Hospital	none	none	none	
Deputy General Manager	Republic of China	He Weiguan	2020/08/01	0	0	0	0	0	0	1. Bachelor of Information Engineering, National Chiao Tung University 2. Master of Information Engineering, National Taiwan University 3. Director of the Digital Service Innovation Institute of the Institute for Information Industry Promotion 4. Manager of Information Department/Director of Marketing Department of TTV 5. Host of the Smart Innovation Service Promotion Project of the Industrial Development Bureau, Ministry of Economic Affairs 6. Host of the IoT Smart Manufacturing Base Project of the Industrial Development Bureau, Ministry of Economic Affairs 7. Host of the Internet Community Innovative Service Development Project of the Department of Commerce,	1. Chairman of Founder Information Co., Ltd. Director of Medical Electronics Digital Transformation Co., Ltd. 3. Director of Universal Biotech Multimedia Corporation 4. Director of Leap Lion Health Co., Ltd. 5. Director of Shengshi Digital Health Co., Ltd.	none	none	none	

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
										Ministry of Economic Affairs 8. Co-host of the Digital TV/Telecommunication Value-added Service Demonstration Information Application Development Project of the Technology Department of the Ministry of Economic Affairs					
Deputy General Manager	Republic of China	Li Hongyi (Note 4)	2019/09/03	0	0	0	0	0	0	1. Institute of Business Administration, University of South Australia Director of Financial Investment Department , Rih Sun International Commercial Bank 3. Cathay Commercial Bank / Audit Office Specialist	1. General Manager of Precision Health Co., Ltd. 2. Supervisor of First Long-term Care Platform Co., Ltd.	none	none	none	
Deputy General Manager	Republic of China	Cai Yufang	2019/09/01	0	0	0	0	0	0	1. National Central University Executive Master of Business Administration scholar 2. Department of Law, Soochow University 3. Shenghong Pharmaceutical Co., Ltd./Director of Administration Department 4. Minsheng Medical Control Co., Ltd./Legal Affairs Institute 5. Ford Lioho Motors Co., Ltd./Legal Affairs 6. State-owned Assets Bureau of the Ministry of Finance/Legal Affairs	1. Executive Vice President of Precision Health Co., Ltd. 2. Supervisor of Chung Yuan Medical Management Co., Ltd. 3. Supervisor of Smart Medical City Co., Ltd.	none	none	none	
Deputy General Manager	Republic of China	Zhong Yiting (Note 5)	2024/11/01	0	0	0	0	0	0	1. Chang Gung University of Science and Technology, Department of Aging and Health Care graduate School 2. Yuan Ze University Graduate School of Management 3. Department of Nursing, Department of Medical	1. CEO of Minsheng Smart Health Management Center 2. Executive Director of Minsheng Health and Welfare College	none	none	none	

job title	Count ry of Citize nship	Name	Date of appointme nt	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareh olding ratio	Number of shares	Shareh olding ratio	Number of shares	Shareh olding ratio			job title	Name	relation	
										Management, Yuanpei University of Science and Technology 4. Vice President and CEO of Harvard Health Clinic 5. Director of Nursing Department, Minsheng General Hospital 6. Director of Nursing Department, Beijing Aiyuhua Women and Children's Hospital Supervisor 7. Director of Nursing Department, Beijing Mingde Hospital 8. Director's Office of Beijing Smiley Angel Children's Hospital Deputy Director of the Office 9. Director of the Administration Department of Longtan Minsheng Hospital 10. Quality Control Group of Asia Pacific Health Corporation long 11. Team Leader of Medical Secretary Office, Minsheng General Hospital 12. Case Manager at Minsheng General Hospital 13. Shenghong Pharmaceutical Co., Ltd. Purchasing Drug Store Leader 14. Anesthesiologist at Dayuan Minsheng Hospital 15. Part-time lecturer at Xinsheng Medical College 16. Lecturer appointed by the Ministry of Education					

job title	Country of Citizenship	Name	Date of appointment	Shareholding		Spouse and minor children Shareholding		Using someone else's name Shareholding		Major Educational Background	Currently holding other positions in other companies	Managers who are spouses or have a relationship within the second degree of kinship			Remark
				Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio			job title	Name	relation	
Accounting Supervisor	Republic of China	Huang Yamei	2018/05/01	12,665	0.02%	0	0	0	0	1. Department of Accounting, Ming Chuan University 2. Deputy Audit Team Leader, Ernst & Young Director and Financial Director of Hekang Biotechnology Co., Ltd. 4. Audit Manager of Hekang Biotechnology Co., Ltd. 5. Accounting Manager of Minsheng Medical Control Co., Ltd. 6. Accounting Manager of Shenghong Pharmaceutical Co., Ltd.	Director of Centaline Medical Management Co., Ltd.	none	none	none	
Audit Supervisor	Republic of China	Leaf cultivation	2022/03/25	0	0	0	0	0	0	1. Graduated from the Institute of Finance and Banking, Central University 2. Liande Electronics Co., Ltd./Audit Assistant Manager 3. Juyan Hutong International Co., Ltd./Audit Assistant Manager 4. Jingcai Technology Co., Ltd./Senior Audit Manager	none	none	none	none	

Note 1: The Company has 11 directors. Four directors are also employees, of which two are vice presidents or above, two are also general senior managers, and more than half of the directors are not employees.

Since the Chairman also serves as the Chief Executive Officer, in order to strengthen the independence of the Board of Directors, the company has added one independent director and one director in 2013 to enhance the functions of the Board of Directors and strengthen its supervisory function.

Note 2: Vice President Fu Lanying resigned on 2024.03.31.

Note 3: Vice President Chen Pengxuan took office on 1 January 2025.

Note 4: Vice President Li Hongyi was transferred to the subsidiary on June 24, 2024.

Note 5: Vice President Zhong Yiting took office on November 01, 2024

(4) Remuneration paid to directors, supervisors, general manager and deputy general manager in the most recent year

1. Remuneration of directors (including independent directors):

Unit: NT\$1,000; % ; 1,000 shares

job title	Name	Directors' remuneration								Total amount of A, B, C and D and their proportion in net profit after tax		Part-time employees receive relevant remuneration								A, B, C, D, E, F and G, etc. Total amount of seven items and their proportion in net profit after tax		Receive remuneration from a subsidiary or parent company			
		Remuneration (A)		Retirement pension (B)		Directors' Remuneration (C)		Business execution expenses (D)				Salaries, bonuses and special expenses, etc. (E)		Retirement pension (F)		Employee remuneration (G) (Note)									
		Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	Book male manager	All companies in the financial report	The Company		All companies in the financial report						Book male manager	All companies in the financial report
																		Cash Amount	Stock Amount	Cash Amount	Stock Amount				
Chairman	of Minsheng Medical Control Co., Ltd.: Yang Hongren																								
director	of Minsheng Medical Control Co., Ltd.: Xu Shengxin																								
director	of Minsheng Medical Control Co., Ltd.: Liu Qingwen																								
director	of Minsheng Medical Control Co., Ltd.: Sun Zhili	3,000	3,000	0	0	1,676	1,687	355	550	5,031 2.51%	5,237 2.62%	15,457	15,673	289	298	13,000	0	13,000	0	33,777 16.88%	34,208 17.10%	680			
director	of Minsheng Medical Control Co., Ltd.: Chen Wenzhong																								
director	Rong Yang Management Consultants Co., Ltd. Representative: Chang-Jung Chang																								
director	Yang Chen Caibi																								

Independent Director	Li Shuxing	950	950	0	0	993	993	335	335	2,278 1.14%	2,278 1.14%	0	0	0	0	0	0	0	2,278 1.14%	2,278 1.14%	0
Independent Director	Wu Genzai																				
Independent Director	Chen Houming																				
Independent Director	Yao Xiubi																				

1. Please describe the policy, system, standards and structure for the payment of remuneration to independent directors, and describe the correlation between the amount of remuneration paid and factors such as responsibilities, risks, and time invested:

The remuneration of independent directors is paid based on a fixed monthly travel fee, meeting (board of directors, compensation committee, audit committee) attendance fee and director remuneration allocation; meeting attendance fee is paid according to market conditions, and the remuneration of independent directors for performing duties is paid according to market conditions.

The principle is based on personal industry experience and professional involvement in the company's operating performance and operations. In addition, performance evaluation is conducted once a year in accordance with company regulations, and weighted data calculations are performed based on each evaluation item before participating in the distribution of director remuneration. Assessment

The remuneration ratio is calculated based on comprehensive considerations including but not limited to the director's status, concurrent manager, meeting attendance, tenure, financing joint guarantees, and the board's performance self-evaluation.

2. In addition to the above disclosure, the remuneration received by the company's directors for providing services to all companies in the financial report (such as serving as consultants other than employees, etc.) in the most recent year: **None**

Note : The company's 2024 annual director remuneration has not yet been approved by the shareholders' meeting and is only expressed in terms of the estimated amount of the proposed distribution.

2. Directors' remuneration range:

Remuneration scale

The remuneration bracket for each director of the Company	Name of Director			
	Total remuneration for the first four items (A+B+C+D)		Total remuneration for the first seven items (A+B+C+D+E+F+G)	
	The Company	All companies in the financial report	The Company	Parent company and all its invested businesses
lower than 1,000,000 yuan	Xu Shengxin, Liu Qingwen, Sun Zhili, Chen Wenzhong, Zhang Changrong, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming, Yao Xiubi, Rongyang Management Consultants Co., Ltd.	Xu Shengxin, Liu Qingwen, Sun Zhili, Chen Wenzhong, Zhang Changrong, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming, Yao Xiubi, Rongyang Management Consultants Co., Ltd.	Xu Shengxin, Sun Zhili, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming, Yao Xiubi	Xu Shengxin, Sun Zhili, Yang Chen Caibi, Wu Genzai, Li Shuxing, Chen Houming, Yao Xiubi
1,000,000Yuan (inclusive) ~2,000,000 yuan (not including)	none	none	none	none
2,000,000 yuan (inclusive)~3,500,000 yuan (not included)	Yang Hongren	Yang Hongren	Rong Yang Management Consultants Limited Zhang Changrong	Rong Yang Management Consultants Limited Zhang Changrong
3,500,000 yuan (inclusive) ~ 5,000,000 yuan (exclusive)	Minsheng Medical Control Co., Ltd.	Minsheng Medical Control Co., Ltd.	Chen Wenzhong	Chen Wenzhong
5,000,000 yuan (inclusive) ~10,000,000 yuan (not included)	none	none	Liu Qingwen	Liu Qingwen
10,000,000 yuan (inclusive)~15,000,000 yuan (not included)	none	none	none	none
15,000,000 yuan (inclusive) ~ 30,000,000 yuan (exclusive)	none	none	Yang Hongren	Yang Hongren
30,000,000 yuan (inclusive) ~ 50,000,000 yuan (exclusive)	none	none	Minsheng Medical Control Co., Ltd.	Minsheng Medical Control Co., Ltd.
50,000,000 yuan (inclusive) ~ 100,000,000 yuan (exclusive)	none	none	none	none
More than 100,000,000 yuan	none	none	none	none
total	13	13	13	13

3. Remuneration of the General Manager and Deputy General Manager: (Summarize and disclose names by level) Unit: NT\$ thousand; %

job title	Name	Salary(A)		Retirement pension (B)		Bonus and Special expenses, etc. (C)		employee remuneration (D) (Note)				Total amount of A , B , C and D and their proportion in net profit after tax (%)		remuneration from a subsidiary or parent company
		The Company	Financial Reports All company	The Company	All financial reports company	The Company	Financial Reports All company	The Company		All financial reports company		The Company	Financial Report Report to the internal office There is a company	
								Cash Amount	Stock Amount	Cash Amount	Stock Amount			
Chief Executive Officer	Yang Hongren	16,651	18,733	579	639	4,246	4,978	13,000	0	13,000	0	34,476 (17.23%)	37,350 (18.67%)	810
President	Liu Qingwen													
Deputy General Manager	Fu Lanying													
Deputy General Manager	Wu Mingxun													
Deputy General Manager	Ke Weixin													
Deputy General Manager	He Weiguang													
Deputy General Manager	Li Hongyi													
Deputy General Manager	Cai Yufang													
Deputy General Manager	Zhong Yiting													

Note: The company's employee remuneration for 2024 has not yet been approved by the shareholders' meeting and is only expressed as an estimated amount of the proposed distribution .

4. Remuneration range for general manager and deputy general manager:

The remuneration range for each general manager and deputy general manager of the company	Name of General Manager and Deputy General Manager	
	The Company	Parent company and all its invested businesses
Less than 1,000,000 yuan	Fu Lanying, Li Hongyi, Zhong Yiting	Fu Lanying, Zhong Yiting
1,000,000 yuan (inclusive) ~ 2,000,000 yuan (exclusive)	He Weiguang	Li Hongyi
2,000,000 yuan (inclusive) ~ 3,500,000 yuan (exclusive)	Wu Mingxun, Ke Weixin, Cai Yufang	Wu Mingxun, Ke Weixin, Cai Yufang
3,500,000 yuan (inclusive) ~ 5,000,000 yuan (exclusive)	none	He Weiguang
5,000,000 yuan (inclusive) ~ 10,000,000 yuan (exclusive)	Liu Qingwen	Liu Qingwen
10,000,000 yuan (inclusive) ~ 15,000,000 yuan (exclusive)	none	none
15,000,000 yuan (inclusive) ~ 30,000,000 yuan (exclusive)	Yang Hongren	Yang Hongren
RMB 30,000,000 (inclusive) to RMB 50,000,000 (exclusive)	none	none
50,000,000 yuan (inclusive) ~ 100,000,000 yuan (exclusive)	none	none
100,000,000 Yuan or more	none	none
total	9	9

Note: Vice President Fu Lanying resigned on 2024.03.31, Vice President Li Hongyi transferred to a subsidiary on 2024.06.24, and Vice President Zhong Yiting took office on 2024.11.01.

5. Name of the manager who distributes employee remuneration and the distribution situation:

Unit: NT\$ thousand; %

April 15, 2025

project	job title	Name	Stock Amount	Cash Amount	total	Total as a percentage of net profit after tax The proportion (%)
Manager	Chief Executive Officer	Yang Hongren	0	13,850	13,850	6.92%
	President	Liu Qingwen				
	Deputy General Manager	Fu Lanying				
	Deputy General Manager	Wu Mingxun				
	Deputy General Manager	Ke Weixin				
	Deputy General Manager	He Weiguang				
	Deputy General Manager	Li Hongyi				
	Deputy General Manager	Cai Yufang				
	Deputy General Manager	Zhong Yiting				
	Accounting Supervisor	Huang Yamei				
	Audit Supervisor	Leaf cultivation				

Note 1: Individual names and titles should be disclosed, but profit distribution may be disclosed in aggregate form.

Note 2: This is the actual amount of employee remuneration (including stocks and cash) distributed to managers in the most recent year approved by the board of directors. If it is impossible to estimate, the proposed distribution amount for the current year will be calculated based on the proportion of the actual distribution amount last year. Net profit after tax refers to the net profit after tax of the most recent year. For those that have adopted International Financial Reporting Standards, net profit after tax refers to the net profit after tax of the most recent year's individual or separate financial reports.

Note 3: The scope of application of managers is as follows, in accordance with the SFC's Order No. 0920001301 dated March 27, 2003:

- (1) General Manager and persons of equivalent rank
- (2) Deputy General Manager and persons of equivalent rank
- (3) Associate and equivalent
- (4) Head of Finance Department
- (5) Head of Accounting Department
- (6) Other persons who have the right to manage the company's affairs and sign

Note 4: If the director, general manager and deputy general manager receive employee remuneration (including stocks and cash), they should fill in this form in addition to filling in Appendix 1-2.

Note 5: The Company's employee remuneration for 2024 has not yet been approved by the shareholders' meeting and is only expressed as an estimated amount of the proposed distribution.

Note 6: Special Assistant Lin Fangyu will act as Chief Financial Officer.

6. Remuneration policy:

(1) Remuneration determination and payment policy:

Directors' remuneration (including independent directors') is mainly divided into two parts: directors' remuneration, fixed travel expenses, meeting attendance fees and business execution expenses.

Remuneration of directors and concurrent employees: including concurrent employees' salaries, various additional allowances and bonuses.

Directors' remuneration is based on Article 21 of the Company's Articles of Association: If the Company makes a profit in a year, the Board of Directors may, by resolution, allocate no more than 3% of the above profit as directors' remuneration. According to this principle, the company's individual portion of the 2024 allocation ratio is 1% of the net profit before tax. This ratio has been approved by the sixth meeting of the eighth session of the company's board of directors and is planned to be submitted for payment after approval by the shareholders' meeting in 2025 .

The remuneration of directors for performing their duties is based on the directors' attendance rate, personal industry experience and professional involvement in the company's operating performance and company operations. In addition, performance evaluation is conducted once a year in accordance with company regulations, and directors participate in the distribution of directors' remuneration after weighted data calculation based on each evaluation item. The remuneration ratio is calculated based on comprehensive considerations including but not limited to the director's status, concurrent manager, meeting attendance rate, tenure, financing joint guarantees, and the board's self-evaluation of performance. The remuneration of directors and supervisors of other subsidiaries is also allocated in accordance with the company's articles of association and can only be paid after approval in accordance with legal procedures. Fixed travel expenses are set according to market conditions, and meeting attendance fees are paid based on actual attendance when the board of directors, compensation committee or audit committee are convened.

The remuneration of employees (including managers) is based on the employee remuneration method established by the company, and is assessed based on the scope of each job responsibility and with reference to the industry standards, including: salary, various allowances and bonuses, employee remuneration, etc.

Employee remuneration is based on Article 21 of the Company's Articles of Association: If the Company makes a profit in a year, it shall set aside 6% to 10% as employee remuneration, which shall be distributed in the form of stock or cash by resolution of the Board of Directors, and the recipients shall include employees of affiliated companies who meet certain conditions . Based on this principle, the company's individual portion of the 2024 allocation ratio is 6% of net profit before tax. This ratio has been approved by the sixth meeting of the eighth session of the company's board of directors and is planned

to be submitted to the shareholders' meeting for approval in 2025 . The Company considers the talent conditions required for the Company's operation and development and submits the salary and remuneration to the Remuneration Committee for review and approval by the Board of Directors in accordance with the scope of job responsibilities. In the performance evaluation, the Company implements a performance appraisal system for managers. The evaluation of this system includes the value of the individual's overall performance to the organization, the ability to cooperate with members and team spirit, the risk of poor performance, whether there is work potential, and promotion evaluation. The scoring mechanism includes category selection and score evaluation, and the principle of payment is based on comprehensive considerations such as the target achievement rate of the management department and the company's profitability, so as to build a reasonable, fair, incentive and business performance-linked compensation structure.

(2) Relationship with operating performance and future risks:

The Company's managers' performance evaluation is based on the principle of risk management to ensure that possible risks within the scope of their duties are managed and prevented. Rating results are determined based on actual performance and are linked to relevant rewards. The relevant remuneration payment standards and systems are based on the company's overall operating conditions as the main consideration, and the payment standards are determined based on performance achievement rate and contribution. We also refer to the industry salary standards to ensure that the remuneration of the company's management is competitive in the industry so as to retain outstanding management talents.

In line with the company's ESG policy and sustainable development, it is planned to link ESG performance with the remuneration of the company's senior managers. The performance evaluation items include but are not limited to the following:

(1) Financial indicators, accounting for 90%, are based on the following achievement rates: department target achievement rate, operating income, ROA, EPS, etc.

(2) Sustainable development indicators, accounting for 10%, including:

Environmental aspect (E): Greenhouse gas inventory and certification, energy management.

Social dimension (S): community care participation, implementation of labor laws, and employee health management.

Corporate governance aspect (G): Strengthen communication channels with stakeholders and investor relationship management.

Important decisions made by management are based on a consideration of various risk factors. The performance of related decisions is reflected in the company's profitability. In addition to the linkage with the performance bonuses of business departments, it is also reflected in the distribution of annual year-end bonuses. The remuneration of the company's managers is reviewed by the Remuneration Committee and submitted to the Board of Directors for approval before being paid and reviewed and adjusted in a timely

manner to comply with the remuneration policy and the spirit of sustainable operation of the company.

Proportion of directors' remuneration and general manager and deputy general manager's remuneration in the company's net profit after tax in the most recent two years

Unit: NT\$ thousand ; %

project job title	The Company				Consolidated financial statements for all companies			
	2023		2024		2023		2024	
	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax	lump sum	Proportion of net profit after tax
Directors' remuneration	5,382	4.32%	7,309	3.65%	5,779	4.64%	7,515	3.76%
Remuneration of directors and employees	15,931	12.79%	28,746	14.37%	15,931	12.79%	28,971	14.48%
Remuneration of General Manager and Deputy General Manager	24,427	19.61%	34,476	17.23%	26,765	21.49%	37,350	18.67%
Net profit after tax	124,557		200,097		124,557		200,097	

Note: The net profit after tax in 2024 increased compared to 2023, so the proportion of related remuneration payment increased.

In 2024, the Board of Directors approved a fixed monthly travel allowance for independent directors, so the amount increased:

As net profit increased, directors' remuneration also increased accordingly.

The difference in the remuneration amounts of the general manager and the deputy general manager is entirely reflected in the distribution of employee remuneration. The employee remuneration for 2014 has not yet been approved by the shareholders' meeting, so the distribution estimate is temporarily based on the proposed number.

2.2 Corporate Governance Operation

(I) Information on the operation of the board of directors

The Board of Directors held 7 meetings in fiscal year 2024 (A) , and the attendance of directors and supervisors was as follows:

job title	Name (Note 1)	Actual attendance Number of times (B)	Delegated Attendance frequency	Actual output (column) Attendance rate (%) 【 B / A 】 (Note 2)	Remark
Chairman	Minsheng Medical Control Co., Ltd. Representative : Yang Hongren	7	0	100%	none
Vice President Chairman	Minsheng Medical Control Co., Ltd. Representative : Xu Shengxin	7	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Liu Qingwen	7	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Sun Zhili	7	0	100%	none
director	Minsheng Medical Control Co., Ltd. Representative : Chen Wenzhong	7	0	100%	none
director	Rong Yang Management Consultants Limited Representative: Zhang Changrong	7	0	100%	none
director	Yang Chen Caibi	4	3	57.14%	none
independent director	Wu Genzai	7	0	100%	none
independent director	Li Shuxing	7	0	100%	none
independent director	Chen Houming	7	0	100%	none
independent director	Yao Xiubi	7	0	100%	none

Other matters that should be recorded:

一、 If the operation of the board of directors involves any of the following circumstances, the date, period, content of the proposals, opinions of all independent directors, and the company's handling of the opinions of the independent directors shall be stated.

(一) The Company has established an Audit Committee. All matters listed in Article 14-3 of the Securities and Exchange Act shall be reviewed and approved by the Audit Committee before being submitted to the Board of Directors for resolution. For details, please refer to Pages 35-36 , Other Matters to be Recorded by the Audit Committee 1. (I) Matters listed in Article 14-5 of the Securities and Exchange Act.

(二) In addition to the above matters, other board meeting decisions that have been objected to or reserved by independent directors and have records or written statements
Item: None.

二、The implementation of directors' recusal of resolutions with conflicts of interest shall state the director's name, resolution content, reason for recusal and voting participation:

Board of Directors date	Period	Contents of the proposal	Avoidance of interest and reasons	Voting situation
2024/12/21	5th Session of the 8th Session	Donated NT\$1 million to the United Medical Foundation	In this case, Director Yang Hongren had a conflict of interest and therefore avoided the issue.	The Acting Chairman consulted with the other directors present and passed the resolution
2024/12/21	5th Session of the 8th Session	Principles for the distribution of year-end bonuses to managers of the company	In this case, Directors Yang Hongren and Liu Qingwen avoided conflicts of interest because of conflicts of interest.	The Acting Chairman consulted with the other directors present and passed the resolution

3. Listed or OTC companies shall disclose information such as the evaluation cycle and period, evaluation scope, method and content of the board of directors' self-evaluation (or peer evaluation), and the daily implementation status.

Evaluation cycle (Note 1)	Evaluation period (Note 2)	Scope of assessment (Note 3)	Evaluation method (Note 4)	Evaluation Content (Note 5)
Performed once a year	January 1, 2024 to December 31, 2024	the board of directors, functional committees and individual directors	Self-evaluation by the board of directors and by board members	1. Board Performance Evaluation : A. Degree of participation in company operations B. Improve the quality of board decision-making C. Board Composition and Structure D. Election and Continuing Education of Directors E. Internal control. 2. Individual board member performance evaluation A. Understanding of company goals and tasks B. Awareness of directors' responsibilities C. Degree of participation in company operations D. Internal relationship management and communication

				E. Professional and Continuing Education of Directors F. Internal Control 3. Functional Committee Performance Evaluation A. Degree of participation in company operations B. Recognition of functional committee responsibilities C. Improve the decision-making quality of functional committees D. Composition of functional committees and selection of members E. Internal Control	
--	--	--	--	--	--

Note 1: This is the execution cycle of the board evaluation, for example: once a year.

Note 2: This is the period covered by the board evaluation, for example: evaluating the performance of the board of directors from January 1, 2019 to December 31, 2019.

Note 3: The scope of the evaluation includes the performance evaluation of the Board of Directors, individual directors and functional committees.

Note 4: Evaluation methods include internal self-evaluation by the Board, self-evaluation by directors, peer evaluation, and performance evaluation by external professional institutions, experts or other appropriate methods.

Note 5: The assessment content shall include at least the following items according to the assessment scope:

- (1) Board performance evaluation: at least including the degree of participation in the company's operations, the quality of the board's decision-making, the composition and structure of the board, the selection and continuing education of directors, and internal control.
- (2) Performance evaluation of individual directors: at least including the understanding of the company's goals and tasks, the director's understanding of responsibilities, the degree of participation in the company's operations, the management of internal relationships and communication, the director's professional and continuing education, and internal control.
- (3) Functional committee performance evaluation: level of participation in company operations, awareness of functional committee responsibilities, quality of functional committee decision-making, composition of functional committees and selection of members, internal control, etc.

Implementation of the Board of Directors' Evaluation : During the 2024 Board of Directors' Performance Evaluation and Assessment period from January 1 to December 31, 2024, 11 self-evaluation questionnaires were issued to board members and 11 were collected, with an average self-evaluation score of 97.9. The performance appraisal self-assessment questionnaires were sent out to the Board of Directors, Audit Committee, Remuneration Committee and Sustainable Development Committee, and were scored by the corporate governance unit. The performance appraisal self-assessment score of the Board of Directors was 98.9 points, and the performance appraisal self-assessment scores of the Audit Committee, Remuneration Committee and Sustainable Development Committee were 100 points, 100 points and 99.3 points respectively. The results were reported at the 6th meeting of the 8th Board of Directors on March 14, 2025.

4. Strengthening the functions of the board of directors: The goals for strengthening the functions of the board of directors in the current year and the most recent year (e.g., establishing an audit committee, improving information transparency, etc.) and an evaluation of the implementation status.

1. The Company established an Audit Committee on June 27, 2018 to monitor and improve the quality of decision-making by the Board of Directors.
2. In terms of strengthening the functions of the board of directors: the company has already formulated the "Board of Directors Meeting Rules", "Audit Committee Organization Charter", "Remuneration Committee Organization Charter" and "Board of Directors and Functional Committee Performance Evaluation Method", and the operation, evaluation and assessment of the board of directors and functional committees are all carried out in accordance with them.
3. In terms of improving information transparency: the company has spokespersons and deputy spokespersons to respond to external inquiries, and has set up a company website

(<https://www.share-hope.com/>), which includes: business development, investor relations, corporate governance, stakeholders, ESG sustainable development and other areas.

4. In May 2019, the "Standard Operating Procedures for Handling Directors' Requests" were formulated, and in November 2011, a corporate governance director was appointed to assist directors in obtaining appropriate and sufficient information on company operations and to provide the latest information on amendments to laws and regulations related to corporate governance.
5. In compliance with regulatory requirements, the Company held two director training courses on August 9 and November 10, 2024, in order to enable directors to meet the annual training hours requirement.

Note 1 : If the director or supervisor is a legal person, the name of the legal person shareholder and the name of its representative shall be disclosed.

Note 2 : (1) If a director or supervisor resigns before the end of the year, the date of resignation shall be noted in the remarks column. The actual attendance rate (%) shall be calculated based on the number of board meetings held during his/her tenure and the number of his /her actual attendance .

- (2) If there is a re-election of directors and supervisors before the end of the year, both the new and old directors and supervisors should be listed, and the remarks column should indicate whether the director and supervisor is the old, new or re-elected director and supervisor and the date of re-election. The actual attendance rate (%) is calculated based on the number of board meetings held during the term of office and the number of actual attendances .

(II) Operation of the audit committee or participation of supervisors in the operation of the board of directors

1. The Company established an Audit Committee at its June 27, 2018, general meeting of shareholders in accordance with Article 14-4 of the Securities and Exchange Act.
2. Annual work priorities of the Audit Committee

The Company's Audit Committee is composed of four independent directors. The main purpose of the Audit Committee is to supervise the fair presentation of the Company's financial statements , the selection (dismissal) and independence and performance of the certifying accountants, the effective implementation of internal controls, compliance with relevant laws and regulations, and the control of existing or potential risks. The annual work highlights are summarized as follows :

(1) Review financial reports

The board of directors prepared the company's 2024 annual business report, financial statements and profit distribution proposal, among which the financial statements have been audited by Anhou Jianye Joint Accounting Firm and an audit report has been issued. The above business report, financial statements and profit distribution proposal have been reviewed by this Audit Committee and are considered to be in good condition .

(2) Review the effectiveness of internal control

The Audit Committee reviews the procedures and implementation results of the company's internal control self-assessment system and reviews the audit department's audit reports, including risk management and legal compliance. The Audit Director regularly meets with the convener of the Audit Committee to understand the problems that may be faced in the internal audit execution review process. Therefore, the Audit Committee believes that the company's risk management and internal control systems are effective and the company has adopted necessary control mechanisms to monitor and correct violations .

(3) Review the independence and performance evaluation of the certified

public accountants

The Audit Committee evaluates the independence and competence of its certified public accountants every year. In addition to requiring the certified public accountants to provide "independence statements" and "audit quality indicators (AQIs)", the Audit Committee also prepares an independence evaluation form and 13 AQI indicators for evaluation based on the contents of the Republic of China's Certified Public Accountants' Professional Ethics Bulletin No. 10 "Independence of Audits and Reviews". The results of the most recent year's evaluation were discussed and approved by the Audit Committee on March 14, 2025, and submitted to the Board of Directors on March 14, 2025 to approve the independence and competence evaluation of the accountants.

(4) Supervision of legal compliance and risk control

The Audit Committee shall review in advance the Company's major investment benefits and possible risks of asset transactions, the appointment and removal of audit supervisors, endorsements and guarantees, and report the results of the review to the Board of Directors.

3. The term of office of the current Audit Committee is from June 24, 2024 to June 23, 2027.

The operation is as follows:

The Audit Committee held 6 meetings (A), with independent directors attending as follows:

job title	Name	Actual attendance (B)	Number of delegated attendances	Actual attendance rate (%) (B/A)(Note)	Remark
Independent Director	Wu Genzai	6	0	100%	none
Independent Director	Li Shuxing	6	0	100%	none
Independent Director	Chen Houming	6	0	100%	none
Independent Director	Yao Xiubi	6	0	100 %	none

Other matters that should be recorded:

1. If the operation of the Audit Committee involves any of the following circumstances , the date , period, content of the board of directors meeting, the Audit Committee's resolution, and the company's handling of the Audit Committee's opinion shall be stated.

(1) Matters listed in Article 14-5 of the Securities and Exchange Act :

Audit Committee Date	Period	Contents of the proposal	Audit Committee Decision Results	The Company's Response to the Audit Committee's Opinions
2024.03.15	The 16th Session of the Second Session	<ol style="list-style-type: none"> 1. 2023 annual business report and financial statements. 2. The 2024 CPA Independence and Competence Assessment Case. 3. 2024 CPA appointment case. 4. Review of the internal control system statement. 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
2024.05.10	The 17th session of the 2nd session	<ol style="list-style-type: none"> 1. First quarter consolidated financial statements for 2024. 2. Profit distribution plan for fiscal year 2023. 3. A case of issuing new shares by converting surplus into capital. 4. Proposed proposal to lift the non-competition restrictions on newly elected directors (including independent directors). 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
2024.08.09	The 1st Session of the 3rd Session	<ol style="list-style-type: none"> 1. Second quarter consolidated financial statements for 2024. 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
		<ol style="list-style-type: none"> 2. It is proposed to abandon the cash capital increase and new share issuance case of its important subsidiary Yueshi Health (Stock) Co., Ltd. 	Please provide additional explanation before discussing	The board of directors decided to ask the management team to provide additional explanations before proposing a new

				proposal
2024.11.08	The 2nd Session of the 3rd Session	<ol style="list-style-type: none"> 1. Third quarter consolidated financial statements for 2024. 2. Revised the company's "Internal Control System" and "Internal Audit Implementation Rules". 3. Independent expert appointment case. 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
2024.12.06	The 3rd Session	<ol style="list-style-type: none"> 1. Sale of the Dayuan Minsheng Hospital building. 2. The merger of our company and Smart Medical City Co., Ltd. 3. Investment project for the decoration and equipment of the "Smart Medical Residence" in the Smart Medical City Building. 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
2024.12.21	The 4th Session of the 3rd Session	<ol style="list-style-type: none"> 1. Formulate the 2025 annual audit plan. 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.
2025.03.14	The 5th Session of the 3rd Session	<ol style="list-style-type: none"> 1、2024 Annual Business Report and Financial Statements. 2、Profit distribution plan for fiscal year 2024. 3、A case of issuing new shares by converting surplus into capital. 4、The 2025 CPA Independence and Competence Assessment Case. 5、2025 CPA appointment case. 6、Review of the internal control system statement. 7、Revised the company's "Internal Control System" and "Internal Audit Implementation Rules". 	Approved as per the proposal	After being submitted to the board of directors for discussion, the resolution was passed.

(2) In addition to the above matters, other matters that have not been approved by the Audit Committee but have been agreed upon by more than two-thirds of all directors : None.

2. The independent director's recusal of a proposal in which he has a conflict of interest shall be clearly stated, including the independent director's name, proposal content, reason for recusal and voting participation : None .

3. The communication between the independent directors and the internal audit director and the accountant (including the major matters, methods and results of communication on the company's financial and business conditions).

1. Communication between independent directors and audit supervisors

In addition to submitting monthly audit reports to independent directors to report on the implementation of internal audits, the company's internal audit director regularly reports audit results and improvements to internal control deficiencies to the Audit Committee. If a major violation is found or the company is at risk of suffering major damage, it will be reported to the Audit Committee members immediately.

The main communication situations are summarized as follows, and none of the independent directors expressed any objection.

(1) Communication with the Audit Committee:

date	Communication focus
2024/3/15	1. Implementation status of audit work from October to December 2023. 2. 2023 Internal Control System Self-Assessment Report.
2024/5/10	Implementation status of audit work in the first quarter of 2024 .
2024/8/9	Implementation status of audit work in the second quarter of 2024 .
2024/11/8	1. Implementation status of audit work in the third quarter of 2024 . 2. Revised the company's "Internal Control System" and "Internal Audit Implementation Rules" .
2024/12/21	2025 Annual Audit Plan.
2025/3/14	1. Implementation status of audit work in the fourth quarter of 2024 . 2. 2024 year internal control system self-assessment report. 3. Revised the company's "Internal Control System" and "Internal Audit Implementation Rules" .

(2) Communicate with independent directors individually:

date	Communication focus
2024/3/11	1. Implementation status of audit work from October to December 2023. 2. Self-assessment report on the internal control system in 2023.
2024/5/7	Implementation status of audit work in the first quarter of 2024.
2024/8/5	Implementation status of audit work in the second quarter of 2024.
2024/11/8	1. Implementation status of audit work in the third quarter of 2024 . 2. Revised the company's "Internal Control System" and "Internal Audit Implementation Rules" .
2024/12/21	2025 Annual Audit Plan.
2025/3/14	1. Implementation status of audit work in the fourth quarter of 2024 . 2. 2024year internal control system self-assessment report. 3. Revised the company's " Internal Control System" and "Internal Audit Implementation Rules" .

2. Communication between independent directors and certified public accountants

The Company's certified public accountants regularly report to the Audit Committee the results of the annual financial statement audit or review, as well as other communication matters required by relevant laws and regulations. If there are special circumstances, they will also report to the Audit Committee members immediately.

The main communications between the independent directors and the certifying accountants in 2024 are summarized as follows. None of the independent directors expressed any objection .

date	Communication focus
2024/3/15 Audit Committee, Board of Directors	1. Audit results of the 2023 annual financial statements and consolidated financial statements. 2. Passed the independence and competency assessment of our company's certified accountants . 3. The accountants discussed and communicated with the participants based on their questions.
2024/5/10 Audit Committee, Board of Directors	1. quarter of 2024 . 2. The accountants discussed and communicated with the participants based on their questions.
2024/8/9 Audit Committee, Board of Directors	1. quarter of 2024 . 2. The accountants discussed and communicated with the participants based on their questions.
2024/11/8 Audit Committee, Board of Directors	1. third quarter of 2024 . 2. The accountants discussed and communicated with the participants based on their questions.
2025/3/14 Audit Committee, Board of Directors	1. 11. Audit results of the annual financial statements and consolidated financial statements. 2. Passed the independence and competency assessment of our company's certified accountants . 3. The accountants discussed and communicated with the participants based on their questions.

3. Communication between independent directors, audit supervisors and accountants

date	Communication focus
2024/3/ 15	2023 Annual consolidated and individual financial report results and internal control audit status report , and discuss and communicate on key audit items , implementation status and results .
2024/11/8	Annual audit plan - communication of audit scope and matters of concern (including key audit matters).
2025/3/14	2024Annual consolidated and individual financial report results and internal control audit status report , and discuss and communicate on key audit items , implementation status and results .

Continuing education for directors and supervisors

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
Legal representative	Yang Hongren	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Legal representative	Xu Shengxin	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Legal representative	Liu Qingwen	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Legal representative	Sun Zhili	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/09/03	China Independent Directors Association	From ESG transformation to impact investment and business opportunity capture	3
		2024/09/26	China Independent Directors Association	Introduction to the carbon pricing and trading mechanism and the latest IFRs international sustainability standards (S1 & S2)	3
		2024/09/27	Taiwan Institute of Financial Research	Corporate Governance Forum #83	3
		2024/10/01	China Independent Directors Association	【ESG Sustainability Forum】Win-win situation for environment and	3

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
				economy in 2024: Taiwan's ESG practice path	
		2024/11/06	China Intangible Assets and Enterprise Evaluation Association	2024 ESG and International Intellectual Property Evaluation and Operation Practice Summit Forum	4
Legal representative	Chen Wenzhong	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Legal representative	Zhang Changrong	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
director	Yang Chen Caibi	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Independent Director	Wu Genzai	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Independent Director	Li Shuxing	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3

Directors and Supervisors	Name	Further studies date	Organizer	Course Title	Study Hours
		2024/09/13	China Independent Directors Association	A new path for corporate net-zero transformation! The hidden force of carbon reduction: ocean blue carbon	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
		2024/11/29	China Independent Directors Association	Information security governance under the trend of financial technology	3
Independent Director	Chen Houming	2024/08/02	Cross-Strait Business Development Foundation	Sustainability equals innovation_Value management trends under the net zero challenge	3
		2024/08/02	Cross-Strait Business Development Foundation	Discussing the natural positive growth of enterprises from the perspective of the COP28 theme	3
		2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3
Independent Director	Yao Xiubi	2024/08/09	China Corporate Governance Association	Innovation, digital technology and competitive advantage	3
		2024/11/08	China Corporate Governance Association	How the board of directors supervises the post-merger integration and establishment of management mechanisms	3

(III) Corporate governance operations and differences between the corporate governance practices of listed and OTC companies and their causes

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
1. Has the company formulated and disclosed its corporate governance code of practice in accordance with the corporate governance code of practice for listed and OTC companies?	√		<p>1. The Company has formulated its own "Corporate Governance Code" in accordance with the "Corporate Governance Practice Guidelines for Listed Companies " and it was approved by the 19th meeting of the 4th Board of Directors on March 18, 2015.</p> <p>2. The Company approved the revision of the "Corporate Governance Code " at the third meeting of the eighth board of directors on November 8 , 2024 .</p> <p>3. The Company's current operating methods are in line with the spirit of the "Code of Practice for Corporate Governance of Listed Companies". Based on the "Code of Practice for Corporate Governance of Listed Companies" and taking into account the actual operating needs of the Company, the Company has established "Rules of Procedure for Board Meetings", "Rules of Procedure for Shareholder Meetings", "Code of Ethical Conduct", "Director Election Methods", "Corporate Governance Code", " Sustainable Development Code of Practice", "Integrity Management Operating Procedures and Behavior Guidelines" and other methods, requiring all employees to strictly comply with the regulations.</p> <p>4. The Company's corporate governance code and various related corporate governance measures have been disclosed on the Company's website, annual</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			report and public information observatory. Investors can download them at the Company's website\Corporate Governance\Corporate Governance Regulations.	
2. Company Equity Structure and Shareholders' Equity (1) Has the company established internal operating procedures to handle shareholder suggestions, doubts, disputes and litigation, and has it implemented them in accordance with the procedures?	√		<p>1. The Company has formulated "Spokesperson System Specifications", whereby the spokesperson or proxy spokesperson will work with the shareholder agency to jointly handle shareholders' suggestions and questions.</p> <p>2. If there are any shareholder disputes or litigations, the Legal Affairs Office will be responsible for handling them together with the company's legal advisors and appointed lawyers.</p> <p>3. Our company's website\ Investor Relations \ Investor Services contains specific contacts and contact information to specifically respond to investors' questions.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies
(2) Does the company have a list of the major shareholders who actually control the company and the ultimate controllers of the major shareholders?	√		<p>1. The Company has designated a dedicated person in the Finance Department to update the major shareholders who actually control the company with the stock affairs agency at any time; and to establish communication channels with relevant personnel designated by the major shareholders to obtain information about the major shareholders.</p> <p>2. Economic Affairs' business registration website regularly to check the major corporate shareholders and the change registration status of their corporate shareholders.</p> <p>3. The major shareholders of the legal person shareholders of the Company, and the major shareholders and shareholdings of the major shareholders who are legal</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			persons, are disclosed on the Company's website, annual report and public information observation station . Investors can go to the Company's website\ Investor Relations \ Shareholders' Meeting Information\Top Ten Shareholders for enquiries .	
(3) Has the company established and implemented risk control and firewall mechanisms with related companies?	√		<p>1. The Company has formulated "Subsidiary Supervision Operation Guidelines" and " Financial and Business Related Operation Standards among Related Parties " to ensure that the invested businesses have clear strategies and specific operation standards in terms of operation, finance and business management . In addition to requiring that business dealings between the Company and its affiliated companies must comply with the principles of fairness, openness and impartiality , the Company also requires and assists its subsidiaries in establishing sound accounting, financial systems, important operational controls , etc., and guides them in establishing internal control systems .</p> <p>2. The Company's auditors conduct audits on subsidiaries based on the "Annual Audit Plan" to confirm that the subsidiaries' operating activities and related control operations are operating effectively.</p> <p>3. For subsidiaries that have not yet been publicly issued, their major business and financial matters and proposals submitted to the board of directors must be reviewed in advance by the company's investment management unit and responsible supervisor before they can be carried out.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
(iv) Has the company established internal regulations to prohibit company insiders from using undisclosed information in the market to buy or sell securities?	√		<ol style="list-style-type: none"> 1. In order to prevent insiders from using undisclosed market information to buy and sell securities, the Company has formulated "Insider Trading Prevention Management Measures" and requires all personnel to strictly implement them. 2. The Company has amended the "Administrative Measures for Preventing Insider Trading" in accordance with the Financial Supervisory Commission's letter No. 1100373495 issued on December 6, 2021. The amendment was approved by the 6th meeting of the 7th Board of Directors on March 25, 2022, adding new colleagues in charge of stock affairs and the board of directors' meeting, who are responsible for fulfilling the reminder responsibilities for the closed period before the announcement of financial reports. 	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
<p>3. Composition and Responsibilities of the Board of Directors</p> <p>1. Does the board of directors formulate a diversity policy , specific management objectives , and implement them?</p>	√		<p>1. On May 9, 2018, the 22nd meeting of the 5th Board of Directors of our company approved the revision of the "Director Election Rules" . Article 3 of this rule clearly stipulates that the composition of the board of directors should consider the policy of diversity. In addition to the basic conditions, there are also standards for professional qualities, skills, and management capabilities to achieve the purpose of comprehensive supervision.</p> <p>2. The company currently has 11 directors , 36% of whom are employees and 27 % are women . We will continue to work hard to increase the proportion of women directors in the future.</p> <p>3. The Company has four independent directors who possess the professional qualifications and work experience in business management , finance, and accounting required by the Company, which will be of substantial help to the Company in implementing investor protection and strengthening corporate governance. Independent directors account for 33% of the board seats, and their terms of office have not exceeded three terms. They include Wu Genzai, who took office as independent director on June 27, 2018, Li Shuxing, who took office as independent director on June 28, 2019, Chen Houming, who took office on July 30, 2021 , and Yao Xiubi, who took office on June 30, 2023.</p> <p>4. This term has eleven board seats, including seven directors and four independent directors. The diverse work experience and professional qualifications of the board members are complementary. The relevant implementation is shown in the following table, which is disclosed on the company's website and annual report. Investors can go to the company's website\Corporate Governance\Board of Directors\Member Diversity and Professional Competence Matrix for information.</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)										Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies																																																																																																																																																											
	yes	no	Summary																																																																																																																																																																			
			<table><tr><th colspan="11">Implementation of the diversity policy by members of board directors</th></tr><tr><th rowspan="2">Director Name</th><th colspan="10">Core Project</th></tr><tr><th>Staff</th><th>Seniority of Independent Director</th><th>Operational Judgment</th><th>Accounting and Financial Analysis Ability</th><th>Management ability</th><th>Crisis handling ability</th><th>Industry knowledge</th><th>International Market View</th><th>Leadership</th><th>Decision-making capacity</th></tr><tr><td>Yang Hongren</td><td>V</td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Xu Shengxin</td><td></td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Liu Qingxin</td><td>V</td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Sun Zhili</td><td></td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Chen Wenzhong</td><td>V</td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Zhang Changrong</td><td>V</td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Yang Chen Celi</td><td></td><td>0</td><td>V</td><td>V</td><td></td><td></td><td>V</td><td></td><td></td><td>V</td></tr><tr><td>Wu Genxi</td><td></td><td>0</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td></td><td>V</td><td>V</td></tr><tr><td>Li Shuang</td><td></td><td>5</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Chen Houming</td><td></td><td>3</td><td>V</td><td>V</td><td>V</td><td></td><td>V</td><td>V</td><td>V</td><td>V</td></tr><tr><td>Yao Xubi</td><td></td><td>2</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td><td>V</td></tr></table>										Implementation of the diversity policy by members of board directors											Director Name	Core Project										Staff	Seniority of Independent Director	Operational Judgment	Accounting and Financial Analysis Ability	Management ability	Crisis handling ability	Industry knowledge	International Market View	Leadership	Decision-making capacity	Yang Hongren	V	0	V	V	V	V	V	V	V	V	Xu Shengxin		0	V	V	V	V	V	V	V	V	Liu Qingxin	V	0	V	V	V	V	V	V	V	V	Sun Zhili		0	V	V	V	V	V	V	V	V	Chen Wenzhong	V	0	V	V	V	V	V	V	V	V	Zhang Changrong	V	0	V	V	V	V	V	V	V	V	Yang Chen Celi		0	V	V			V			V	Wu Genxi		0	V	V	V	V	V		V	V	Li Shuang		5	V	V	V	V	V	V	V	V	Chen Houming		3	V	V	V		V	V	V	V	Yao Xubi		2	V	V	V	V	V	V	V	V	
Implementation of the diversity policy by members of board directors																																																																																																																																																																						
Director Name	Core Project																																																																																																																																																																					
	Staff	Seniority of Independent Director	Operational Judgment	Accounting and Financial Analysis Ability	Management ability	Crisis handling ability	Industry knowledge	International Market View	Leadership	Decision-making capacity																																																																																																																																																												
Yang Hongren	V	0	V	V	V	V	V	V	V	V																																																																																																																																																												
Xu Shengxin		0	V	V	V	V	V	V	V	V																																																																																																																																																												
Liu Qingxin	V	0	V	V	V	V	V	V	V	V																																																																																																																																																												
Sun Zhili		0	V	V	V	V	V	V	V	V																																																																																																																																																												
Chen Wenzhong	V	0	V	V	V	V	V	V	V	V																																																																																																																																																												
Zhang Changrong	V	0	V	V	V	V	V	V	V	V																																																																																																																																																												
Yang Chen Celi		0	V	V			V			V																																																																																																																																																												
Wu Genxi		0	V	V	V	V	V		V	V																																																																																																																																																												
Li Shuang		5	V	V	V	V	V	V	V	V																																																																																																																																																												
Chen Houming		3	V	V	V		V	V	V	V																																																																																																																																																												
Yao Xubi		2	V	V	V	V	V	V	V	V																																																																																																																																																												
(II) In addition to establishing a salary and remuneration committee and an audit committee in accordance with the law, does the company voluntarily establish other functional committees?	√		<p>1. In addition to the "Remuneration Committee" and "Audit Committee", the company has also set up a " M&A Special Committee " to improve the corporate governance structure . In order to practice corporate social responsibility and achieve the goal of sustainable management, the board of directors approved the establishment of a Sustainable Development Committee on August 9, 2024 .</p> <p>2. On July 6, 2016, the Company passed the " Organizational Rules of the Merger and Acquisition Special Committee " at the 8th meeting of the 5th Board of Directors, and it has been implemented since 2016. On May 10, 2024, the Company passed</p>										Comply with the Code of Practice on Corporate Governance for Listed Companies																																																																																																																																																									

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>the "Organizational Rules of the Sustainability Committee" at the 19th meeting of the 7th Board of Directors , and it has been implemented since 2024 .</p> <p>3. The Company has formulated the "Compensation Committee Organizational Rules", "Audit Committee Organizational Rules" , " Mergers and Acquisitions Special Committee Organizational Rules" and "Sustainability Committee Organizational Rules" , which serve as the management basis for the "Compensation Committee", "Audit Committee" , " Mergers and Acquisitions Special Committee " and " Sustainability Committee " respectively.</p>	
<p>(3) Does the company establish performance evaluation methods for the board of directors and conduct performance evaluations on a regular basis every year? Does the company submit the results of the performance evaluations to the board of directors and use them as a reference for the remuneration and nomination of individual directors?</p>	√		<p>1. The Company approved the "Board of Directors Performance Evaluation Measures" and its evaluation method at the fifth meeting of the fifth board of directors on December 23, 2015, and began to implement the performance evaluation of the Board of Directors and individual directors since 2015.</p> <p>2. In 2018, the Company added performance evaluation of functional committees, and on August 9, 2024 , the 2nd meeting of the 8th Board of Directors approved the revision of the "Performance Evaluation Methods of the Board of Directors and Functional Committees".</p> <p>The performance evaluation method, evaluation approach and evaluation results of the Board of Directors and functional committees are disclosed on the Company's website and annual report . Investors may visit the Company's website\Corporate Governance for inquiries.</p> <p>4. In August 2023, the Company commissioned an external organization, the China</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>Corporate Governance Association , to evaluate the effectiveness of the Board of Directors and issued a performance evaluation report on October 16, 2023.</p> <p>5. The results of the 2023 Board of Directors ' performance evaluation were reported in Item 6 of the 8th Board of Directors' Sixth Meeting on March 14 , 2024 . The assessment period is from January 1, 2023 to December 31, 2023 . The self-assessment questionnaires for the performance appraisal of the board of directors and the self-assessment questionnaires for the performance appraisal of the functional committees are scored by the corporate governance unit. The board of directors' self-assessment score for performance appraisal was 97.9 points, the audit committee's self-assessment score for performance appraisal was 100 points , the remuneration committee's self-assessment score for performance appraisal was 100 points , and the sustainable development committee's self-assessment score for performance appraisal was 99.3 points .</p> <p>6. The Company's "Remuneration Committee" shall determine the remuneration of Board members based on the results of the Board's performance evaluation, as well as each director's attendance rate, industry experience, professional skills, personal performance , the Company's long-term operating performance , and the responsibilities of executive independence.</p> <p>7. The suitability of the members of the Company's Board of Directors shall be determined based on the performance evaluation as described in the preceding paragraph. The list of nominees for each member to serve as a director or</p>	

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			independent director of the Company shall be submitted to the shareholders' meeting for voting after discussion by the Board of Directors.	
4. Does the company regularly assess the independence of its certified public accountants?	√		<p>1. The Company's Audit Committee shall regularly evaluate the independence and suitability of the certifying accountants each year and submit the evaluation results to the Board of Directors.</p> <p>2. The company 's evaluation results were approved by the Audit Committee on March 15 , 2024 , and submitted to the Board of Directors for approval on March 15 , 2024 . The evaluation mechanism is as follows:</p> <p>2.1 . With reference to Article 47 of the Accounting Act and the Code of Ethics for Accounting Professionals No. 10, the Company shall self-assess the independence and competence of accountants based on the independence statement and audit quality indicators (AQIs) provided by the accountants .</p> <p>2.2. There are 15 items in total for the independence assessment, which are described as follows:</p> <p>(1) As of the last visa application, the visa has not been renewed for seven years.</p> <p>(2) Has no significant financial interest in the client.</p> <p>(3) Avoid any inappropriate relationship with the client.</p> <p>(4) Accountants should ensure that their assistants observe honesty ,</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>impartiality and independence.</p> <p>(5) The financial statements of the service agencies within the two years before practicing shall not be audited and certified.</p> <p>(6) The name of the accountant shall not be used by any other person.</p> <p>(7) Does not hold any shares in the Company or its affiliated companies.</p> <p>(8) There is no monetary loan or borrowing between the Company and its affiliated companies.</p> <p>(9) Has no joint investment or profit-sharing relationship with the Company or its affiliated companies.</p> <p>(10) Not holding regular work for the Company or its affiliated companies and receiving a fixed salary.</p> <p>(11) Has no management function involving decision-making for the Company or its affiliates.</p> <p>(12) It does not engage in other businesses that might cause it to lose its independence.</p> <p>(13) No spouse , direct blood relative, direct in-law, or collateral blood relative within the second degree of kinship with any of the Company's management personnel.</p> <p>(14) No commission was received in connection with the business.</p> <p>(15) To date, there has been no disciplinary action or any violation of the</p>	

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>principle of independence.</p> <p>2.3 . The above-mentioned assessment contents are in compliance with the independence and competence of the accountants.</p>	
<p>4. Does the listed company have an appropriate number of qualified corporate governance personnel and has designated a corporate governance supervisor to be responsible for corporate governance- related matters (including but not limited to providing directors and supervisors with information necessary for performing their duties, assisting directors and supervisors in complying with laws and regulations , handling matters related to board and shareholders meetings in accordance with the law , and preparing minutes of board</p>	√		<p>1. In order to cooperate with the Corporate Governance 3.0 issued by the Financial Supervisory Commission and strengthen the functions of the board of directors to enhance the sustainable value of the enterprise , the Company, in accordance with Articles 20 and 23 of the "Main Points for the Establishment and Exercise of Powers of the Board of Directors of OTC Companies", approved the appointment of Deputy General Manager Cai Yufang of the Administration Department as the Director of Corporate Governance at the 18th Meeting of the Seventh Board of Directors on March 15 , 2024 , to assist in handling corporate governance evaluation work. Deputy General Manager Cai Yufang has served as the company's legal director for more than 10 years and is qualified to be the corporate governance director. The main business contents are as follows :</p> <p>1.1 Assist the board of directors in the operation of meeting affairs.</p> <p>1.2 Provide board members with the latest corporate governance-related legal and regulatory revision information.</p> <p>1.3 Promote corporate governance evaluation work.</p> <p>1.4 External Assessment of Executive Board Performance.</p> <p>1.5 Review the qualifications of independent director nominees and report the</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
and shareholders meetings, etc.) ?			<p>results to the board of directors .</p> <p>2. The Board of Directors of the Company has designated the Finance Department to be responsible for the Board of Directors' meeting affairs , and a dedicated person is responsible for coordinating and providing the information required by the directors to perform their duties and matters related to corporate governance , including :</p> <p>2.1 Seven days before the Board of Directors /Audit/Remuneration Committee meeting, the meeting shall be convened with the reason and sufficient meeting materials and notified to each meeting member. The minutes of each meeting shall also be signed or stamped by the chairman and recorder of each meeting , and distributed to each meeting member within 20 days after the meeting and included in the company's important files for safekeeping.</p> <p>2.2 Assist directors to take office and comply with laws and regulations; and assist directors to complete annual training courses.</p> <p>2.3 Provide the company information required by the directors, maintain smooth communication and exchanges between the directors and the supervisors, and assist in arranging communication meetings between the independent directors and the internal audit supervisor, certifying accountants, or supervisors of other internal units to facilitate the independent directors to perform their duties.</p> <p>2.4 In accordance with the latest laws and regulations related to the company's</p>	

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>business areas and corporate governance, revise internal regulations related to corporate governance and submit them to the board of directors for resolution.</p> <p>2.5 Complete the insurance or renewal of the directors ' liability insurance of the Company .</p> <p>2.6 Prepare, hold, and prepare minutes of shareholders' meetings and other stock-related matters, and provide sufficient information to shareholders to ensure that the interests of shareholders are well protected.</p> <p>2.7 Responsible for reviewing the release of important information, ensuring the legality and accuracy of the content of important information, so as to protect the equality of investors' trading information.</p>	
5. Has the company established communication channels with stakeholders (including but not limited to shareholders, employees, customers and suppliers, etc.), set up a stakeholder area on the company website, and appropriately responded to	√		<p>The company is happy to assume corporate social responsibility to its employees , customers , shareholders , suppliers , the community and the overall environment. It not only plays a role in sustainable growth, but also actively implements corporate responsibility. The company has good communication channels and dedicated personnel who are responsible for listening to the needs of various stakeholders, and responding to and tracking the feedback information collected through different communication channels according to the status of the issue. A stakeholder area is set up on the company website. The following are the priority topics and</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies				
	yes	no	Summary					
important corporate social responsibility issues of concern to stakeholders ?			communication status of the Company's stakeholders:					
			Types of interested parties	Priority issues		Communication and response mechanism	Response Department	Contact Window
			Investors	<ul style="list-style-type: none">• Company Vision•Operational performance and financial information•Shareholders' equity•Corporate Governance•Sustainable development strategy•Risk Management•Regulatory compliance•Corporate image		1. Annual report and shareholders meeting : financial performance of the company's operations each year 2. Company website: Investor area updates information from time to time 3. Spokesperson and stock affairs department 4. Public Information Observation Station 5. Legal seminars	<ul style="list-style-type: none">•spokesman•Acting Spokespers on•Stock Affairs	【 spokesman Mr. He (03)346-9595 vincent.ho@share-hope.com
			client	<ul style="list-style-type: none">•Customer Privacy & Satisfaction•Customer rights protection•Customer relationship maintenance•Service		1. Personnel from each business department visit customers from time to time to communicate and understand service quality . 2. Each department	<ul style="list-style-type: none">• Each business department	[Ms. Zheng from General Manager's Office] (03) 336-1508 # 525 A003799@share-hope.com

Evaluation Project	Operation Status (Note)					Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary			
				(product) quality •Information transparency & security	conducts customer satisfaction surveys regularly	
			staff	• Employee compensation and benefits policy • Labor-Management Relations • Talent training and development • Occupational Health and Safety • Employee assessment mechanism	1. Announce company policies and employee benefits from time to time through the company's internal network 2. Set up an employee welfare committee and hold regular meetings every quarter to communicate 3.Hold labor-management meetings once a quarter 4. Provide free health check-up for employees every year 5. Conduct employee performance appraisal every six months 6. Set up an	• Human Resources Office [Ms. Li from the Human Resources Office] (03)346-9595#603-582 shhr@share-hope.com

Evaluation Project	Operation Status (Note)					Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies		
	yes	no	Summary					
					employee mailbox to provide employees with a channel for feedback and complaints			
			Government and competent authorities	<ul style="list-style-type: none">Regulatory complianceCorporate GovernanceCommunication with competent authoritiesRisk Management	1. Government policy advocacy and promotion of related systems 2. Attend relevant units from time to time and participate in the competent authority's seminars/public hearings/policy briefings, etc. 3. Exchange of official documents 4. Cooperate with the competent authorities in supervision and inspection 5. Visit competent authorities and establish direct communication opportunities	<ul style="list-style-type: none">spokesmanActing Spokespersons onAudit Department		【 Ms. Ye from Audit Office 】 (03)346-9595#600 A003976@share-hope.com
			supplier	<ul style="list-style-type: none">Supplier ManagementInformation transparency &	1. Ask suppliers to sign a letter of commitment to honest management	<ul style="list-style-type: none">General Manager's Office		[Ms. Zheng from General Manager's Office] (03)3 36 - 1508 #525 A003799@share-hope.com

Evaluation Project	Operation Status (Note)						Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies	
	yes	no	Summary					
				safety	2. When signing contracts with major suppliers , the content must comply with the company's corporate integrity and business ethics requirements.			
			media	<ul style="list-style-type: none">Corporate imageOperational strategyOperational Performance & Financial InformationSocial responsibility and careCommunicate with the public and investors	1. Conduct two-way communication with the media from time to time through public relations companies to convey the company's business philosophy and important operating strategies to the public and investors. 2. Issue operation-related press releases from time to time 3. Accept media interviews and inquiries from time to time (immediately)	·spokesman · PR company	【 spokesman Mr. He (03)346-9595 vincent.ho@share-hope.com	

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
6. Has the company appointed a professional stock affairs agency to handle shareholders' meeting affairs?	√		The Company has appointed a professional stock affairs agency, "Stock Affairs Agency Department of Qunyi Jinding Securities Co., Ltd." to handle matters related to the shareholders' meeting in order to safeguard the interests of shareholders.	Comply with the Code of Practice on Corporate Governance for Listed Companies
VII. Information Disclosure 1. Does the company have a website to disclose its financial, business and corporate governance information?	√		The Company's corporate governance and financial business information has been disclosed on the Company's website at: http://www.share-hope.com . Investors may inquire on the Company's website.	Comply with the Code of Practice on Corporate Governance for Listed Companies
(2) Does the company adopt other methods of information disclosure (such as setting up an English website, designating a person to be responsible for the collection and disclosure of company	√		<ol style="list-style-type: none"> 1. The company's website has set up an English version for the general public to inquire . 2. All information that should be disclosed in our company is handled by a dedicated person . 3. The briefing and recording files of the legal representative briefing have been disclosed on the company's website. Investors can go to the company's 	Comply with the Code of Practice on Corporate Governance for Listed

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
information, implementing a spokesperson system, placing information on the company website during corporate briefings, etc.)?			<p>website\Investor Relations \Major Information for inquiries.</p> <p>4. The Company implements a spokesperson system. The investing public can use the Company's website\Investor Relations\Investor Services to contact spokespersons and proxy spokespersons by phone or email .</p>	Companies
(3) Does the company announce and file its annual financial report within two months after the end of the fiscal year , and announce and file its first , second , and third quarter financial reports and monthly operating results in advance of the prescribed deadline ?		√	The Company currently reports financial reports and monthly operating conditions on the dates specified in the "Business Matters to be Performed by Issuers of Listed Securities" , but has not yet announced and reported the annual financial report within two months after the end of the fiscal year, nor has it announced the work in advance before the prescribed deadline.	Announcement and reporting must be completed before the deadline specified by law

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
8. Does the company have other important information that is helpful in understanding the operation of corporate governance (including but not limited to employee rights, employee care, investor relations, supplier relations, rights of stakeholders, training for directors and supervisors, implementation of risk management policies and risk measurement standards, implementation of customer policies, and the company's purchase of liability insurance for directors and supervisors, etc.)?	√		<p>1. Important information on the Company's corporate governance operations , including corporate governance regulations, investor relations information, stakeholder priority issues and communication status, ESG sustainable development promotion policies and implementation status, etc., have been disclosed on the Company's website. Investors can visit the Company's website for inquiries.</p> <p>2. Our company website\ Stakeholders \ Stakeholders' priority issues, providing contact information and response mechanisms for employees, suppliers, customers, investors, suppliers, government and regulatory authorities , media, and business ethics.</p> <p>3. The company has always attached great importance to employee rights and employee care , holding regular employee welfare meetings and labor-management meetings every quarter , and providing regular health checks for employees .</p> <p>4. The Company provides multiple channels to enable shareholders , stakeholders and customers to be informed of the Company's operating and financial status in real time , maintaining smooth communication channels and operating well .</p> <p>5. The company adheres to the business philosophy of always being honest and trustworthy, and establishes long-term cooperative relationships with suppliers. Since 2021, we have required suppliers to sign a letter of commitment to honest management. As of 2024, 590 letters of commitment have been signed. .</p>	Comply with the Code of Practice on Corporate Governance for Listed Companies

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
			<p>6. All major proposals concerning the Company's major operating policies , investments , bank financing, endorsements and guarantees, and capital loans are evaluated and analyzed by the responsible units in accordance with the relevant regulations of the Company, and then submitted to the Board of Directors and the Audit Committee for decision, and the supervision and risk control mechanisms are implemented .</p> <p>7. The Company arranges for directors to participate in relevant professional knowledge training from time to time and obtain training hour certificates .</p> <p>8. The Company approved the "Risk Management Code of Practice" at the 12th meeting of the 7th Board of Directors on December 23, 2022 , which includes the Company's risk management policies and procedures, and established a risk management working group under the Audit Committee to promote the work.</p> <p>9. The Company purchases liability insurance for directors and supervisors : On May 10, 2024 , at the 19th meeting of the Seventh Board of Directors, the Company reported on the directors and supervisors liability insurance coverage for 2024. The insurance period was from May 1, 2024 to May 1, 2025 , with a total insured amount of NT\$30 million.</p>	
<p>9. Please explain the improvements that have been made based on the corporate governance evaluation results released by the Corporate Governance Center of the Taiwan Stock Exchange Corporation in the most recent year, and propose priority improvement items and measures for those that have not yet been improved. (Companies not included in the rated list do not need to fill in)</p> <p>Our company's 2024 (11th) corporate governance evaluation results ranked in the 6%~20% range among OTC companies, with a total score of 80.94. The</p>				

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
score has improved by 4.84 points compared with the previous year. The review is as follows: <u>Improved indicators :</u> 1. 2.14 The company shall establish a non-statutory functional committee such as a sustainable development committee, with no fewer than three members, more than half of whom shall be independent directors, and at least one member shall have the professional capabilities required of the committee, and disclose its composition, responsibilities and operation status on the company's website. 2. 2.27 The Company shall formulate an intellectual property management plan that is linked to its operational objectives, disclose the implementation status on the Company's website, and report to the Board of Directors at least once a year. 3. 3.18 The Company shall establish an English company website which shall include financial, business and corporate governance related information. 4. 4.1 The company shall set up a dedicated (or part-time) sustainable development unit to conduct risk assessments on environmental, social or corporate governance issues related to the company's operations based on the principle of materiality, formulate relevant risk management policies or strategies, and the board of directors shall supervise the promotion of sustainable development and disclose it on the company's website and annual report. 5. 4.17 Disclose the supplier management policy on the company website, requiring suppliers to comply with relevant regulations on issues such as environmental protection, occupational safety and health, or labor human rights, and explain the implementation status. 6. 4.21 The Company shall assess the risks or opportunities to the community and take corresponding measures, and shall disclose the specific measures taken and the results of their implementation on the Company's website. <u>Specific improvement plans have been drawn up :</u> 1. The Company conducted a greenhouse gas inventory in 2014 and an external greenhouse gas verification in 2015, disclosing greenhouse gas emissions. 2. The Company prepared the 2014 Sustainability Report to disclose the status of promoting sustainable development.				

Evaluation Project	Operation Status (Note)			Differences and reasons from the Code of Corporate Governance Practice for listed and OTC companies
	yes	no	Summary	
3. The Company will be committed to employee training to enhance the career capabilities of employees and conduct regular employee satisfaction surveys.				

Note: Regardless of whether you tick “Yes” or “No”, the operating status should be stated in the summary column.

(IV) If a company has established a remuneration committee, it shall disclose its composition, responsibilities and operation:

1. Information of members of the Remuneration Committee

April 15,2025

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
Independent Director (convener)	Li Shuxing	<ol style="list-style-type: none"> Period of office: 08/09/2024-06/23/2027. Current position: Professor of Digital Financial Technology Department, Chang Gung University Professor Emeritus, Department of Accounting, National Taiwan University Major: PhD in Accounting from New York University; Lecturer at public or private colleges and universities with relevant majors required by our company's business: Professional experience in business, finance, accounting and other areas required by our company's business. Experience: Chair Professor of the Department of Accounting and Dean of the School of Management, Tunghai University Vice President for Finance/Dean of College of Management, National Taiwan University Chairman of the Chinese Accounting Education Association Independent Director Li has a background in accounting and has many years of experience as an independent director in 	<ol style="list-style-type: none"> The Company has obtained the election statement of independent director Li Shuxing and complied with all provisions of the Securities and Exchange Act. Meet the following independence qualifications: (1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies. (2) The person and his/her spouse's second degree relatives do not hold any company shares. (3) No circumstances are covered by the provisions of Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation and Remuneration Committee of Companies with Stocks Listed or 	3

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		other industries. He is able to share his experience in operating the Company's diverse industries and provide management decision-making advice in industry integration analysis, risk management, etc. Therefore, when performing the duties of an independent director, his expertise can be leveraged to improve the quality of the Compensation Committee's operations.	Traded on Over-the-Counter Markets. (4) None of the circumstances set out in Article 30 of the Company Act exists. 3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .	
Independent Director	Wu Genzai	<ol style="list-style-type: none"> 1. Period of office: 08/09/2024-06/23/2027 . 2. Current position: Director of Zhanyu United Accounting Firm. 3. Major: Department of Accounting, National Taiwan University (passed the 1991 Higher Certified Public Accountant Examination); has working experience in accounting, finance and the business requirements of the company. 4. Experience: Auditor/audit team leader at Deloitte Touche Tohmatsu CPA LLP, CFO of manufacturing industry, director of management department, partner accountant at Chengxin CPA LLP, special lecturer at the Small and Medium Enterprises Department of the Ministry of Economic Affairs, and corporate management consulting company. 5. Mr. Wu Du has extensive experience in accounting practice. Through his 	<ol style="list-style-type: none"> 1. The Company has obtained Wu Genzai's election statement as independent director and complied with all provisions of the Securities and Exchange Act. 2. Meet the following independence qualifications: <ol style="list-style-type: none"> (1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies. (2) The person and his/her spouse's second degree relatives do not hold any company shares. (3) No circumstances are covered by the provisions of Article 6, Paragraph 1, Items 5-8 of the 	0

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		expertise, he can provide insightful guidance in all aspects of data review and can offer appropriate suggestions. Therefore, when exercising the duties of an independent director, the quality of the operation of the remuneration committee must be improved.	<p>Regulations Governing the Establishment and Exercise of Powers of the Compensation and Remuneration Committee of Companies with Stocks Listed or Traded on Over-the-Counter Markets.</p> <p>(4) None of the circumstances set out in Article 30 of the Company Act exists.</p> <p>3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .</p>	
Independent Director	Chen Houming	<p>1. 2024/08/09-2027/06/23.</p> <p>2. Professor Emeritus, Department of International Business, National Taiwan University .</p> <p>3. Major: PhD in Marketing from the Graduate School of Business at National Taiwan University; Lecturer at public or private colleges and universities with majors related to our company's business; Professional experience in business and our company's business.</p> <p>4. Experience: Dean of the College of Social Sciences and Management, National Central University, Dean of the College of Social Sciences and Management, National Chung Hsing University, President of the Business Development Research</p>	<p>1. The Company has obtained the election statement of independent director Chen Houming and complied with all provisions of the Securities and Exchange Act.</p> <p>2. Meet the following independence qualifications:</p> <p>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its affiliated companies.</p> <p>(2) The person and his/her spouse's second degree relatives do not hold</p>	3

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		<p>Institute, Chairman of the Chinese Negotiation Management Association, Chairman of the Taiwan Marketing Science Association</p> <p>5. Independent Director Chen has management expertise and experience as an independent director in other industries. He can provide diverse suggestions on operations and management in a timely manner and give clear guidance on practical operations. Therefore, when performing the duties of an independent director, he can improve the quality of the operation of the Compensation Committee.</p>	<p>any company shares.</p> <p>(3) The circumstances specified in Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation Committee of a company that has no shares and whose stocks are not listed or traded on the over-the-counter market.</p> <p>(4) There is no any of the circumstances specified in Article 30 of the Company Act.</p> <p>3. Not receiving compensation for business, legal, financial, accounting, etc. services provided by the Company or its affiliates .</p>	
Independent Director	Yao Xiubi	<p>1.Term of office: 2024/08/09-2027/06/23.</p> <p>2. Current position: Manager of Strategic Investment Department of Yongsheng Optical Co., Ltd. Director of Formosa Optical Technology Co., Ltd. Director of Haichang Biochemical Technology Co., Ltd. Director of Yujiasheng Co., Ltd.</p> <p>3. Major: Department of Finance, National Chung Cheng University Master of Business Administration from Tunghai University, EPOST,</p>	<p>1. The Company has obtained the election statement of Yao Xiubi as independent director and complied with all provisions of the Securities and Exchange Act.</p> <p>2. Meet the following independence qualifications:</p> <p>(1) The individual and his/her spouse's relatives within the second degree of kinship are not directors, supervisors or employees of the company or its</p>	0

Separation of body (Note 1)	condition Name	Professional qualifications and experience (Note 2)	Independence conditions met (Note 3)	Number of companies concurrently serving as members of the remuneration committee of other publicly traded companies
		<p>University of Missouri - Columbia</p> <p>4. Experience: Ginko International Co.,LTD Acting Spokesperson Director of the Chairman's Office of Yongsheng Optical Co., Ltd.</p> <p>5. Independent Director Yao has professional financial knowledge and rich practical experience in company operations and investment management. He can provide industry experience and appropriate management advice and guidance. Therefore, when exercising the duties of an independent director, the quality of the operation of the remuneration committee must be improved.</p>	<p>affiliated companies.</p> <p>(2) The person and his/her spouse's second degree relatives do not hold any company shares.</p> <p>(3) The circumstances specified in Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Powers of the Compensation Committee of a company that has no shares and whose stocks are not listed or traded on the over-the-counter market.</p> <p>(4) None of the circumstances set out in Article 30 of the Company Act exists.</p> <p>3. Not receiving remuneration for business, legal, financial, accounting, etc. services provided by the Company or its affiliated companies .</p>	

Note 1: Please specify in the table the relevant years of service, professional qualifications and experience, and independence of each member of the Remuneration Committee. If the member is an independent director, please indicate the relevant contents of Appendix 1 (Information of Directors and Supervisors (I)) on page 16 . Please fill in whether you are an independent director or others (if you are the convener, please add a note)

Note 2: Professional qualifications and experience: State the professional qualifications and experience of individual members of the Remuneration Committee.

Note 3: Independence: Describe whether the members of the Remuneration Committee meet the conditions for independence, including but not limited to whether the member, his/her spouse, or relatives within the second degree of kinship serve as directors, supervisors, or employees of the company or its affiliated companies; the number and proportion of company shares held by the member, his/her spouse, or relatives within the second degree of kinship (or using the names of others); whether the member serves as a director, supervisor , or employee of a company with a specific relationship with

the company (refer to Article 6, Paragraph 1, Items 5-8 of the Regulations Governing the Establishment and Exercise of Rights of Remuneration Committees of Companies Listed or Traded at Over-the-Counter Securities Firms); and the amount of remuneration received for providing business, legal, financial, accounting, and other services to the company or its affiliated companies in the past two years.

Note 4: For disclosure methods, please refer to the best practice reference examples on the Taiwan Stock Exchange Corporate Governance Center website.

2. The Remuneration Committee of the Company shall, with the care of a good manager, faithfully perform the following duties and powers and submit its recommendations to the Board of Directors for discussion:

- (1) Establish and regularly review the performance evaluation methods and salary and remuneration policies, systems, standards and structures of the Company's directors and managers.
- (2) Regularly evaluate and determine the remuneration of directors and managers.

3. Information on the operation of the Remuneration Committee

- (1) The Company's Remuneration Committee has four members .
- (2) Term of office of the Sixth Committee: August 9, 2024 to June 23, 2027.
- (3) The number of meetings held in the most recent year was 2 , with the date range being (August 9 , 2024 - March 14, 2025) and the attendance was as follows :

job title	Name	Actual attendance (B)	Delegated Attendance frequency	Actual attendance rate (%) (B/A)(Note)	Remark
Chairman	Li Shuxing	2	0	100%	
Member	Wu Genzai	2	0	100%	
Member	Chen Houming	2	0	100%	
Member	Yao Xiubi	2	0	100%	

Other matters that should be recorded:

－ 、 The operation of the Remuneration Committee is as follows:

Meeting Date	Period	Contents of the proposal	Resolution results	The Board of Directors' Response to the Remuneration Committee's Opinions
2024.12.21	The first session of the sixth	1. The CEO's Office Special case on the remuneration of the deputy general	The Chairman consulted with the attending members and the case was passed without objection	The Chairman consulted all the directors present and made a resolution

			manager, discuss.	and submitted to the Board of Directors for discussion.	The case was passed.
			2. The company's year-end bonus Planning and Manager Year Final bonus payment case, Bring it up for discussion.	The Chairman consulted with the attending members and the case was passed without objection and submitted to the Board of Directors for discussion.	The case was approved by Director Xu Shengxin, who served as acting chairman, after consulting with the other directors present.
			3. Please discuss the company's employee remuneration payment case.	The Chairman consulted with the attending members and the case was passed without objection and submitted to the Board of Directors for discussion.	The case was approved by Director Xu Shengxin, who served as acting chairman, after consulting with the other directors present.
			4. 2025 employee of the company Workers' salary adjustment case, discuss.	The Chairman consulted with the attending members and the case was passed without objection and submitted to the Board of Directors for discussion.	The proposal was approved by all directors present after consultation with the chairman .
	2025.03.14	The 2nd session of the 6th session	1. The remuneration proposal for the deputy general manager of the Smart Medical City business unit of our company is submitted for discussion.	The Chairman consulted with the attending members and the case was passed without objection and submitted to the Board of Directors for discussion.	The proposal was approved by all directors present after consultation with the chairman.

			2. Proposal on the proportion and amount of directors' and employees' remuneration for 2024 Please discuss.	This case was consulted by the Chairman Chairperson, no objection The proposal was approved and submitted to the Directors Things will be discussed.	The proposal was approved by all directors present after consultation with the chairman.	
			3. The definition of the company's grassroots employees and the ratio of profit allocation to grassroots employees are submitted for discussion.	This case was consulted by the Chairman Chairman, Amendment Corporation Distribution of grassroots employees After approval, it was submitted to the Director Things will be discussed.	The proposal was approved by all directors present after consultation with the chairman.	

二、If the Board of Directors does not adopt or amend the Remuneration Committee's recommendation, it shall state the date, period, content of the proposal, resolution of the Board of Directors, and the Company's handling of the disagreement of the Remuneration Committee (if the remuneration approved by the Board of Directors is better than the Remuneration Committee's recommendation, the difference and reason shall be stated: None.

三、If a member of the Remuneration Committee objects to or reserves an opinion on a resolution and there is a record or written statement, the date, term, content of the resolution, opinions of all members, and the handling of the opinions of the members shall be stated: None.

Note 1: If a member of the Remuneration Committee resigns before the end of the year, the date of resignation should be noted in the remarks column. The actual attendance rate (%) is calculated based on the number of Remuneration Committee meetings held during his/her tenure and the number of actual attendances.

Note 2: If there is a re-election of the Remuneration Committee before the end of the year, both the new and old members of the Remuneration Committee should be listed, and the member should be indicated in the remarks column as old, new or re-elected, as well as the date of re-election. The actual attendance rate (%) is calculated based on the number of Remuneration Committee meetings held during the employee's tenure and the number of actual attendances.

(V) Implementation of sustainable development and differences with the Code of Practice for Sustainable Development of Listed and OTC Companies and reasons:

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
1. Has the company established a governance structure to promote sustainable development and set up a dedicated (or part-time) unit to promote sustainable development? Has the board of directors authorized senior management to handle the matter, and has the board of directors provided supervision?	✓		<p>1. In order to fulfill our corporate social responsibility and promote economic, social and environmental progress to achieve the goal of sustainable development, the Company has revised the Company's Code of Practice for Sustainable Development with reference to the "Code of Practice for Sustainable Development of Listed Companies". The revision was approved at the 6th meeting of the 7th Board of Directors on March 25, 2022. In addition , the 2nd meeting of the 8th Board of Directors on August 9, 2024 approved the establishment of a Sustainable Development Committee in order to specifically cooperate with the "Sustainable Development Action Plan for Listed Companies" issued by the Financial Supervisory Commission, implement sustainable development goals, and deepen the corporate sustainable governance culture.</p> <p>2. The Board of Directors of the Company has fulfilled its duty of care as a good manager, urging the Company to implement sustainable development and reviewing the progress of the strategy from time to time. When necessary, it will actively urge the management team to conduct reviews and adjustments to help ensure that the sustainable development policy can be implemented in the daily operations of the Company .</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>3. The company 's sustainable development dedicated unit is the "Information Planning Office" appointed by the Chairman in 2019 to assist in the integration and implementation of various internal functional organizations, and also report the implementation status to the Board of Directors on a regular basis.</p> <p>4. The Company 's promotion and implementation of sustainable business in 2024 was reported at the 5th meeting of the 8th Board of Directors on December 21, 2024. In addition to reviewing the relevant implementation status of the current year , the Board of Directors also shared opinions and provided guidance on the short-, medium- and long-term planning of the Company's subsequent sustainable business development. The relevant report content has been disclosed on the company's website \ ESG Sustainable Development \ Goals and Performance.</p> <p>5. The Company's " Sustainable Development Code of Practice" is disclosed in the Company's annual report, website and public information observatory. Investors can download it from the Company's website \ Corporate Governance \ Corporate Governance Regulations.</p>	
2. Does the company conduct risk assessments on environmental, social and corporate governance issues related to its operations in accordance with the principle of materiality, and establish relevant risk management policies or strategies? (Note 2)	✓		<p>1. The company's business characteristics are pharmaceutical logistics-related services . Although it does not involve manufacturing, the company still pays attention to global risk trends to reduce operational impacts, and reviews and integrates the value of horizontal resources, actively connects with the international community, and takes into account multiple channels of quality and quantity to improve</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>the management efficiency of corporate social responsibility and meet the expectations of stakeholders for corporate governance, environmental protection and social care.</p> <p>2. In order to establish a sound risk management system and operate the business steadily towards the goal of sustainable development, the Company has formulated its own Risk Management Practice Guidelines in reference to the "Risk Management Practice Guidelines for Listed and OTC Companies" formulated by the competent authority to strengthen the risk management system. On December 23, 2022, the 12th meeting of the 7th Board of Directors approved the formulation of the "Risk Management Code of Practice", and resolved that the Audit Committee would replace the functions of the Risk Management Committee and report on the company's risk management policies, procedures and scope (the complete content of the above has been disclosed on the company's website \Corporate Governance\Functional Committees) .</p> <p>3. The board of directors of the Company is the highest governance unit for risk management. In addition, it is considered that supervising audit work is one of the responsibilities of the Audit Committee. Audit personnel have identified various possible risks when performing audit work, and recorded risk analysis, assessment and response suggestions in the audit report, and regularly reported the audit execution status to the members of the Audit Committee. The risk management function already exists, so there is no need to set up a risk</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>management committee. The Audit Committee will replace the functions of the Risk Management Committee and set up a working group under the Audit Committee as the risk management promotion and execution unit.</p> <p>4. The Company also conducts risk assessments on important issues based on the materiality principle of sustainable development and formulates relevant risk management policies based on the assessed risks . The full content has been disclosed on the Company's website \ESG Sustainable Development\Policy Promotion\Sustainable Development Policy .</p>	
<p>3. Environmental Issues</p> <p>1. Has the company established an appropriate environmental management system based on the characteristics of its industry ?</p>	✓		<p>The company's main businesses are pharmaceutical supply services , specialist services (mainly leasing of medical equipment) and health management services . It does not have any manufacturing plants and the waste generated by its business is general garbage. There is no air pollution , wastewater or waste that requires special treatment. The company has appointed a dedicated cleaning staff to maintain the office environment, and the company's general affairs office supervises the environmental maintenance.</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
(ii) Is the company committed to improving energy efficiency and using recycled materials with low environmental impact?	✓		In order to implement the environmental awareness of the green earth, the company hopes to create a paperless office through appropriate IT planning, and is committed to helping customers or suppliers save time and manpower in checking orders, delivery orders, etc. in an electronic way, and save a large amount of printing documents and physical invoices. Employees are required to increase the recycling rate of paper and various items and are encouraged to use personal environmentally friendly tableware to reduce the use of various disposable tableware, and actively implement garbage classification and reduction, hoping to fulfill the responsibility of being a member of the earth and protect the earth's resources.	Comply with the Code of Practice for Sustainable Development of Listed Companies
(3) Has the company assessed the potential risks and opportunities that climate change poses to the business now and in the future, and taken relevant response measures?		✓	1.Our company is in the biotechnology industry. In order to respond to the impact of climate change on corporate operations and disclose information on climate change, in addition to regularly reporting to the Board of Directors and the Audit Committee and their risk management working group to let the Board of Directors and senior management understand the impact of climate change on the company, since 2018, all departments of the company have also begun to conduct business inventory and risk identification for climate change, including direct or indirect impacts caused by extreme climate, transformation effects of regulations, technology or market demand, and other human and social aspects. Risks and	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>opportunities caused by the company's operating activities are analyzed. Based on the analysis results, a risk management strategy plan is established as the core of climate change response actions, and management costs and financial impacts are estimated. Through the data collected above, the company's climate change governance can be strengthened, and financial connections can be systematically evaluated to reduce risks and seize business opportunities.</p> <p>2. In terms of climate change impact assessment, since our company is not a manufacturing industry, the impact of climate change is relatively low risk. However, as a member of the global living community, we still have relevant practical actions and measures to respond to and cope with climate change :</p> <ul style="list-style-type: none"> · The houses and buildings invested and constructed shall comply with the standards of the Green Building Label. · When the company's business development energy source policy rewards the replacement of equipment, it will cooperate with the government subsidy policy and apply for relevant energy-saving subsidies. · When renovating office areas, in addition to the decoration being in compliance with green building standards, office equipment that meets energy-saving standards should be purchased. 	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
4. Has the company compiled statistics on greenhouse gas emissions, water consumption, and total weight of waste in the past two years, and formulated policies for greenhouse gas reduction, water reduction, or other waste management?	✓		1. The company's current business is mainly in pharmaceutical supply services, specialist services (mainly medical equipment leasing) and health management services. Its operations are little affected by climate change and the greenhouse effect. However, as a corporate citizen, the company has formulated the "Corporate Environment and Energy Saving and Carbon Reduction Management Measures", and has clearly defined environmental policies , energy saving and carbon reduction plans, climate change assessments and related response measures, and actively implemented relevant energy saving and carbon reduction measures. In addition, it is actively committed to reducing greenhouse gas emissions, water consumption and waste. The specific implementation results in the past two years are as follows :	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes																		
	yes	no	Summary																			
			<table><thead><tr><th></th><th>2023</th><th>2024</th></tr></thead><tbody><tr><td>CO2 emissions (tCO2e)</td><td>89.4</td><td>198.41</td></tr><tr><td>Water consumption (metric tons)</td><td>1591</td><td>1997.3</td></tr><tr><td>Water consumption (tCO2e)</td><td></td><td>0.47</td></tr><tr><td>Total weight of waste (metric tons)</td><td>27.97</td><td>22.21</td></tr><tr><td>Total weight of waste (tCO2e)</td><td></td><td>16.37</td></tr></tbody></table> <p>Remark:</p> <p>1. The data on greenhouse gas emissions, water consumption and total weight of waste covers the parent company.</p> <p>2. The parent company is in the healthcare services industry. The original greenhouse gas emissions are the greenhouse gas emissions disclosed in Scope 2 (Taipower imported electricity). The warm-up session started in 2014, and the disclosure scope is categories one to three.</p> <p>3. The total weight of waste does not need to be distinguished according to regulations because the parent company is not a manufacturing company. The reference for calculating the weight of waste (tons) is the average daily general waste generation per person in Taoyuan City's important environmental statistics from the Ministry of Environment's Environmental Data Open Platform, which was 1.534 kg in 2023 and 1.439 kg in 2024.</p> <p>The above-mentioned relevant data are also disclosed on the company's website, in the hope that the company can fulfill its corporate social responsibility to mitigate global warming.</p> <p>The total tons of CO2 emissions in 2024 were 198.411 tons, an increase of 109.011 tons from 89.40 tons in 2023. The main reason is that the company started the warm-up operation on</p>		2023	2024	CO2 emissions (tCO2e)	89.4	198.41	Water consumption (metric tons)	1591	1997.3	Water consumption (tCO2e)		0.47	Total weight of waste (metric tons)	27.97	22.21	Total weight of waste (tCO2e)		16.37	
	2023	2024																				
CO2 emissions (tCO2e)	89.4	198.41																				
Water consumption (metric tons)	1591	1997.3																				
Water consumption (tCO2e)		0.47																				
Total weight of waste (metric tons)	27.97	22.21																				
Total weight of waste (tCO2e)		16.37																				

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>December 29, 2023, and took 2023 as the base year to check the greenhouse gas emissions. The scope of the inventory is from Category 1 to Category 3. Compared with 2023 (only Category 2, Taipower imported electricity) and previous years, the warm-up data will be presented more accurately. Due to the addition of Category 1 and 3 carbon emissions, the increase in emissions is normal. In response to the subsequent merger of the Comfort Inn Division (hotel industry) into the parent company as a new business department, the boundaries of the warm-up will be expanded in 2024. The reason for the increase in water consumption should be that after the epidemic, colleagues generally raised their awareness of epidemic prevention, implemented hand washing operations, and strengthened cleaning and disinfection of office areas. The reason for the reduction in waste is estimated to be related to the implementation of garbage classification by colleagues. In conjunction with the launch of the warm plate operation, we continue to work on energy conservation measures based on the warm plate data and sources to reduce carbon dioxide emissions, water consumption and total weight of waste.</p> <p>2. The various reduction policies and specific practices are as follows :</p> <p>(1) Energy saving and carbon reduction</p> <ul style="list-style-type: none"> • Continue to seek and replace more energy-efficient office facilities. • Implement power-saving plans in three major 	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>areas: air-conditioning systems, electric lighting, and other electricity consumption. Regularly inspect energy-consuming equipment and replace them as necessary.</p> <ul style="list-style-type: none"> • Organize energy conservation and carbon reduction education and training courses and promotion. • Regularly inspect the unit to inspect individual actions to save energy and reduce carbon emissions. <p>(2) Water management</p> <ul style="list-style-type: none"> • Requires the company to implement water conservation plans internally. • Regularly check the normal operation of the water supply system to avoid water consumption beyond normal use. • Organize water management education training courses and promotions. <p>(3) Waste reduction</p> <ul style="list-style-type: none"> • Carry out stricter waste recycling and classification operations. • Accelerate your journey towards a fully paperless process. • Organize waste reduction education and training courses and promotions. • Audit the implementation of waste classification (including food waste) in each unit from time to time, and submit the unit's implementation report to the company meeting. <p>3. In addition, according to the "Sustainable</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>Development Roadmap for Listed Companies" issued by the Financial Supervisory Commission in March 2022, our company is a company with a paid-in capital of less than 5 billion yuan. The individual company (i.e., the parent company) should apply for greenhouse gas inventory in the third phase (i.e., complete the inventory in 2026 and complete the verification in 2028), and according to regulations, it is only required to disclose greenhouse gas emissions in Scope 1 and Scope 2 ; there is no need to verify the above-mentioned related information in 2023 . Subsequently, the Company will continue to control the completion of greenhouse gas inventory and verification disclosure schedules in accordance with the reference guidelines and relevant regulations issued by the competent authorities .</p> <p>The company's current reduction target is to reduce greenhouse gas emissions, water usage and waste generation by another 5% by the end of 2025 (compared to 2020). We will also obtain more accurate data based on the results of the 2024 warm market and make adjustments accordingly. Although our company is only required to disclose Scope 1 and Scope 2 greenhouse gas emissions according to regulations, our company is in the healthcare service industry and many of our business operations have greenhouse gas emissions that fall under Scope 3. Therefore, our initial goal is to disclose Scopes 1 to 3.</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes														
	yes	no	Summary															
4. Social Issues 1. Has the company formulated relevant management policies and procedures in accordance with relevant laws and regulations and international human rights conventions?	✓		<p>1. The Company supports and follows internationally recognized human rights norms and principles. We have established human rights policies including the United Nations Declaration of Human Rights, the International Labor Convention, and the Taiwan Labor Standards Act . We also strive to promote diversity and equality in the workplace. For example, our company adheres to the principle of gender equality in terms of salary payment conditions and the selection of various positions. Salaries are allocated based on professional expertise, experience, and the scope of responsibilities. We also adhere to the principle of fairness in promotions and job transfers, without any gender-based discrimination.</p> <p>(1) Ratio of female employees:</p> <table border="1"> <tr> <td>Indicator of number of female employees</td> <td>percentage(%)</td> </tr> <tr> <td>Female employees (%)</td> <td>68.6%</td> </tr> <tr> <td>Female supervisors account for all supervisors (%)</td> <td>57.5%</td> </tr> <tr> <td>Female managers account for all managers (%)</td> <td>44.4%</td> </tr> </table> <p>(2) Ratio of female employees' salary to male employees:</p> <table border="1"> <tr> <td>Salary Index</td> <td>Ratio of male salary</td> </tr> <tr> <td>Average salary of female employees</td> <td>92.6%</td> </tr> <tr> <td>Median salary of female employees</td> <td>97.8%</td> </tr> </table>	Indicator of number of female employees	percentage(%)	Female employees (%)	68.6%	Female supervisors account for all supervisors (%)	57.5%	Female managers account for all managers (%)	44.4%	Salary Index	Ratio of male salary	Average salary of female employees	92.6%	Median salary of female employees	97.8%	Comply with the Code of Practice for Sustainable Development of Listed Companies
Indicator of number of female employees	percentage(%)																	
Female employees (%)	68.6%																	
Female supervisors account for all supervisors (%)	57.5%																	
Female managers account for all managers (%)	44.4%																	
Salary Index	Ratio of male salary																	
Average salary of female employees	92.6%																	
Median salary of female employees	97.8%																	

Promote the project	Implementation status (Note 1)							Sustainable development with listed companies Differences in codes of practice and their causes																																									
	yes	no	Summary																																														
			<p>(3) Statistics of gender and age structure by job title:</p> <table><tr><th>Position</th><th colspan="2">Manager</th><th colspan="2">Supervisor</th><th colspan="2">Non-supervisory positions</th><th>total</th></tr><tr><th>Gender</th><th>male</th><th>female</th><th>male</th><th>female</th><th>male</th><th>female</th><th></th></tr><tr><td>Under 30 years old</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2.7%</td><td>9.5%</td><td>12.2%</td></tr><tr><td>30-50 years old</td><td>0</td><td>0</td><td>2.1%</td><td>6.1%</td><td>6.1%</td><td>40.1%</td><td>54.5%</td></tr><tr><td>Over 50 years old</td><td>3.4%</td><td>2.7%</td><td>6.1%</td><td>6.8%</td><td>10.9%</td><td>3.4%</td><td>33.3%</td></tr></table> <p>Source: Employee statistics in December 2024</p> <p>2. In terms of policy, the company has established internal regulations in terms of "work rules", "prevention of sexual harassment", "recruitment and appointment management", etc. to eliminate discrimination based on gender; the conditions such as employment age, working hours, and leave clearly regulate employee rights to ensure that colleagues are properly taken care of, and evaluate and set positive practices through human rights issues to protect the rights and interests of employees.</p> <p>3. Implementation policy:</p> <p>(1) Create a safe and healthy working environment</p> <p>(2) Maintaining a balance between employees' work and health</p> <p>(3) Eliminate illegal discrimination</p>						Position	Manager		Supervisor		Non-supervisory positions		total	Gender	male	female	male	female	male	female		Under 30 years old	0	0	0	0	2.7%	9.5%	12.2%	30-50 years old	0	0	2.1%	6.1%	6.1%	40.1%	54.5%	Over 50 years old	3.4%	2.7%	6.1%	6.8%	10.9%	3.4%	33.3%	
Position	Manager		Supervisor		Non-supervisory positions		total																																										
Gender	male	female	male	female	male	female																																											
Under 30 years old	0	0	0	0	2.7%	9.5%	12.2%																																										
30-50 years old	0	0	2.1%	6.1%	6.1%	40.1%	54.5%																																										
Over 50 years old	3.4%	2.7%	6.1%	6.8%	10.9%	3.4%	33.3%																																										

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes										
	yes	no	Summary											
			<p>(4) Strictly comply with labor laws</p> <p>4. Specific measures and results review are as follows:</p> <table><tr><th>Implementation Guidelines</th><th>Specific implementation measures</th></tr><tr><td>Create a safe and healthy working environment</td><td>Drinking water testing in offices Disinfection of working environment Workplace operating environment monitoring (such as CO₂, lighting) Fire protection education course Providing masks to colleagues during COVID-19</td></tr><tr><td>Maintaining a balance between employees' work and health</td><td>Better than the law, all employees, regardless of age, undergo routine physical examinations Used for on-site nursing planning and timely adjustment of physical examination items Increase self-funded physical examination items and strive for preferential prices Remind unit supervisors of special leave arrangements for employees</td></tr><tr><td>Eliminate illegal discrimination</td><td>Formulate sexual harassment prevention guidelines and count the number of complaints Carry out human rights education and training to promote human rights awareness.</td></tr><tr><td>Comply with labor laws</td><td>Prohibition of employment of child laborers under the age of 16 Prepare a compliance annual calendar and submit it to the labor-management meeting</td></tr></table>	Implementation Guidelines	Specific implementation measures	Create a safe and healthy working environment	Drinking water testing in offices Disinfection of working environment Workplace operating environment monitoring (such as CO ₂ , lighting) Fire protection education course Providing masks to colleagues during COVID-19	Maintaining a balance between employees' work and health	Better than the law, all employees, regardless of age, undergo routine physical examinations Used for on-site nursing planning and timely adjustment of physical examination items Increase self-funded physical examination items and strive for preferential prices Remind unit supervisors of special leave arrangements for employees	Eliminate illegal discrimination	Formulate sexual harassment prevention guidelines and count the number of complaints Carry out human rights education and training to promote human rights awareness.	Comply with labor laws	Prohibition of employment of child laborers under the age of 16 Prepare a compliance annual calendar and submit it to the labor-management meeting	
Implementation Guidelines	Specific implementation measures													
Create a safe and healthy working environment	Drinking water testing in offices Disinfection of working environment Workplace operating environment monitoring (such as CO ₂ , lighting) Fire protection education course Providing masks to colleagues during COVID-19													
Maintaining a balance between employees' work and health	Better than the law, all employees, regardless of age, undergo routine physical examinations Used for on-site nursing planning and timely adjustment of physical examination items Increase self-funded physical examination items and strive for preferential prices Remind unit supervisors of special leave arrangements for employees													
Eliminate illegal discrimination	Formulate sexual harassment prevention guidelines and count the number of complaints Carry out human rights education and training to promote human rights awareness.													
Comply with labor laws	Prohibition of employment of child laborers under the age of 16 Prepare a compliance annual calendar and submit it to the labor-management meeting													

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes						
	yes	no	Summary							
			<table><tr><td></td><td>for review The principle of overtime is that employees must proactively apply for it.</td></tr><tr><td></td><td>Elect labor and capital committee members and conduct meetings in accordance with the law.</td></tr><tr><td></td><td>Comply with laws and employee needs to assist in handling childcare leave.</td></tr></table> <p>Please read the company's official website for the execution results.</p>		for review The principle of overtime is that employees must proactively apply for it.		Elect labor and capital committee members and conduct meetings in accordance with the law.		Comply with laws and employee needs to assist in handling childcare leave.	
	for review The principle of overtime is that employees must proactively apply for it.									
	Elect labor and capital committee members and conduct meetings in accordance with the law.									
	Comply with laws and employee needs to assist in handling childcare leave.									
(2) Does the company formulate and implement reasonable employee welfare measures (including salary, vacation and other benefits) and appropriately reflect operating performance or results in employee remuneration?	✓		<p>1. System regulations: The company has established work rules and relevant personnel management regulations, which cover the basic wages, working hours, vacations, pension benefits, labor and health insurance benefits, occupational accident compensation, etc. of the workers employed by the company, all of which comply with the relevant provisions of the Labor Standards Act.</p> <p>2. Employee Compensation: Salary: The Company has established a salary assessment method for employees. The assessment principle is based on the employee's job category and manager level and takes into account the market salary level, including monthly salary and performance bonus. Bonus: There is an employee appraisal method, and performance appraisals are conducted twice a year. Managers are also subject to this performance</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies						

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>appraisal system. Evaluation factors include the unique value of an individual's overall performance to the organization, the ability to work with others and team spirit, the risk of harming customers or the team, and whether there is potential for promotion. Employee remuneration is reflected based on performance results, such as the issuance of year-end bonuses.</p> <p>3. Welfare measures: The company promotes labor-management harmony and improves labor welfare through employee welfare committees and labor-management meetings. The above two organizations elect labor representatives through employee elections to propose, coordinate, communicate and supervise labor-management related issues on behalf of employees, including but not limited to labor-management relations, labor conditions, labor welfare, workplace sexual harassment and bullying, employee diversity and equality issues. Employees are ex-officio members and have the right to raise the above issues to the labor committee for discussion and negotiation. Labor-management meetings are held once a quarter, four times a year; the employee welfare committee meets once a quarter, four times a year. The company allocates 0.08% of its revenue each month as employee welfare funds to handle various welfare matters, including but not limited to wedding and funeral allowances, birthday gifts, scholarships, travel allowances, etc.; annual employee health examinations are provided in</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>accordance with the law, and annual employee influenza vaccinations are provided.</p> <p>4. Reflection of operating performance:</p> <p>Performance bonus: Budget review and performance target setting are conducted every year, and performance bonuses are issued based on the achievement of performance targets.</p> <p>Employee remuneration: The amount of remuneration paid out due to the company's profits will be submitted to the Remuneration Committee for review and submitted to the Board of Directors for approval, depending on the employee's performance and job contribution; the company is committed to providing employees with a remuneration and level that is above the industry average.</p>	

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes								
	yes	no	Summary									
(3) Does the company provide employees with a safe and healthy working environment and provide regular safety and health education to employees?	✓		<p>1. Our company complies with the relevant regulations of the Occupational Safety and Health Act, and stipulates that smoking is prohibited in all office premises. We also require annual safety inspections of office equipment and facilities in accordance with government fire safety regulations. We have also been conducting comprehensive work environment monitoring since 2019 to provide employees with a safe working environment. 2024 projects implemented: 2 times of work environment monitoring, 4 times of drinking water equipment related inspections, and 4 times of workplace environment disinfection.</p> <p>2. The Company will cooperate with the requirements of the office space management unit and regularly participate in actual drills on fire escape and the use of fire extinguishing equipment.</p> <p>3. The company regularly conducts health checks on employees and provides safety and health education to employees every year. It also provides on-site labor health services (the implementation situation in 2024 is: 24 times/year by nurses and 2 times/year by doctors).</p> <p>4. In order to promote the health of employees, the company organized related health promotion activities, including stress relief courses, virtual island walking, and 2025 group organization walking relay. The performance of the activities is as follows:</p> <table><tr><th>Project</th><th>Related Statistics</th></tr><tr><td>Stress Relief Course</td><td>3 sessions/107 participants</td></tr><tr><td>Health lecture</td><td>1 session/40 people</td></tr><tr><td>Virtual island walking</td><td>31 people/23,367,737 steps</td></tr></table>	Project	Related Statistics	Stress Relief Course	3 sessions/107 participants	Health lecture	1 session/40 people	Virtual island walking	31 people/23,367,737 steps	Comply with the Code of Practice for Sustainable Development of Listed Companies
Project	Related Statistics											
Stress Relief Course	3 sessions/107 participants											
Health lecture	1 session/40 people											
Virtual island walking	31 people/23,367,737 steps											

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes				
	yes	no	Summary					
			<table><tr><td>Xiaobaiyue Climbing Competition</td><td>19 people/390 mountains</td></tr><tr><td>2025 Group Walking Relay</td><td>250 people/3475km</td></tr></table> <p>In addition to health promotion activities, we also conduct employee health checkups every year. On-site nurses assist in tracking abnormal results, conducting follow-up visits and re-examinations, and conducting health management and health education. The outlier statistics for 2024 are as follows: Body fat was abnormal by 60%, cholesterol was abnormal by 49.5%, and BMI was abnormal by 47%. Through health education, health lectures and participation in health promotion activities, we are committed to maintaining the health of employees, actively preventing chronic diseases such as cardiovascular and metabolic diseases that are prone to occur in modern people, creating a healthy workplace and sharing the good with employees.</p> <p>5. In fiscal 2024 , there was a total of 1 employee occupational accident (accidents on the way to and from work) , involving 1 person (accounting for 0.68% of the total number of employees at the end of 2024) .</p>	Xiaobaiyue Climbing Competition	19 people/390 mountains	2025 Group Walking Relay	250 people/3475km	
Xiaobaiyue Climbing Competition	19 people/390 mountains							
2025 Group Walking Relay	250 people/3475km							
4. Does the company establish an effective career development training program for its employees?	✓		<p>1. In order to implement lifelong learning and improve work skills and quality, the company has established the "Employee Continuing Education and Training Measures", provided training subsidies, and encouraged employees to study on the job . There are also scholarships to provide substantial rewards to employees and their children with excellent learning results.</p> <p>2. The company reviews and evaluates the skills,</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies				

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			expertise and management capabilities of employees through the supervisors of each unit. When a higher-level supervisor is vacant, employees with outstanding performance will be promoted first. There is also a job transfer mechanism to give outstanding employees the opportunity to develop a second expertise.	
(V) Regarding issues such as customer health and safety, customer privacy, marketing and labeling of products and services, does the company comply with relevant laws and regulations and international standards, and has established relevant policies and complaint procedures to protect the rights and interests of consumers or customers?	✓		<p>1. The Company's main operating activities are the sale of medicines and medical consumables, the leasing of medical equipment and the provision of hospital health examination and laboratory management services. Among them, medicines, medical consumables and medical equipment are closely related to the life safety of the general public. During the process of research and development, manufacturing, importation, sales, transportation, storage and use, international and domestic regulations impose higher verification standards than those for general products . Our company also complies with the domestic Good Distribution Practice (GDP) for Western Medicines in terms of drug sales .</p> <p>2. When selecting products for operational purposes, our company will comply with international and domestic laws and regulations. The company has good communication channels and dedicated personnel who are responsible for listening to the needs of various stakeholders and responding to and tracking the feedback information collected through different communication channels according to the status of the issue . For detailed communication</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>channels, please refer to the company's official website.</p> <p>3. The laboratory managed by our company has been approved for ISO 9001 2015 revision certification, and the scope of accreditation includes: clinical testing services, teaching training and academic research.</p>	
(VI) Does the company have a supplier management policy that requires suppliers to comply with relevant regulations on issues such as environmental protection, occupational safety and health, or labor human rights, and its implementation?	✓		<p>1. In order to implement the company's commitment to fair, honest, trustworthy and transparent business activities, the "Supplier Management Policy" was formulated in accordance with the company's integrity management operating procedures and behavioral guidelines , requiring cooperation with suppliers to follow relevant standards on issues such as quality, environmental protection, safety and hygiene, and jointly strive to improve and perfect the relevant standards for corporate sustainable development ; and the content enhancement was completed in July 2020.</p> <p>The Company also formulated a new "Supplier Integrity Management Commitment" in November 2021, and added new supplier (organization or individual) assessments. All suppliers are required to sign the aforementioned Integrity Management Commitment in stages to commit to operating in an honest and ethical manner, fulfilling corporate social responsibility, promoting environmental sustainability, and safeguarding basic human rights.</p> <p>2. Before dealing with suppliers and customers, our company will follow the established "Supplier Management and Price Inquiry and Bargaining</p>	Comply with the Code of Practice for Sustainable Development of Listed Companies

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			<p>Operation Methods" and "Credit Management Methods" to investigate and confirm the integrity of suppliers and customers, such as whether they have obtained drug or medical device licenses, whether they have obtained drug dealer licenses, whether they have any tax arrears or debts, etc. We must confirm that their products have obtained national standard certification and that the company's operations are in line with integrity before transactions can be conducted.</p> <p>3. The contracts signed between our company and suppliers stipulate that "both parties shall comply with ○○industry-related laws and ethical standards and act in good faith", or "if the contracting party commits any dishonest behavior or its products have a significant impact on the environment and society, resulting in a breach of contract or damage, we may terminate the contract at any time and demand compensation in accordance with the contract or damage situation" to ensure the company's rights and interests.</p>	
5. Does the company prepare perpetual reports and other reports that disclose the company's non-financial information by referring to internationally accepted reporting standards or guidelines? Has the above-mentioned report obtained confirmation or assurance from a third-party verification agency?		✓	<p>The Company complies with the latest version of the GRI General Standards (GRI Standards 2021 Edition) of the Global Reporting Initiative, " references " the SASB standards issued by the Sustainability Accounting Standards Board (published in November 2018) , " references " the ESG standards established by the TCFD for climate-related financial disclosures , etc. At the same time, in accordance with the "Operational Guidelines for the Preparation and Submission of Sustainability Reports by Listed</p>	The company plans to start preparing a sustainability report in 2014

Promote the project	Implementation status (Note 1)			Sustainable development with listed companies Differences in codes of practice and their causes
	yes	no	Summary	
			Companies" and regulatory requirements, we strengthen the disclosure of industry-specific sustainability disclosure indicators (stock exchanges, OTC markets), and "references" the standards of the United Nations Sustainable Development Goals (SDGs) according to the needs of the Company, etc., to prepare the 2024 Sustainability Report.	
<p>6. If the company has its own sustainable development code based on the "Sustainable Development Best Practices Code for Listed and OTC Companies", please describe the differences between its operation and the established code:</p> <p>The Company has formulated its own Code of Practice for Sustainable Development with reference to the "Code of Practice for Sustainable Development of Listed Companies " and is actively moving in the direction set out in the Code. There is no difference in the implementation content.</p>				
<p>7. Other important information that helps to understand the implementation of sustainable development :</p> <p>Our company firmly believes in the impact of enterprises on the country's social responsibility. In addition to working hard to operate our core business, providing employees with a stable and high-quality employment environment, and seeking the greatest benefits for the company's shareholders and related stakeholders, we are also actively committed to practicing sustainable development while engaging in business operations to meet the international trend of balancing the development of the environment, society and corporate governance.</p>				

Note 1: If you select "Yes" for implementation, please specify the important policies, strategies, measures and implementation status adopted; if you select "No" for implementation, please explain the differences and reasons in the column "Differences and reasons from the Code of Best Practice on Sustainable Development of Listed and OTC Companies" and explain the plans for the adoption of relevant policies, strategies and measures in the future.

Note 2: The materiality principle refers to environmental, social and corporate governance issues that have a significant impact on the company's investors and other stakeholders.

Note 3: For disclosure methods, please refer to the best practice reference examples on the Taiwan Stock Exchange Corporate Governance Center website.

(VI) Implementation of climate-related information

- 一、 According to the "Sustainable Development Roadmap for OTC Companies" issued by the Financial Supervisory Commission in March 2022, our company is a company with paid-in capital of less than NT\$5 billion. The individual company (i.e., the parent company) should apply for greenhouse gas inventory in the third phase (i.e., complete the inventory in 2026 and complete the verification in 2028). We will continue to control the completion of the greenhouse gas inventory and verification disclosure schedule in accordance with the reference guidelines and relevant regulations issued by the competent authority.
- 二、 The Board of Directors and management have implemented some of the following in terms of their oversight and governance of climate-related risks and opportunities :
 1. According to the Financial Supervisory Commission's regulations, the greenhouse gas inventory and verification schedule for the parent company and the group (including subsidiaries) must be completed by the end of the second quarter of 2022 and the end of the first quarter of 2023, respectively, and submitted to the board of directors for approval.
 2. The aforementioned implementation progress shall be submitted to the Board of Directors on a quarterly basis in accordance with regulations. In 2022, the Board of Directors has been submitted on a quarterly basis on May 13, 2022, August 12, 2022, and November 11, 2022 respectively. The dates for the implementation status report submitted to the Board of Directors in 2023 are March 24, 2023, May 12, 2023, August 11, 2023, and November 10, 2023. Continue to monitor the completion of greenhouse gas inventory and verify the disclosure schedule. The company's professional services department serves as a part-time unit for greenhouse gas inventory and verification .
 3. of subsidiaries in the consolidated financial statements is as follows and will be submitted to the first quarter board of directors in accordance with regulations. The dates for the implementation status report submitted to the Board of Directors in 2023 are March 24, 2023, May 12, 2023, August 11, 2023, and November 10, 2023. The dates for the implementation status report submitted to the Board of Directors in 2024 are March 15, 2024, May 10, 2024, August 9, 2024, and November 8, 2024.
 4. The company's directors and supervisors participated in relevant courses for a total of 54 hours in 2024 (36 hours in 2023). The course content includes " Net Zero Emissions, Carbon Neutrality and Corporate Compliance", "Carbon Pricing Mechanism - How Should Taiwan Choose?", "TCFD Assessment under Climate Change ", "Net Zero Carbon Emissions and Corporate Governance", and "Promotion and Future Outlook of Taiwan's Sustainability Classification Standards". For related information, please refer to the public information observation station content, path URL: <https://mops.twse.com.tw/mops/web/t100sb07>
 5. The Chairman and General Manager participated in the greenhouse gas inventory kick-off meeting and education and training course held by the company on December 29, 2023 .
 6. In line with our company's ESG plan, we plan to start the construction of the "ESG Corporate Sustainability Report" in June 2024, and will also initiate relevant climate risk assessments and development opportunities at the same time.
- 三、 Greenhouse gas emission information, greenhouse gas inventory and confirmation :
 1. Currently, the company collects statistics on greenhouse gases, water use, waste weight, etc. every year and discloses them on its official website.
 2. The company's greenhouse gas emissions in 2024 are shown in the following table :

Greenhouse gas emissions	Total emissions (metric tons CO ₂ e)	Density (metric tons CO ₂ e/million yuan)	Confirmed institution	Confirmed Circumstances	Data coverage
illustrate	198.411	$198.41/4325.831 = 0.04587$	French Standard International Certification Co., Ltd.	It is expected that external verification will be conducted in 2015, and the verification unit has been arranged to be French Standard International Certification Co., Ltd.	Greenhouse gas emissions data for 2014 are from Scope 1 to Scope 3

On December 29, 2023, Shenghong Company, together with Huayu Consulting Company and Dingxin Computer Company, held a kick-off meeting for the company's greenhouse gas inventory and verification work. 2024 was used as the inventory base year, and the inventory scope was Category 1 to 3, which will present the company's carbon emission data more accurately. It is also planned to conduct verification (by a third-party agency) in 2025. The verification unit has been arranged to be French Standard International Certification Co., Ltd. The temperature inventory and verification operations are continuing according to the established schedule, and the greenhouse gas inventory operation will be listed as an annual routine operation. The consolidated financial statements of the subsidiaries will be launched in 2025.

(VII) Implementation of good faith management and differences from the good faith management rules of listed and OTC companies and their reasons

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
<p>1. Formulate integrity management policies and plans</p> <p>(1) Has the company formulated a business integrity policy approved by the board of directors, and has it clearly stated its business integrity policy and practices in its bylaws and external documents, as well as the board of directors and senior management's commitment to actively implement the business integrity policy?</p>	✓		<p>1. "Integrity" is the primary core value of the Company. In order to ensure that all members of the Company and its subsidiaries implement the commitment to integrity management in their work, the Company has formulated the "Integrity Management Operating Procedures and Behavior Guidelines" with reference to the "Integrity Management Code for Listed Companies". It was approved by the 19th meeting of the 4th Board of Directors on March 18, 2015 ; and was amended by the 12th meeting of the 6th Board of Directors on March 20, 2020.</p> <p>2. The Company's " Integrity Management Operating Procedures and Behavior Guidelines" are disclosed in the Company's annual report, website and public information observatory. Investors can download them from the Company's website\ Corporate Governance \Corporate Governance Regulations .</p> <p>3. The Company has established a "Code of Ethical Conduct" to regulate the Company's directors , supervisors , and managers to strictly prevent conflicts of interest , avoid opportunities for personal gain , maintain confidentiality , fair trade , protect and properly use company assets , and comply with laws and regulations when engaging in</p>	<p>Comply with the Integrity Management Code of Conduct for Listed Companies</p>

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			operational activities for the Company based on their authority. They should set an example and shape the company's corporate culture of honest management. 4. The company has established "employee work rules" to regulate the service code of all staff at work, including: not taking advantage of the position to engage in malpractice, accept gifts, seek benefits for others or yourself, strictly abide by the principle of integrity in handling official business, and not engage in breach of trust, fraud, or behavior that damages the company's rights and interests, etc., to implement the policy of honest management in work.	
(2) Has the company established a mechanism to assess the risk of dishonest behavior, regularly analyze and assess business activities within its business scope that carry a higher risk of dishonest behavior, and formulate a plan to prevent dishonest behavior based on the risk, and at least cover the preventive measures for each of the behaviors in Article 7, Paragraph 2 of the "Code of Conduct for Listed and OTC Companies"?	✓		The "Integrity Management Operating Procedures and Behavior Guidelines" established by our company have detailed regulations prohibiting the company's directors, managers and all employees from engaging in any business activities that are in violation of the provisions of Article 7, Paragraph 2 of the "Integrity Management Code for Listed Companies" or other business activities that have a higher risk of dishonest behavior within the scope of other business.	Comply with the Integrity Management Code of Conduct for Listed Companies
(III) Does the company clearly define operating procedures, behavioral guidelines, disciplinary measures for	✓		1. The company has established "Integrity Management Operating Procedures and Behavior Guidelines" to regulate specific integrity management practices and prevent	Comply with the Integrity Management Code of Conduct for Listed

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
violations, and complaint systems in its plan to prevent dishonest behavior, implement them, and regularly review and revise the plan?			<p>dishonest behavior plans, including operating procedures, behavioral guidelines, and the establishment of a promotion , punishment, complaint system and disciplinary sanctions, etc., to regulate matters that personnel should pay attention to when performing business, prohibit the provision or acceptance of improper benefits, in order to implement the prevention of dishonest behavior. The company will also continue to review and revise it.</p> <p>2. The company has also established "Procedures for Handling Reports of Illegal, Immoral or Dishonest Behavior Cases" to establish internal and external reporting channels and handling systems to implement the " Code of Ethical Conduct " and " Integrity Management Operating Procedures and Behavior Guidelines " formulated by the company to ensure the sustainable development of the company's foundation and to ensure the legitimate rights and interests of reporters and related persons. Reporting of any illegal, immoral, and dishonest behavior is encouraged, and the standards for punishment are set in the "Employee Work Rules" and "Employee Reward and Punishment Methods".</p>	Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
<p>2. Implementing Integrity Management</p> <p>1. Does the company evaluate the integrity records of its trading partners and clearly stipulate good faith behavior clauses in the contracts signed between it and its trading partners ?</p>	✓		<p>1. Before dealing with suppliers and customers, our company will follow the established "Supplier Management and Price Inquiry and Negotiation Operation Methods" and "Credit Management Methods" to investigate and confirm the integrity of suppliers and customers, such as whether they have obtained drug or medical device licenses, whether they have obtained drug dealer licenses, whether they have any tax arrears, etc. We must confirm that their products have obtained national standard certification and that the company's operations are in line with integrity before transactions can be conducted.</p> <p>2. The contracts signed between our company and suppliers stipulate that "both parties shall comply with ○○industry-related laws and ethical standards and act in good faith", or "if the contracting party commits any dishonest behavior or its products have a significant impact on the environment and society, resulting in a breach of contract or damage, we may terminate the contract at any time and demand compensation in accordance with the contract or damage situation" to ensure the company's rights and interests.</p> <p>3. Our company states in its procurement regulations that suppliers who comply with environmental, safety and health</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>regulations will be given priority, meaning that we will not cooperate with suppliers who have concerns about environmental , safety or health issues, thereby encouraging suppliers to comply with relevant regulations and work together to enhance corporate social responsibility.</p> <p>4. In accordance with the implementation of the company's supplier management policy, the official contract (agreement) and the revision of relevant methods and forms of each department were completed in 2021. New suppliers will sign a letter of commitment to honest management in accordance with the company's regulations.</p>	
(II) Does the company have a dedicated unit under the board of directors to promote corporate integrity management, and does it regularly (at least once a year) report to the board of directors on its integrity management policy and plan for preventing dishonest behavior and the status of its supervision of implementation?	✓		<p>1. Regarding the promotion of the Company's integrity management, in addition to the independent internal audit unit's audit and internalization of the relevant systems and regulations for promotion, the "Integrity Management Operating Procedures and Behavior Guidelines" formulated by the Company designates the Chairman's Office as the dedicated unit for promoting integrity management matters, and handles the revision , implementation , interpretation , consulting services, and notification content registration and filing of the operating procedures and behavior guidelines, as well as related operations and supervision of implementation .</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>2. In 2019, the Chairman appointed the "Information Planning Office" to assist in the integration of various internal functional organizations and the implementation of relevant policies and report to the Board of Directors on a regular basis. This year, the annual implementation status was reported at the 16th meeting of the Seventh Board of Directors on November 10 , 2023. No major incidents of violating integrity management occurred in 2023 .</p> <p>3. The Company implements the policy of honest business operation. The relevant implementation status in 2024 is as follows: (1) The Company has established internal and external reporting channels and handling systems, and has set up a dedicated unit and contact information channels for reporting; no relevant reports were received in 2024. (2) "Supplier Integrity Management Commitment": Since November 2021 , the Company has required all suppliers to sign a Supplier Integrity Management Commitment (or to include integrity management clauses in the contract) in stages, committing to operate in an honest and ethical manner, fulfilling corporate social responsibility, promoting environmental sustainability and safeguarding basic human rights . The number of implementation cases in 2024 was 59 .</p>	

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
(3) Has the company formulated a policy to prevent conflicts of interest, provided appropriate channels for representation, and implemented it?	✓		<p>1. Our company's "Integrity Management Operating Procedures and Behavior Guidelines" have clear instructions on the prohibition of providing or accepting improper benefits , prohibition of facilitation payments , conflict of interest policies , handling procedures, and handling of reported cases, and require all personnel to implement them.</p> <p>2. The Company regularly confirms the competitive situations of directors and managers for use in business operation review and approval to grasp the potential risks of conflicts of interest.</p> <p>3. If the board of directors of our company encounters a case of conflict of interest, it shall strictly follow Article 15 of the company's "Board of Directors' Meeting Rules". If a director has a conflict of interest with himself or the legal person he represents in the meeting matters, he shall explain the important details of his conflict of interest at the current board meeting. If there is a possibility of harming the interests of the company, he shall not participate in the discussion and voting, and shall recuse himself from the discussion and voting, and shall not exercise the voting rights on behalf of other directors; and detailed records shall be made in the meeting minutes.</p>	Comply with the Integrity Management Code of Conduct for Listed Companies
(IV) Has the company established an effective accounting system and	✓		1. The accounting system and internal control system of the Company are designed under	Comply with the Integrity Management Code of

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
internal control system to implement honest business operations? Has the internal audit unit formulated relevant audit plans based on the results of the assessment of dishonest behavior risks and used them to verify compliance with the plan to prevent dishonest behavior, or has it entrusted a certified public accountant to perform the audit?			<p>the framework for the purpose of implementing honest business operations. The internal audit unit conducts regular audits and reports the audit results and implementation status to the board of directors every quarter.</p> <p>2. The Company appoints an accountant to conduct annual audits and certifications to conduct random confirmation of the implementation of internal controls in order to reasonably ensure that the Company's accounting system and internal control system are operating effectively.</p>	Conduct for Listed Companies
(V) Does the company regularly hold internal and external education and training on integrity management?	✓		<p>1. The company encourages employees to participate in various education and training courses, and promotes relevant methods such as "Integrity Management Operating Procedures and Behavior Guidelines" and "Code of Ethical Conduct" at internal meetings from time to time to let employees understand their importance.</p> <p>2. The company regularly holds (once a year) education and promotion sessions on honest business practices and related laws. Course topics include: Guidelines for honest business practices, prevention of insider trading, etc., to prevent dishonest behavior. The implementation of the internal education and promotion courses in 2024 is as follows: a) On November 28, we invited external lecturers to give two themed courses to all employees, including</p>	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			<p>" Integrity in Internal Management " and " Prevention of Insider Trading " , which were held in the form of physical and online participation; b) The remaining 2024 employees' external education and training are disclosed on page 191-192 of the annual report.</p> <p>3. The Company also provides information on director responsibilities, integrity management, legal knowledge, etc. for directors' reference from time to time. The training status of directors and independent directors in 2024 is disclosed on pages 52-54 of the annual report.</p>	
<p>3. Operation of the company's whistleblower system</p> <p>1. Has the company established a specific reporting and reward system, established convenient reporting channels, and assigned appropriate personnel to handle reports?</p>	✓		<p>1. The company has established "Regulations for Handling Reports of Illegal, Immoral or Dishonest Behavior Cases", which assign appropriate dedicated personnel to handle reports, and specify the reporting channels , types of reporting matters , reporting procedures , protection policies , and rewards and obligations of reporters.</p> <p>2. The specific reporting and reward system includes: establishing a confidential and direct reporting channel , designating dedicated personnel to handle the reporting, standard operating procedures for investigating reported matters and related confidentiality mechanisms , measures to protect reporters from being improperly dealt with due to reporting , and</p>	<p>Comply with the Integrity Management Code of Conduct for Listed Companies</p>

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			measures to reward reporting of dishonest behavior.	
(II) Does the company have established standard operating procedures for investigating reported matters, follow-up measures to be taken after the investigation is completed, and related confidentiality mechanisms?	✓		Our company's "Procedures for Handling Reports of Illegal, Immoral or Dishonest Behavior" clearly stipulates the reporting procedures, including what should be recorded in the report, the handling procedures for reports, and improvement measures.	Comply with the Integrity Management Code of Conduct for Listed Companies
(3) Has the company taken measures to protect whistleblowers from being improperly punished for reporting?	✓		Our company's "Procedures for Handling Reports of Illegal, Immoral or Dishonest Behavior" clearly stipulates a protection policy: the identity of the reporter and the content of the report should be kept completely confidential and verified through independent channels. The Company will maintain confidentiality and protect whistleblowers or persons involved in the investigation from unfair treatment or retaliation. Let the whistleblower feel at ease and reassured, and maintain a positive and kind corporate culture and atmosphere.	Comply with the Integrity Management Code of Conduct for Listed Companies
4. Strengthening Information Disclosure established integrity management code and the effectiveness of its promotion on its website and public information observatory ?	✓		1. The Company's "Integrity Management Operating Procedures and Behavior Guidelines" have been disclosed in the Company's annual report, website and public information observatory. Investors can check the Company's website \ Corporate Governance \ Corporate Governance Regulations. 2. The Company discloses the Company's	Comply with the Integrity Management Code of Conduct for Listed Companies

Evaluation Project	Implementation status (Note 1)			Differences and reasons from the Integrity Management Code of the listed companies
	yes	no	Summary (Note 2)	
			integrity management policies, activities and implementation status for the current year in the Corporate Governance and Integrity Management area of the Company's website.	
<p>5. If the company has its own integrity management code based on the "Integrity Management Code for Listed and OTC Companies" , please describe the differences between its operation and the established code: The Company has established the "Integrity Management Operating Procedures and Behavior Guidelines" in accordance with the "Integrity Management Code for Listed Companies". Currently, there is no significant difference between the relevant operations and the established code, and the implementation is normal.</p>				
<p>6. Other important information that helps to understand the company's integrity management operations: (such as the company's review and revision of its established integrity management code, etc.) If the Company amends the "Integrity Management Operating Procedures and Behavior Guidelines", it will first submit the proposal to the Board of Directors for approval , send it to each independent director and submit a report to the shareholders' meeting, and then announce it for implementation.</p>				

Note: Regardless of whether you tick “Yes” or “No”, the operating status should be stated in the summary column.

(8) Other important information that is sufficient to enhance understanding of the company's governance operations may also be disclosed :

1. In order to strengthen the prevention of insider trading, the Company has established a mechanism for handling and disclosing important information within the Company to avoid improper information leakage, ensure the security of the Company's important information and the consistency and accuracy of external information. The Company has formulated the "Management Measures for Preventing Insider Trading" for insiders to follow.

2. Public Information Observation Station: <http://mops.twse.com.tw/mops/web/index>
(Stock Code: 8403)

(9) The implementation status of the internal control system should disclose the following matters :

1. Internal Control Statement, website:

<https://mops.twse.com.tw/mops/#/web/t06sg20>

2. Those who entrust an accountant to conduct a special audit of the internal control system shall disclose the accountant's audit report: Not applicable.

(X) Important resolutions of the shareholders' meeting and the board of directors in the most recent year and up to the date of publication of the annual report

1. Board of Directors

Meeting Date	Major resolutions
2024.03.15 The 18th Session of the 7th Session Board of Directors	<p>(I) Reporting matters:</p> <ol style="list-style-type: none"> 1. Resolutions of the previous meeting and their implementation status. 2. Business report. 3. Audit business report. 4. The Company purchased 1.5 million shares of Smart Medical City Co., Ltd. from Yaosheng Information Co., Ltd., with a total investment of NT\$22.5 million. 5. Investment report of Super Biotech Co., Ltd. 6. The actual amount of the 2023 year-end bonuses paid to the company's managers and the 2023 annual salary review report. 7. Implementation of greenhouse gas inventory and verification. 8. Report on the performance evaluation results of the Board of Directors and functional committees in 2023. <p>(II) Matters for discussion:</p> <ol style="list-style-type: none"> 1. The 2023 annual business report and financial statements are submitted for discussion. 2. The proposal on the proportion and amount of directors' and supervisors' remuneration and employees' remuneration in 2023 is submitted for discussion. 3. The proposal on remuneration of the company's independent directors is submitted for discussion. 4. The independence and competency assessment case of the 2024 CPA is submitted for discussion. 5. The 2024 visa accountant appointment case is submitted for discussion. 6. The proposal for review of the internal control system statement is submitted for discussion. 7. The proposal for change of the head of corporate governance of our company is submitted for discussion. 8. The case of changing the spokesperson of our company is brought up for discussion.

Meeting Date	Major resolutions
	<p>9. The proposal to amend the Company's "Audit Committee Organizational Charter" and "Board of Directors Meeting Rules" is submitted for discussion.</p> <p>10. The case of extending the bank's short-term credit loan quota is submitted for discussion.</p> <p>11. The proposal for a comprehensive re-election of the company's directors (including independent directors) is submitted for discussion.</p> <p>12. The 2024 shareholders' meeting was held to discuss the proposal.</p>
<p>2024.05.10</p> <p>The 19th session of the 7th session Board of Directors</p>	<p>(I) Reporting matters:</p> <ol style="list-style-type: none"> 1. Resolutions of the previous meeting and their implementation status. 2. Business report. 3. Audit business report. 4. 2023 Corporate Governance Evaluation Report. 5. Implementation of greenhouse gas inventory and verification. 6. the dissolution and liquidation report cases for subsidiaries including Shengshi Digital Health Co. , Ltd. , Shengtai Food Technology Co. , Ltd. and Huiyun Microfluidics Co. , Ltd. 7. Deputy General Manager Fu Lanying's retirement and resignation from the General Manager's Office. 8. Directors, supervisors and key personnel liability insurance coverage report. <p>(II) Matters for discussion:</p> <ol style="list-style-type: none"> 1. The case of consolidated financial statements for the first quarter of 2024 is submitted for discussion. 2. The 2024 fiscal year profit distribution proposal is submitted for discussion. 3. The case of issuing new shares by converting surplus into capital is submitted for discussion. 4. The proposal to amend the company's "Articles of Incorporation" is submitted for discussion. 5. Formulate the "Organizational Charter of the Sustainability Committee" of our company and submit it for discussion.

Meeting Date	Major resolutions
	<ol style="list-style-type: none"> The board of directors' nomination of a list of candidates for directors (including independent directors) is submitted for discussion. A proposal to lift the non-competition restriction on newly elected directors (including independent directors) is submitted for discussion. Revise the proposal of the 2024 Annual General Meeting of Shareholders of the Company and submit it for discussion. The case of extending the bank's short-term credit loan quota is submitted for discussion.
2024.06.24 The 1st session of the 8th session Board of Directors	(1) Election matters: <ol style="list-style-type: none"> We hereby propose the election of the eighth chairman of the board of directors of our company. We hereby propose the election of the eighth Vice Chairman of the Company.
113.08.09 The 2nd Session of the 8th Session Board of Directors	(I) Reporting matters: <ol style="list-style-type: none"> Resolutions of the previous meeting and their implementation status. Business report. Audit business report. Implementation of greenhouse gas inventory and verification. Deputy General Manager of the Finance Department, Li Hongyi, was transferred and resigned. (II) Matters for discussion: <ol style="list-style-type: none"> The second quarter consolidated financial statements for 2024 are submitted for discussion. We propose to set the ex-rights and dividend base date for the company's 2023 profit distribution and other related matters for discussion. The proposal for appointment of members of the Sixth Remuneration Committee is submitted for discussion. We propose to set up a new "Sustainable Development Committee" for our company and submit it for discussion. Revise the company's "Board of Directors and Functional Committee

Meeting Date	Major resolutions
	<p>Performance Evaluation Methods" and submit it for discussion.</p> <p>6. It is proposed to abandon the case of issuing new shares through cash capital increase of an important subsidiary, Yueshi Health (Stock) Co., Ltd., and submit it for discussion.</p> <p>7. The case of extending the bank's short-term credit loan quota is submitted for discussion.</p>
<p>2024.11.08</p> <p>The 3rd Session of the 8th Session Board of Directors</p>	<p>(I) Reporting matters:</p> <ol style="list-style-type: none"> 1. Resolutions of the previous meeting and their implementation status. 2. Business report. 3. Audit business report. 4. Implementation of greenhouse gas inventory and verification. 5. Report on acquisition of 100,000 shares of Zhiyicheng Co., Ltd. 6. Report on the payment of cash capital increase and share subscription for the 2024 investment business of Precision Health Co., Ltd. 7. Report on the performance of communication with stakeholders in 2024. 8. 2024 Corporate Integrity Management Implementation Report. <p>(II) Matters for discussion:</p> <ol style="list-style-type: none"> 1. The case of consolidated financial statements for the third quarter of 2024 is submitted for discussion. 2. New "Operational Procedures for the Preparation and Submission of Sustainability Reports" are proposed for discussion. 3. A proposal to amend the company's "Internal Control System" and "Internal Audit Implementation Rules" is submitted for discussion. 4. A proposal to amend the Company's "Corporate Governance Code" is submitted for discussion. 5. The case of financial institution applying for credit line is submitted for discussion.
<p>2024.12.06</p> <p>The 4th Session of the 8th</p>	<p>(I) Reporting matters:</p> <ol style="list-style-type: none"> 1. Resolutions of the previous meeting and their implementation status. <p>(II) Matters for discussion:</p>

Meeting Date	Major resolutions
Session Board of Directors	<ol style="list-style-type: none"> 1. The proposal to appoint the Deputy General Manager for the Chief Executive Officer's Office of the Company is submitted for discussion. 2. The sale of the Dayuan Minsheng Hospital building is submitted for discussion. 3. The merger between our company and "Smart Medical City Co., Ltd." is submitted for discussion. 4. The investment case for the decoration and equipment of the "Smart Medical City Building - Healthy Living and Wellness Home" is put forward for discussion.
2024.12.21 The 5th Session of the 8th Session Board of Directors	<p>(I) Reporting matters:</p> <ol style="list-style-type: none"> 1. Resolutions of the previous meeting and their implementation status. 2. Business report. 3. 2024 Annual Risk Management Working Group Operation Report. 4. 2024 Annual Sustainable Business Promotion and Implementation Report. 5. Information Security Executive Report. 6. Intellectual Property Management Plan. <p>(II) Matters for discussion:</p> <ol style="list-style-type: none"> 1. 2024 Budget and Operating Plan is submitted for discussion. 2. Formulate the 2025 annual audit plan and submit it for discussion. 3. The proposal to donate NT\$1 million to the United Medical Foundation is submitted for discussion. 4. The case of financial institution applying for credit line is submitted for discussion. 5. The appointment proposal of the Deputy General Manager of the Smart Medical City Division of our company is submitted for discussion. 6. The remuneration proposal for the Deputy General Manager of the Executive Office of our company is submitted for discussion. 7. The company's year-end bonus plan and managers' year-end bonus distribution plan are submitted for discussion. 8. The case of payment of remuneration to the employees of our

Meeting Date	Major resolutions
	<p>company is submitted for discussion.</p> <p>9. The company's 2025 employee salary increase proposal is submitted for discussion.</p>
<p>2025.03.14</p> <p>The 6th Session of the 8th Session Board of Directors</p>	<p>(I) Reporting matters:</p> <p>1 、 Resolutions of the previous meeting and their implementation status.</p> <p>2 、 Business report.</p> <p>3 、 Audit business report.</p> <p>4 、 The company's managers' 2024 year-end bonus distribution and 2024 annual salary review report.</p> <p>5 、 Implementation of greenhouse gas inventory and verification.</p> <p>6 、 Report on the performance evaluation results of the Board of Directors and functional committees in 2024.</p> <p>(II) Matters for discussion:</p> <p>1 、 2024 annual business report and financial statements are submitted for discussion.</p> <p>2 、 The proposal on the proportion and amount of directors' and employees' remuneration in 2024 is submitted for discussion.</p> <p>3 、 2024 fiscal year profit distribution proposal is submitted for discussion.</p> <p>4 、 The case of issuing new shares by converting surplus into capital is submitted for discussion.</p> <p>5 、 The definition of the company's grassroots employees and the ratio of profit allocation to grassroots employees are submitted for discussion.</p> <p>6 、 The case of replacing the old bidirectional cardiac catheters at Minsheng General Hospital with new ones is submitted for discussion.</p> <p>7 、 The independence and competency assessment case of the 2025 Certified Public Accountants is submitted for discussion.</p> <p>8 、 2025 annual visa accountant appointment case is submitted for discussion.</p> <p>9 、 The proposal for review of the internal control system statement is submitted for discussion.</p> <p>10 、 A proposal to amend the company's "Internal Control System"</p>

Meeting Date	Major resolutions
	<p>and "Internal Audit Implementation Rules" is submitted for discussion.</p> <p>11、The proposal to amend the company's "Operational Standards for Financial Affairs between Related Parties" is submitted for discussion.</p> <p>12、The proposal to amend the company's "Articles of Incorporation" is submitted for discussion.</p> <p>13、New (extension) loan cases for short-term comprehensive credit lines of financial institutions are submitted for discussion.</p> <p>14、2025 shareholders' meeting was held for discussion.</p> <p>15、The remuneration proposal for the Deputy General Manager of the Smart Medical City Division of our company is submitted for discussion.</p>

2. Regular shareholders meeting

Meeting Date	Major resolutions	Implementation
2024.6.24 Shareholders' Meeting	1. 2023 Annual Business Report, Financial Statements and Consolidated Financial Statements Approval	Execution completed.
	2. Proposal on profit distribution for fiscal year 2023	On May 10, 2024, the board of directors approved and on August 9, 2024, the board of directors authorized the chairman to set September 2, 2024 as the ex-rights and dividend date (cash dividend of RMB 0.4 per share and stock dividend of RMB 0.40000001 per share).
	3. Profit transfer and capital increase and new stock issuance	1. Number of shares issued: 5,041,771 shares. 2. Paid-in capital after capital increase: NT \$ 1,310,860,410 . 3. Purpose of capital increase: Strengthen financial structure.
	4. Amendment of the Company 's Articles of Incorporation	The revised procedures have been followed and announced on our website.
	5. Election of the 8th Board of Directors and Independent Directors	Execution completed.
	6. Lifting the non-competition restriction on newly elected directors (including independent directors)	Execution completed.

(XI) In the most recent year and up to the date of publication of the annual report, the directors or supervisors had different opinions on important resolutions passed by the board of directors and the main contents of the records or written statements are : None.

2.3 Information on public fees for accountants

(1) Information on the public fees for visa-based accountants:

Visa Accountant Public Fund Information

Amount Unit: NT\$ thousand

Name of accounting firm	Accountant's Name	During the period of audit by accountants	Audit public expenses	Non-audit public expenses	total	Remark
A&H CPA LLP	Kou Huizhi	2024/01/01	3,030	479	3,509	1. Non-audit public expense services: The tax visa fee is 199,000 yuan, the transfer pricing report fee is 180,000 yuan, and the industrial and commercial registration fee is 100,000 yuan.
	Guo Xinyi	~ 2024/12/31				

(2) If the accounting firm is changed and the audit fees paid in the year of change are less than the audit fees paid in the year before the change, the amount of audit fees before and after the change and the reason should be disclosed: Not applicable.

(3) If the audit expenses are reduced by more than 10% compared with the previous year, the amount, proportion and reason of the reduction in audit expenses shall be disclosed: Not applicable.

2.4 Information on change of accountant: None

2.5 The company's chairman, general manager, or manager in charge of financial or accounting affairs who has worked for the firm to which the certifying CPA belongs or its affiliated companies within the past year: None.

2.6 Changes in equity transfers and equity pledges by directors, supervisors, managers, and shareholders holding more than 10% of the shares in the most recent year and up to the date of publication of the annual report:

(I) Changes in the equity of directors, supervisors, managers and major shareholders

Unit: Share

Job title (Note 1)	Name	2024		Until April 15, 2025	
		Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number	Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number
Corporate Director (Major Shareholder)	Minsheng Medical Control Co., Ltd.	1,451,931	970,000	0	0
Chairman	Minsheng Medical Control Co., Ltd. Representative: Yang Hongren	43,450	0	0	0
Vice Chairman	Minsheng Medical Control Co., Ltd. Representative: Xu Shengxin	0	0	0	0
Director and President	Minsheng Medical Control Co., Ltd. Representative: Liu Qingwen	2,273	0	0	0
director	Minsheng Medical Control Co., Ltd. Representative: Sun Zhili	0	0	0	0
director	Minsheng Medical Control Co., Ltd. Representative: Chen Wenzhong	0	0	0	0
Corporate Director	Rong Yang Management Consultants Limited	5,357	0	0	0
director	Rong Yang Management Consultants Limited Representative: Zhang Changrong	0	0	0	0
director	Yang Chen Caibi	56,670	0	0	0
Independent Director	Wu Genzai	0	0	0	0

Job title (Note 1)	Name	2024		Until April 15, 2025	
		Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number	Number of shares held Increase (decrease) number	Number of pledged shares Increase (decrease) number
Independent Director	Li Shuxing	0	0	0	0
Independent Director	Chen Houming	0	0	0	0
Independent Director	Yao Xiubi	0	0	0	0
Deputy General Manager	Chen Pengxuan	5	0	0	0
Deputy General Manager	Wu Mingxun	10,187	0	0	0
Deputy General Manager	Ke Weixin	7	0	0	0
Deputy General Manager	Fu Lanying	1,206	0	0	0
Deputy General Manager	Li Hongyi	0	0	0	0
Deputy General Manager	Cai Yufang	0	0	0	0
Deputy General Manager	He Weiguang	0	0	0	0
Deputy General Manager	Zhong Yiting	0	0	0	0
Accounting Assistant	Huang Yamei	487	0	0	0

- (2) In the most recent year and up to the date of publication of the annual report, the directors, supervisors, managers and shareholders holding more than 10% of the shares to whom the shareholders transferred their shares were related persons: None.

- (3) In the most recent year and up to the date of publication of the annual report, the directors, supervisors, managers and shareholders holding more than 10% of their shares whose counterparties are pledged are related parties: None.

2.7 Information on whether the top ten shareholders in terms of shareholding ratio are related persons or spouses or relatives within the second degree of kinship.

April 18 , 2025/ Unit: Shares; %

NAME (NOTE 1)	PERSONAL SHAREHOLDING		SPOUSE AND MINOR CHILDREN HOLDING SHARES		HOLDING SHARES IN TOTAL UNDER THE NAME OF ANOTHER PERSON		IF THE TOP TEN SHAREHOLDERS ARE RELATED PERSONS OR SPOUSES OR RELATIVES WITHIN THE SECOND DEGREE OF KINSHIP , THEIR NAMES OR FULL NAMES AND THEIR RELATIONSHIP. (NOTE 3)		REMARK
	Number of shares	Share holding ratio	Number of shares	Share holding ratio	Number of shares	Share holding ratio	name (or name)	relation	
Minsheng Medical Control Co., Ltd. Representative :Yang Hongren	37,750,221	28.80	0	0	0	0	none	none	none
	967,930	0.74	0	0	0	0	Yang Chen Caibi	Mother and Child	none
Yang Chen Caibi	1,473,441	1.12	1,261	0	0	0	Yang Hongren	Mother and Child	none
Su Qingrong	1,226,000	0.94	0	0	0	0	none	none	none
Huang En Hui	1,008,000	0.77	0	0	0	0	none	none	none
Yang Hongren	967,930	0.74	0	0	0	0	Yang Chen Caibi	Mother and Child	none
Tian Yulong	800,818	0.61	0	0	0	0	none	none	none
Yang Zheng Investment Co., Ltd. Representative :Yang Chen Caibi	739,940	0.56	0	0	0	0	none	none	none
	1,473,441	1.12	1,261	0	0	0	Yang Hongren	Mother and Child	none
Fu Fengcheng	658,000	0.50	0	0	0	0	none	none	none

NAME (NOTE 1)	PERSONAL SHAREHOLDING		SPOUSE AND MINOR CHILDREN HOLDING SHARES		HOLDING SHARES IN TOTAL UNDER THE NAME OF ANOTHER PERSON		IF THE TOP TEN SHAREHOLDERS ARE RELATED PERSONS OR SPOUSES OR RELATIVES WITHIN THE SECOND DEGREE OF KINSHIP, THEIR NAMES OR FULL NAMES AND THEIR RELATIONSHIP. (NOTE 3)		REMARK
	Number of shares	Share holding ratio	Number of shares	Share holding ratio	Number of shares	Share holding ratio	name (or name)	relation	
Minsheng Asset Management Co., Ltd. Representative :Zhang Changrong	619,001	0.46	0	0	0	0	none	none	none
	0	0	0	0	0	0	none	none	none
Xu Rongyuan	603,976	0.46	0	0	0	0	none	none	none

Note 1 : The top ten shareholders should all be listed. If they are legal person shareholders, the names of the legal person shareholders and the names of their representatives should be listed separately.

Note 2 : The calculation of shareholding ratio refers to the calculation of shareholding ratio in one's own name, spouse, minor children or in the name of another person.

Note 3 : The shareholders listed above include both legal persons and natural persons, and the relationship between them should be disclosed .

2.8 The number of shares held by the company, its directors, supervisors, managers and enterprises directly or indirectly controlled by the company in the same invested enterprise, and the calculation of the comprehensive shareholding ratio

March 31 ,2025 ; Unit: 1,000 shares ; %

Reinvestment business (Note)	Our investment		Directors, supervisors, managers and those who directly or indirectly control the business investments		Comprehensive Investment	
	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio
Mytrex Health Technologies, Inc.	22,454	61.46%	0	0	22,454	61.46%
Share Hope Medicine Co., Ltd. (Hong Kong)	1,500	100 %	0	0	1,500	100 %
Chungyuan Medical Management Co., Ltd	1,000	100 %	0	0	1,000	100 %
Pregetic Medical Health Co., Ltd.	12,601	38.19%	0	0	12,601	38.19%
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	100	100%	0	0	100	100%
Minsheng (Tianjin) Investment Management Co., Ltd	0	100%	0	0	0	100%
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	0	100%	0	0	0	100%
Mytrex Industries, Inc	0	0	6,000	100%	6,000	100%
First Long-term Care Platform Co., Ltd.	0	0	867	29.08%	867	29.08%
Mytrex USA Co.	0	0	800	88.89%	800	88.89%
Sheng Yo Rehabilitative Technologies, Inc.	0	0	4,381	47.62%	4,381	47.62%
TECHGROUP Integrate Design Co., Ltd.	1	51%	0	0	1	51%
Global Biotech Investments	500	23.98%	0	0	500	23.98%
Shengyu Health Technology Co., Ltd.	200	40%	0	0	200	40%
Macro Global Corporation	0	0	6,460	100%	6,460	100%
YES Health Co., Ltd.	0	0	6,035	100%	6,035	100%

Reinvestment business (Note)	Our investment		Directors, supervisors, managers and those who directly or indirectly control the business investments		Comprehensive Investment	
	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio	Number of shares	Shareholding ratio
Digimed Co., Ltd.	600	60%	200	20%	800	80%
Hung-Han Medical Health Co., Ltd.	0	0	3,420	100%	3,420	100%
Craftsman Group Co. , Ltd.	0	0	170	48.57%	170	48.57%
Harvard Health Inc. (formerly known as: Fuyi Health Co., Ltd.)	0	0	12,000	100%	12,000	100%
Anzhun Technology Co. , Ltd.	0	0	2,000	40%	2,000	40%
Shangjia Health Enterprise Co. , Ltd.	0	0	3,390	30.82%	3,390	30.82%

3. Participation and Fund Raising

3.1 Capital and Shares

1. Source of equity

Unit: 1,000 shares; 1,000 yuan

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
92.10	10	1,000	10,000	1,000	10,000	Establishment capital	none	Note 1
96.11	10	21,000	210,000	21,000	210,000	Cash capital increase	none	Note 2
97.05	15	50,000	500,000	23,100	231,000	Cash capital increase	none	Note 3
97.08	10	50,000	500,000	25,000	250,000	Surplus transfer to capital increase	none	Note 4
98.09	10	50,000	500,000	27,000	270,000	Surplus transfer to capital increase	none	Note 5
	13.25			27,150	271,500	Employee bonus transfer to capital increase		
98.10	27	50,000	500,000	30,150	301,500	Cash capital increase	none	Note 6
99.02	31	50,000	500,000	35,148	351,480	Cash capital increase	none	Note 7
99.07	10	50,000	500,000	37,960	379,598	Surplus transfer to capital increase	none	Note 8
	15.16			38,110	381,098	Employee bonus transfer to capital increase		
100.03	36	50,000	500,000	42,192	421,918	Cash capital increase	none	Note 9
100.09	10	50,000	500,000	43,458	434,576	Surplus transfer to capital increase	none	Note 10
101.10	18.8	100,000	1,000,000	43,708	437,076	Employee Stock Purchase	none	Note 11
	10			45,881	458,805	Surplus transfer to capital increase		
	22.98			51,297	512,971	Convertible bonds convertible into common stock		
102.03	22.98	100,000	1,000,000	51,850	518,497	Convertible bonds convertible into common stock	none	Note 12
102.05	18	100,000	1,000,000	51,854	518,537	Employee Stock Purchase	none	Note 13
	22.98			52,398	523,977	Convertible bonds convertible into common stock		
102.10	18	100,000	1,000,000	52,467	524,672	Employee Stock Purchase	none	Note 14
	10			55,087	550,870	Surplus transfer to capital increase		

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
	22.98			55,152	551,523	Convertible bonds convertible into common stock		
102.12	17.1 18	100,000	1,000,000	55,428	554,283	Employee Stock Purchase	none	Note 15
103.04	17.1	100,000	1,000,000	55,452	554,523	Employee Stock Purchase	none	Note 16
	21.89			55,589	555,894	Convertible bonds convertible into common stock		
103.06	17.1	100,000	1,000,000	55,600	556,003	Employee Stock Purchase	none	Note 17
103.10	17.1	100,000	1,000,000	55,630	556,303	Employee Stock Purchase	none	Note 18
	10			58,410	584,104	Surplus transfer to capital increase		
	21.89			58,734	587,347	Convertible bonds convertible into common stock		
104.01	16.3	100,000	1,000,000	58,745	587,457	Employee Stock Purchase	none	Note 19
	21.89			58,823	588,234	Convertible bonds convertible into common stock		
104.06	16.3	100,000	1,000,000	59,021	590,214	Employee Stock Purchase	none	Note 20
	20.86			59,093	590,933	Convertible bonds convertible into common stock		
	37.85			59,318	593,179	Convertible bonds convertible into common stock		
104.10	37.85	100,000	1,000,000	59,492	594,923	Convertible bonds convertible into common stock	none	Note 21
	10			62,372	623,722	Surplus transfer to capital increase		
104.12	37.85	100,000	1,000,000	63,548	635,479	Convertible bonds convertible into common stock	none	Note 22
	36.09			64,684	646,839	Convertible bonds convertible into common stock		
105.04	36.09	100,000	1,000,000	74,287	742,874	Convertible bonds convertible into common stock	none	Note 23
105.06	36.09	100,000	1,000,000	74,971	749,718	Convertible bonds convertible into common stock	none	Note 24
105.10	36.09	100,000	1,000,000	75,584	755,842	Convertible bonds convertible into common stock	none	Note 25

years	issued price	Authorized share capital		Paid-in capital		Remark		
		Number of shares	Amount	Number of shares	Amount	Source of equity	Using property other than cash to pay for shares	other
106.09	10	100,000	1,000,000	79,288	792,888	Surplus transfer to capital increase	none	Note 26
107.02	10	100,000	1,000,000	77,797	777,978	Cancellation of Treasury Stock	none	Note 27
107.04	30	100,000	1,000,000	92,797	927,978	Cash capital increase	none	Note 28
107.10	10	100,000	1,000,000	97,437	974,378	Surplus transfer to capital increase	none	Note 29
108.10	10	150,000	1,500,000	102,309	1,023,096	Surplus transfer to capital increase	none	Note 30
109.10	34.6	150,000	1,500,000	103,425	1,034,252	Convertible bonds convertible into common stock	none	Note 31
109.10	10			108,541	1,085,407	Surplus transfer to capital increase	none	
110.01	33	150,000	1,500,000	108,697	1,086,969	Convertible bonds convertible into common stock	none	Note 32
110.04	33	150,000	1,500,000	108,882	1,088,818	Convertible bonds convertible into common stock	none	Note 33
110.10	10	150,000	1,500,000	114,326	1,143,259	Surplus transfer to capital increase	none	Note 34
111.09	10	150,000	1,500,000	120,042	1,200,422	Surplus transfer to capital increase	none	Note 35
112.09	10	150,000	1,500,000	126,044	1,260,442	Surplus transfer to capital increase	none	Note 36
113.09	10	200,000	2,000,000	131,086	1,310,860	Surplus transfer to capital increase	none	Note 37

Note 1 : On October 13, 2003 , the Chinese version of the application was granted the Chinese version number 09232793980.

Note 2 : On November 20, 2007 , the Chinese version of the application was granted the Chinese version number 09633073780.

Note 3 : On May 19, 2008 , the Chinese version of the application was granted the Chinese version number 09732260910.

Note 4 : On August 4, 2008 , the Chinese version of the application was granted the Chinese version number 09732765220.

Note 5 : JINGZI No. 0980034558 issued on July 14 , 2009 and JINGZI No. 09833057760 issued on September 15 , 2009

Note 6 : Financial Management Certificate No. 0980037987 issued on July 29 , 2009 and Approval No. 09833206110 issued on October 8 , 2009

Note 7 : Financial Management Certificate No. 0980066075 issued on December 11 , 2009 and Approval No. 09931671870 issued on February 10 , 2009

Note 8 : Financial Management Certificate No. 0990039571 issued on July 28 , 2009 and Approval No. 09932762350 issued on November 1 , 2009

Note 9 : 17 January 2011 , Jinguan Certificate No. 0990073963 and 14 March 2011 , Jingkuo Zhongzi No. 10031753080

Note 10 : JINZHIFAZHI No. 1000031409 issued on July 7 , 2011 and JINZHIZHI No. 10032489230 issued on September 14 , 2011

Note 11 : Financial Management Certificate No. 1010035228 issued on August 10 , 2012 and Business License No. 10101224560 issued on October 30 , 2012

Note 12 : License No. 10201044170 issued on March 12 , 2013

Note 13 : On May 17, 2013 , the license number was granted as 10201091590

Note 14 : Financial Management Certificate No. 1020030545 issued on August 6, 2013 and Business License No. 10201202410 issued on October 1 , 2013

Note 15 : License No. 10201256970 issued on December 20 , 2013

Note 16 : License No. 10301070200 issued on April 22 , 2014

Note 17 : License No. 10301114790 issued on June 17 , 2014

Note 18 : License No. 10301204740 issued on October 3 , 2014
 Note 19 : License No. 10301262300 issued on January 13 , 2015
 Note 20 : License No. 10401117580 issued on June 17 , 2015
 Note 21 : License No. 10401201570 issued on October 5 , 2015
 Note 22 : License No. 10401268730 issued on December 15 , 2015
 Note 23 : License No. 10501077020 issued on April 20 , 2016
 Note 24 : License No. 10501130760 issued on June 28 , 2016
 Note 25 : License No. 10501236380 issued on October 3 , 2016
 Note 26 : On September 27, 2017 , the license number was granted as 10601134570 .
 Note 27 : License No. 10701017630 issued on February 14 , 2018
 Note 28 : License No. 10701037200 issued on April 11 , 2018
 Note 29 : License No. 10701128970 issued on October 9 , 2018
 Note 30 : License No. 10801134510 issued on October 4 , 2019
 Note 31 : License No. 10901186610 issued on October 13 , 2020
 Note 32 : License No. 11001007520 issued on January 19 , 2021
 Note 33 : License No. 11001063430 issued on April 20 , 2021
 Note 34 : License No. 11001184020 issued on October 18 , 2021
 Note 35 : On September 28, 2022, the license number was granted as 11101178780
 Note 36 : On September 20 , 2023 , the license number was granted as 11230178490 .
 Note 37 : On September 23 , 2024 , the license number was granted as 11330167330 .

Types of Shares

April 18 , 2025 /

Unit : Shares

Shares type	Authorized share capital			Remark
	Outstanding shares (Note)	Unissued shares	total	
Common Stock	131,086,041 shares	68,913,959 shares	200,000,000 shares	none

Note: 1. Issued shares are OTC stocks.

2. Information related to the summary declaration system: None.

(II) List of major shareholders: names of shareholders with a shareholding ratio of 5% or more or the top ten shareholders, and the amount and ratio of their shares
April 18 , 2025 ; Unit : Shares

Shares Name of major shareholder	Number of shares held	Shareholding ratio
Minsheng Medical Control Co., Ltd.	37,750,221	28.80
Yang Chen Caibi	1,473,441	1.12
Su Qingrong	1,226,000	0.94
Huang En Hui	1,008,000	0.77
Yang Hongren	967,930	0.74
Tian Yulong	800,818	0.61
Yang Zheng Investment Co., Ltd.	739,940	0.56
Fu Fengcheng	658,000	0.50
Minsheng Asset Management Co., Ltd.	619,001	0.47
Xu Rongyuan	603,976	0.46

(III) The company's dividend policy and implementation status

1. Dividend policy as stipulated in the company's articles of association

If the company's annual financial statements show a surplus, after paying taxes in accordance with the law and making up for accumulated losses, another 10% will be set aside as a statutory surplus reserve. However, if the statutory surplus reserve has reached the company's paid-in capital, no further setting aside may be made; the remainder will be set aside or transferred as a special surplus reserve in accordance with laws and regulations; if there is any balance, together with the accumulated undistributed surplus, the board of directors shall prepare a surplus distribution proposal and submit it to the shareholders' meeting for resolution on the distribution of dividends to shareholders.

The Company's shareholder dividend policy is based on consideration of the Company's current and future investment environment, funding needs, profitability, capital structure and future operating needs, while taking into account shareholder interests, balancing dividends and the Company's long-term financial planning. Dividends are distributed in cash or stock. The proportion of cash dividends distributed in the current year shall not be less than 20% of the total dividends for the current year , and the rest shall be distributed in the form of stock dividends. However, the actual distribution ratio may be adjusted based on the actual profit and operating conditions of the current year.

2. Proposed (already) dividend distribution for this year :

The company 's 2024 shareholders' meeting proposed dividend distribution
(approved by the board of directors on March 14 , 2025)

Dividend Types	Distribution per share (yuan)	source
Cash dividends	0. 50000000	Retained earnings
Stock dividends	0. 49999999	Retained earnings

(IV) The impact of the proposed free rights issue on the company's operating performance and earnings per share: The distributable earnings in 2024 were RMB799,901,957 . The proposed free rights issue is RMB0.49999999 per share, which has no significant impact on the company's operating performance and earnings per share.

(V) Remuneration of employees , directors and supervisors

1. The percentage or range of employee dividends and directors' and supervisors' remuneration as specified in the company's articles of association :

If the Company makes a profit in a year, it shall set aside 6% to 10% as employee remuneration, which shall be distributed in the form of stock or cash by resolution of the Board of Directors, and the recipients shall include employees of affiliated companies who meet certain conditions . The Company may set aside no more than 3% of the above profit amount as remuneration for directors and supervisors by resolution of the Board of Directors . Proposals for employee remuneration and directors' and supervisors' remuneration distribution should be submitted to the shareholders' meeting. However, if the company still has accumulated losses, it should reserve the amount to make up for it in advance and then allocate the employee remuneration and the director and supervisor remuneration in accordance with the proportions in the preceding paragraph.

2. The basis for estimating the remuneration of employees , directors and supervisors in this period, the basis for calculating the number of shares for employee remuneration distributed in the form of stocks, and the accounting treatment when the actual distribution amount differs from the estimated amount :

, directors and supervisors of the Company for this period is calculated based on the Company's internal estimated full-year operating results and the contribution ratio stipulated in the Company's Articles of Association. If the subsequent distribution amount determined by the board of directors differs from the estimated amount, it will be considered a change in accounting estimate and the annual profit or loss will be adjusted to increase or decrease the distribution amount .

3. The board of directors approves the distribution of remuneration :

- (1) Amount of employee compensation and director and supervisor compensation distributed in cash or stock. If there is a difference with the estimated amount of the recognized expense in the year, the difference, reason and treatment should be disclosed :

Unit: Yuan

Assign Project	Amount proposed by the Board of Directors to be allotted (A)	Annual estimated amount of expense recognition (B)	Difference Amount (AB)	Causes of differences and solutions
Employee Remuneration	16,014,437	16,014,437	0	No difference
Remuneration of Directors and Supervisors	2,669,073	2,669,073	0	

(2) Amount of employee compensation distributed in the form of stock and its proportion to the total net profit after tax and total employee compensation of the current period or individual financial statements:
Not applicable .

4. The actual distribution of employee, director and supervisor remuneration in the previous year (including the number of shares distributed, amount and share price); if there is a difference between the employee, director and supervisor remuneration recognized, the difference, reason and handling status shall be stated :

Unit:

Yuan

Assign Project	Amount proposed by the Board of Directors to be allotted (A)	Actual amount distributed (B)	Difference Amount (AB)	Causes of differences and solutions
Employee Remuneration	11,194,299	0	11,194,299	The difference in employee remuneration of the Company is mainly due to the fact that some amounts have not yet been paid due to the payment in installments .
Remuneration of Directors and Supervisors	1,865,717	1,865,717	0	

(VI) The company repurchased its own shares: None

- 3.2 Corporate bond handling status: None .**
- 3.3 Special shares handling situation: None.**
- 3.4 Overseas depositary receipts: None.**
- 3.5 Employee stock option certificates: None.**
- 3.6 Issuance of new shares in the event of a merger or acquisition or transfer of shares of another company: None .**
- 3.7 Fund utilization plan and implementation status: None .**

4. Operation Overview

4.1 Business Content

1. Business scope

1. The main contents and products of our company's business :

Shenghong Pharmaceutical Co., Ltd. is a professional health management and pharmaceutical business organization. The main business areas include supply of medicines and medical materials, leasing of medical instruments and equipment, health management, medical manpower dispatch, medical management consulting and entrusted operation services, remote medical care, hospital management , etc.

The main business items registered by our company with the Ministry of Economic Affairs are as follows:

- 01.F108021 Western medicine wholesale industry.
- 02.F108011 Traditional Chinese medicine wholesale industry.
- 03.F208050 Class B finished medicine retail industry.
- 04.F108031 Medical equipment wholesale industry.
- 05.F108040 Cosmetics wholesale industry.
- 06.F208040 Cosmetics retail industry.
- 07.F118010 Information software wholesale industry.
- 08.F401010 International trade industry.
- 09. I 103060 Management consultancy industry.
- 10. I 301010 Information software services industry.
- 11. I C01010 Pharmaceutical testing industry.
- 12. I Z12010 Human resource dispatch industry.
- 13.JE01010 Leasing industry.
- 14.JZ99050 Intermediary services.
- 15. In addition to permitted business, ZZ99999 may engage in business that is not prohibited or restricted by laws and regulations.
- 16.F102170 Food and sundry goods wholesale industry

- 17.F203010 Food, sundries and beverage retail industry
 18.F208031 Medical equipment retail industry.
 19.J901020 General hotel industry .

2. Business proportion

Unit: NT\$ thousand

<div> <div>year</div> <div>Business Category</div> </div>	2024	
	Business income	Proportion of turnover
Supply of medicines, medical materials and scientific materials	3,539,250	81.82
Health and Medical Management	666,175	15.40
Equipment rental service	120,406	2.78
total	4,325,831	100

3. The company's current products (services)

(1) Pharmaceutical Distribution Department

- A. Pharmaceutical joint procurement platform : including medicines, health materials, home care products, etc.
- B. Warehousing and logistics management of pharmaceutical and medical materials
- C. Professional information consultation and services for pharmaceutical and health materials
- D. Distribution and agency of medicines, health foods and cosmeceuticals

(2) Health Management Department

- A. Medical health examination management consulting and entrusted operation services
- B. Medical laboratory management consulting and entrusted operation services
- C. Integrated marketing of medical testing related instruments, reagents, and consumables
- D. Medical manpower planning and dispatch services
- E. Planning and setting of medical office
- F. Workplace health management consulting services

(3) Specialist Services Department

- A. Medical equipment leasing : including the sale and leasing of medical equipment, engineering, surgical instruments, information hardware and software, and other specific equipment :
 - a. Instruments: including medical imaging equipment, ultrasound, exercise electrocardiogram, hearing test equipment, respirators, bedside physiological monitors, defibrillators, electrocautery machines, surgical air drills, electric drills, anesthesia machines, ECMO, aortic balloon pumps, operating tables, microcomputer autoclaves, electronic gastroscopes, etc., and other instruments and auxiliary equipment and facilities required for treating or prolonging the patient's life.
 - b. Instruments: surgical instruments, soft and hard endoscopes, etc.
 - c. Information: information hardware and software related to medical operations, etc.
- B. Subsequent services for leased medical equipment: including maintenance (original or aftermarket) , repair and related maintenance consultation, and assistance in handling second-hand equipment.
- C. Project leasing: We tailor-make products and services according to customer needs and provide customers with complete and appropriate leasing projects.
- D. Professional Consulting: Provide evaluation related to the establishment, procurement and updating of medical equipment, software and hardware consulting related to the establishment of medical institutions, establishment and cooperation consulting of large medical equipment; floor plan planning, engineering design and cooperation consulting of medical specialties.
- E. Specialized operation: Cooperate with medical specialists in medical institutions to provide high-end medical equipment for specialized operation, combine medical expertise with the equipment supply chain, and provide more advanced and professional medical services to the public.

(4) Dialysis Division

- A. General dialysis : hemodialysis, peritoneal dialysis, maintaining high-quality dialysis medical services .
- B. Special dialysis : critical care dialysis, ascites dialysis, special blood purification-support critical care, blood purification DFPP-
Double plasma filtration .

C.Chronic kidney disease case management, nutritional counseling, and kidney disease nursing guidance.

(services) to be developed

- (1) Domestic and foreign pharmaceutical and medical material agency and development.
- (2) Cooperate with retail channels to expand clinic and pharmacy business.
- (3) We provide customers with a complete range of leasing services through human resource dispatch and professional human resource training, which have been expanded to include long-term care and hemodialysis.
- (4) Agency and distribution of medical instruments and equipment and distribution of special medical materials.
- (5) Establish cooperative business for specialized operation of medical instruments and equipment.
- (6) Provide better long-term chronic medical services through expansion of high-quality hemodialysis centers.

(II) Industry Overview

(1) Pharmaceutical Market

A. Global pharmaceutical market

According to statistics from IQVIA, including COVID-19 vaccines and drugs, the global pharmaceutical market size in 2023 will be approximately US\$1.61 trillion, an increase of approximately 8.40% from US\$1.48 trillion in 2022. Among them, the market size of advanced countries is approximately US\$1.28 trillion, accounting for approximately 79.38% of the global pharmaceutical market size, a significant increase from 73.42% in 2022. The pharmaceutical market size of the top ten advanced countries, namely the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, Canada, Australia and South Korea, will reach approximately US\$1,081.6 billion in 2023, accounting for 67.31% of the global pharmaceutical market; the emerging pharmaceutical markets, mainly in mainland China, Brazil, India and Russia, will reach US\$303.7 billion in 2023, accounting for approximately 18.90% of the global pharmaceutical market; as for low-income countries and regions, their pharmaceutical sales will be US\$27.6 billion, accounting for only 1.72%, as shown in the table below.

Regional distribution of global pharmaceutical sales in 2023

Unit: 100 million US dollars, %

Regional difference	2023 Sales	2019~ 2023 CAGR	2028 Estimated sales	2024~ 2028 CAGR
Advanced countries	12,755	7.3	17,750~18,050	2.5~5.5
-Top Ten Advanced Countries	10,816	7.2	15,050~15,350	2.5~5.5
Emerging Pharmaceutical Countries	3,037	7.8	4,000~4,300	5~8
Low-income countries	276	8.5	330~370	4.5~7.5
total	16,068	7.3	22,250~22,550	6~9

Note: 1. CAGR: Compound Annual Growth Rate Annual Growth Rate) .

2. Emerging pharmaceutical markets by 2023 The standards for 2023 have been adjusted and the countries included have also changed. Year and 2022 The values for the years have changed significantly.

Source: Global Use of Medicines 2024: Outlook to 2028 , IQVIA , 2024-1 moon .

According to a survey by IQVIA, the top five therapeutic drugs in the world in 2028 are estimated to be cancer drugs, immunosuppressants, hypoglycemic drugs, cardiovascular drugs and central nervous system drugs, as shown in Table 2-2. Among them, cancer is a major disease that needs to be overcome urgently in the world. Among the new drugs approved for marketing or under development in various countries, cancer drugs still rank first. Coupled with the development of various innovative cancer therapies, cancer drugs will continue to maintain high growth in the future. It is estimated that the market size will reach US\$444 billion in 2028, with a compound annual growth rate of 14% to 17% from 2024 to 2028. Immunosuppressants have seen a slowdown in sales due to the approval of biosimilar drugs. The market size is estimated to be US\$192 billion in 2028, with a compound annual growth rate of only 2% to 5% from 2024 to 2028. It is worth noting that obesity drugs have produced better results with the use of innovative therapies and are showing rapid growth. The market size is estimated to be US\$74 billion in 2028, with a compound annual growth rate of 24% to 27% from 2024 to 2028.

2028 The top ten therapeutic drug categories in the world

Unit: 100 million US dollars, %

Pharmaceutical field	2028 Forecast sales	CAGR from 2024 to 2028
Oncologics (cancer drugs)	4,440	14~17
Immunology	1,920	2~5
Diabetics (diabetic drugs)	1,840	3~6
Cardiovascular	1,260	2~5
Central Nervous System (Central Nervous System Drugs)	1,030	6~9
Respiratory	990	3~6
Mental health (mental health medication)	810	9~12
Infectious diseases(drugs for infectious diseases)	750	3~6
Obesity	740	24~27
GU sexual health(Urogenital and sexual health medications)	620	3~6

Source: Global Use of Medicines 2024 : Outlook to 2028, IQVIA , 2024 January .

According to the survey statistics of GlobalData, the top ten best-selling drugs in the world in 2030 are predicted as shown in Table 2-7. Among them, Eli Lilly's diabetes drug Mounjaro® will become the top-selling drug in 2030, with a compound annual growth rate of 37.1%, from US\$5.339 billion in 2023 to US\$48.5 billion in 2030. Dupixent®, a drug developed by Sanofi for the treatment of atopic dermatitis, is expected to reach sales of US\$23.682 billion in 2030, with a compound annual growth rate of 10.8%. As for Merck's Keytruda® for the treatment of melanoma, considering that most of its indications have already been developed and the product's growth potential is limited, sales are estimated to be approximately US\$21.297 billion in 2030, with a compound annual growth rate of approximately 2.3% lower. Among the top ten drugs predicted to have the fastest sales growth before 2030, Novo Nordisk's weight loss drug Wegovy® is expected to have a compound annual growth rate of 22.4%, from US\$4.55 billion in 2023 to US\$18.768 billion in 2030. In addition, AbbVie's new psoriasis drug Skyrizi® and rheumatoid arthritis drug Rinvoq® will also have good growth, with estimated growth rates of 14.2% and 17.5% respectively by 2030.

Forecast of the top ten global pharmaceutical sales in 2030

Unit: US\$ billion

Rank ing	product	Manufacturer Name	2023 Sales	2030 Forecast sales	2023~2030 CAGR(%)
1	Mounjaro ®	Eli Lilly	53.39	485.00	37.1
2	Dupixent ®	Sanofi	115.88	236.82	10.8
3	Ozempic ®	Novo Nordisk	138.94	224.36	7.1
4	Keytruda®	Merck & Co	250.11	212.97	- 2.3
5	Skyrizi ®	AbbVie	77.63	196.76	14.2
6	Wegovy ®	Novo Nordisk	45.50	187.68	22.4
7	Darzalex ®	Johnson & Johnson	97.44	174.20	8.7
8	Biktarvy ®	Gilead Sciences	118.50	155.24	3.9
9	Gardasil/Gardasil 9 ®	Merck & Co	88.86	125.85	5.1
10	Rinvoq®	AbbVie	39.69	122.60	17.5

Source: GlobalData , 2024 Year 5 moon.

B. Domestic pharmaceutical market

my country's pharmaceutical industry is divided into areas such as Western medicine preparations, raw materials, biological preparations and traditional Chinese medicine preparations, as shown in Table 1 below. Among them, Western medicine preparations include small molecule new drugs and generic drugs that have exceeded their patent period, and are the main source of revenue for my country's pharmaceutical industry. APIs are the active ingredients of Western medicine preparations, which are made into preparations after being added with excipients. Domestic APIs are mostly supplied to foreign pharmaceutical companies, and the revenue is second only to the Western medicine preparation field, but the proportion of exports is higher than that of Western medicine preparations. As for biological preparations and traditional Chinese medicine preparations, the industry scale is relatively small and accounts for a relatively low proportion of the overall pharmaceutical industry revenue.

In recent years, the pharmaceutical industry has seen a continuous increase in the number of new drugs launched, and domestic generic drug manufacturers have successively obtained marketing authorization for products developed by foreign generic drugs, which has driven an increase in the pharmaceutical industry's revenue. In 2023, the pharmaceutical industry's turnover will be NT\$129.1 billion, an increase of approximately 34.34% from 2022, as shown in Table 2 below.

Scope of my country's pharmaceutical industry and its main product projects

Industry sub-sector	Main product items
API Industry	APIs, intermediates, excipients
Western medicine preparation industry	Small molecule drugs (new drugs or generic drugs)
Biologics Industry	Biological drugs, blood products, vaccines and toxoids, allergen drugs
Chinese medicine preparation industry	New Chinese medicine/ botanical medicine, concentrated Chinese medicine, traditional Chinese medicine, Western medicine preparations of Chinese medicine

Source: Biotechnology Development Center Industry Information Group, 2024 Year .

2019~2023 Overview of my country's pharmaceutical industry in 2018

Unit: New Taiwan Dollar

Year 1 AD	2019	2020	2021	2022	2023
Turnover (100 million yuan)	855	890	917	961	1,291
Number of manufacturers	360	375	378	372	366
Employees (person)	19,100	19,500	19,800	20,380	27,500
Export value (100 million yuan)	310	322	333	403	608
Import value (100 million yuan)	1,680	1,681	1,818	2,176	1,749
Domestic sales:Export sales (%)	63:37	62:38	64:36	58:42	53:47
Domestic market demand (100 million yuan)	2,224	2,249	2,402	2,734	2,432

Source: Pharmaceutical Industry Technology Development Center, 2024 Year.

my country's pharmaceutical industry relies on generic drugs and raw materials as its main revenue sources, but as the number of new drugs launched increases, their contribution to revenue is also increasing year by year. As of April 2024, my country has 15 new drugs launched internationally, including small molecule new drugs, biological drugs (including vaccines), biosimilar drugs and herbal new drugs. In 2023, new drug sales or royalty income will be approximately NT\$9 billion, and its share of the pharmaceutical industry's turnover will continue to rise. In addition, the export value of my country's pharmaceutical industry has also grown significantly thanks to the increase in international sales of generic drugs and new drugs. In the future, as manufacturers

continue to expand sales countries and new indications, and as generic drugs and new drugs continue to be approved for international marketing, it will help accelerate the growth of pharmaceutical industry turnover.



圖 2-6 我國生技產業營業額成長趨勢

資料來源：經濟部生技醫藥產業發展推動小組、財團法人醫藥工業技術發展中心，財團法人工業技術研究院產業科技國際策略發展所，2020 年。

(2) Smart Healthcare

In the future, medical care will look very different than it has in the past. In the past, patients usually only sought treatment and assistance from the medical care system when they were sick or injured. However, with the advancement of various technologies, the medical care industry is about to face huge changes. According to OECD statistics, the global life expectancy will increase by 5.5 years to 80.5 years. In response to this development trend, the potential market for population health management will continue to grow :

It is estimated that the market for population health management will reach US\$ 50.35 billion in 2025 , with the proportion of telehealth applications increasing continuously. As of 2018 , 65% of telemedicine behaviors can be operated through mobile devices, and up to 80% of doctors have provided medical services through smartphones and medical applications. The market sales related to medical technology are expected to grow by 5.1% and reach US\$ 52.98 billion in 2022. Therefore, we expect that future medical care will no longer focus solely on disease treatment. With the assistance of technology

and data, more resources can be invested in maintaining health and preventing diseases.

When it comes to the medical field after the advent of the digital age, the biggest change is the increasing emphasis on data. Therefore, precision medicine has also become a hot topic under data application. For example, data obtained through wearable devices, genetic testing and other technologies can predict major diseases such as cancer and leukemia, and can also provide users with effective health management solutions. By connecting hospitals at all levels through online consultation, telemedicine and other technologies, the allocation of medical resources can be optimized and tiered diagnosis and treatment can be achieved.

Data mining through technologies such as gene sequencing and image recognition can shorten the clinical verification cycle and improve the efficiency of new drug research and development. Data is generating more and more application value in the medical field. On the technical level: through data analysis and mining and a large amount of real-time monitoring, it can effectively support the construction of medical and health management systems ; on the business level: data can provide doctors with clinical decision-making assistance and provide statistics for patient behavior analysis for drug development. With the development of medical data and the continuous innovation of analysis methods and AI , more and more scenarios can accurately use medical data for analysis and prediction. There have been major changes in the way people seek health care, which has also brought new development opportunities to the medical field.

With the help of data, medical behavior will become more personalized, gradually changing from the previous model of "seeing a doctor" to "being watched by a doctor". Wearable devices can help us collect and review our own conditions 24 hours a day. This data collection model is low-cost, high-efficiency, and available to almost everyone. In the medical startup field around the world, many high-tech products based on data applications and disease prevention have begun to emerge. For example, Anmol Madan and his team founded a company that focuses on predicting the occurrence of diseases in mobile phone owners through mobile phone data analysis. After collecting and analyzing more than 320,000 hours of data from the experimental participants'

mobile phones, they were able to build models based on the mobile phone usage data to predict colds, mental illnesses, and more. For example, when a person is depressed, changes can usually be seen in the way they communicate with others, and these changes can be captured through daily mobile phone usage behavior. The test results show that it can correctly judge 60% to 90% of people's daily physiological symptoms and breathing conditions, and notify these changes to the owner himself, and in the future it can also be sent to friends or family.

The application of data in the future is more likely to be as shown in the figure below, providing more accurate and effective preventive medicine and precision medicine through the collection of diverse cross-domain data:



Source: Deloitte research, 2017

(3) Medical examination

With the rapid development of biotechnology, medical testing technology has evolved from early manual testing methods to today's automated analysis technology. The role of medical testing has gradually become prominent in the medical team and has become an important basis for disease diagnosis and treatment. With the change of the times, the medical field has entered the era of

popularization with the development of Internet technology and industrialization. With the advancement of biotechnology and the breakthrough of high-capacity technology, medical testing technology is officially facing the advent of the big data era and the era of precision medicine. In the trend of precision medicine, medical testing also has an unshirkable responsibility. Medical testing can be developed into preventive health care and health consultation. In addition, in response to the emergence of emerging infectious diseases and the development of precision medicine in recent years, the continuous improvement of molecular testing technology and the promotion of the government's latest "Regulations on the Implementation or Use of Specific Medical Technology Inspection and Testing Medical Equipment" will change the requirements and levels of medical care services of health authorities and citizens, from traditional disease treatment to care for sub-healthy groups and preventive health care for healthy groups, and disease treatment will also be upgraded from symptom treatment to personalized medicine. This all depends on cross-industry cooperation to jointly develop genetic testing and precision medicine services.

(4) Medical equipment leasing

According to the latest statistics from the Statistics Department of the Ministry of Economic Affairs, the total turnover of the leasing industry in 2024 was NT \$ 169.54 billion, an increase of NT\$13.19 billion from 2023 (NT \$ 156.35 billion), an annual growth rate of 8.4%. Among them, transportation equipment leasing increased by 5.2%, mainly due to the stable growth of long-term rental business of corporate users and the growing demand for diversified operations (such as mobile leasing) of car rental companies. The personal and household goods rental industry grew rapidly by 20.4%, which was due to the expansion of bicycle rental service outlets, the substantial growth of on-site audio guide equipment and the rental of entertainment activities (such as banquets, dinners, etc.). The machinery and equipment leasing industry also decreased by 9.0%, mainly due to the increase in demand for leasing industrial, medical and other machinery and equipment. Overall, the global economy stagnated slightly in 2024, affected by weak global terminal demand and inventory liquidation in the industrial chain, as well as geopolitical wars in Russia-Ukraine and the Middle East, which led to a decline in exports. Most leasing businesses adopt financial leasing, where the leasing company purchases the equipment needed by the

lessee and then leases it to the lessee, collecting the purchase funds and interest in installments. When the lease expires, the lessee is given the option of purchasing the asset first. Regarding the company's rental revenue, the full-year rental revenue for FY 2018 increased by 12.77% compared to FY 2017. The full-year rental revenue for FY2019 increased by 1.49% compared to FY2018, while the full-year rental revenue for FY2019 decreased by 9.7% compared to FY2019 due to the impact of the epidemic and increased equipment maintenance. Together with the department's other specialty operations (ophthalmology and weight loss), although ophthalmology increased significantly by 74.4% in 2020 compared to 2019, the weight loss business was affected by the shortage and suspension of original consumables caused by the epidemic, and the department's total revenue in 2020 decreased by 11.71% compared to 2019. The department's total revenue in 2021 decreased by 2.55 % compared to 2020, mainly due to the suspension of ophthalmic specialty service business for two months due to the epidemic and the transfer of weight loss consumables to the pharmaceutical distribution department. The department's total revenue in 2022 decreased by 26.09% compared to 2021, mainly due to the conversion of leased assets in the Tzu Chi system inspection equipment leasing case from leasing to sales. The department's total revenue in 2023 increased by 2.61% compared to 2022, mainly due to a 29.3% increase in operating income from ophthalmology. The department's total revenue in 2024 increased by 20.34% compared to 2023, with both the leasing and ophthalmology businesses growing. Excluding regional geopolitical and war factors, the role of the rental business in domestic economic development is becoming increasingly important. Affected by the COVID-19 pandemic, the rental business model has demonstrated its flexibility and elasticity in business operations. For example, the growth of the rental industry of transportation equipment, personal and household goods shows the accelerated development trend of the home economy. As the times progress, new and more advanced medical instruments and equipment are constantly introduced. In addition, the medical instruments currently used by various medical institutions continue to enter the replacement period. In addition, various personnel costs and rising prices have made it even more necessary for hospitals to use their operating funds more effectively. Therefore, through the flexible model of medical instrument and equipment leasing, it is hoped that

medical institutions at all levels can reduce one-time capital expenditures and maintain good operations and improve medical quality, operate sustainably, and create a win-win situation for the medical public, medical institutions and the leasing service industry.

(5) Dialysis business

The company's dialysis business has shifted from self-management to a cooperative management model, mainly providing logistical services such as dialysis center equipment rental and sanitary consumables. Redirect operating working capital toward building an overall health ecosystem and smart medical services.

1. The correlation between upstream, midstream and downstream industries :

The triangular relationship formed by the company, pharmaceutical manufacturers and logistics companies is Shenghong's cooperation model with upstream industries. It is also an innovative trend in the domestic pharmaceutical industry, which has brought about a huge change in the supply and demand ecology of the drug procurement supply chain. Under this new triangular relationship, the negotiation partner for drug unit price is still the pharmaceutical company, but the payment party has shifted to the logistics company. That is, many pharmaceutical companies (especially international pharmaceutical companies) transfer the inventory pressure and accounts receivable risk to the cooperating logistics companies. Therefore, the role of the logistics company is no longer just to distribute drugs on behalf of the pharmaceutical company, but to be a distributor that directly trades with the company and signs a contract. Our company and downstream industries use "innovative medical integration services" as a mutual cooperation model, with high-quality medical professional capabilities, combined with joint procurement and resource integration methods, to effectively integrate existing channels and achieve optimal cost management to meet the client's demand for drugs, instruments and equipment items and quality management, and provide professional health examination and medical testing management consulting and entrusted operation services.

Upstream	Midstream	Downstream
Medical equipment supplier Pharmaceutical Suppliers Hygiene material supplier Logistics Provider	Medical Management Consulting Company Medical Technology Service Company Pharmaceutical Joint Procurement Center	Medical institutions Pharmacy Chain Healthcare System

Source : Compiled by our company

2. Various product development trends

(1) Supply of medicinal materials

Today, medical institutions and pharmacies not only have to face financial pressure caused by the national health insurance system, but also have to take into account the quality of medical services. Among them, the procurement cost and supply quality of medical necessities such as drugs and sanitary materials are the key to the operation of medical institutions and pharmacies. Medical institutions and pharmacies have begun to take the needs of logistics management seriously, that is, they have begun to adopt system tools such as joint procurement and pharmaceutical logistics to effectively reduce procurement costs while taking into account supply quality. In order to achieve the goal, the following development conditions and priorities must be met:

A. Joint purchasing platform with large-scale collection

B. Fast, timely, professional and safe pharmaceutical logistics system and supply chain information system

C. Know-how support from professional medical team

In view of the continued growth of the global and Taiwanese pharmaceutical markets in recent years, and the fact that pharmacy channels are one of the main growth drivers, the strategic cooperation model with community pharmacies is also a focus of continued development.

(2) Entrusted health management

A. Health Check

With the advent of the global aging era, both the government and

individuals are paying more and more attention to health checks, and the requirements for health checks have also increased significantly. Health checks have gradually transformed from simple medical examinations and tests to so-called "health management" services. According to estimates by the Industrial Development Bureau, investment in Taiwan's health care industry could reach NT\$ 350 billion over the seven years starting from 2005 . Taiwan's health care has been listed by the Executive Yuan as one of the four emerging industries in its 2015 economic development vision, with an estimated annual growth rate of 17% . The services of the health management center are no longer limited to health examinations, but also include post-examination medical treatment and care, follow-up tracking, health consultation and disease risk assessment services. In addition, for the sub-healthy group, we also play the role of assistance and teaching, gradually improving and preventing the occurrence of diseases in their lives, and also promote preventive medicine with "disease prevention" as the core concept. The purpose of health check-up is to obtain health information of the examinee, to detect latent or progressive diseases early, to provide timely correction and treatment, and to successfully achieve the effect of "early detection, early treatment". Today, Taiwan's health management market is very competitive. Various demands, such as combining mind-body-spirit therapy, healthy food, tourism and leisure, and other diversified operating methods, have made medical care no longer just medical care, but have also incorporated many lifestyle factors, hoping to attract more people who value health.

To make health services more complete, genetic testing should be included as part of overall health. Therefore, our company is the first stop for the medical industry and health protection. Its main services are "genetic testing" and sales of preventive health foods. On the premise that prevention is more important than cure, we provide the public with a variety of new health options.

In January 2015, US President Barack Obama declared that year the first year of "precision medicine," and the trend toward genetic testing began to gain momentum. The United States plans to collect genetic data from one million people, and the United Kingdom has also announced an investment of

US\$500 million, hoping to complete full genome sequencing (gene decoding) of 100,000 people by 2017. Illumina, the world's largest gene sequencing equipment manufacturer, estimated as early as 2014 that the genetic testing market would reach US\$20 billion (approximately NT\$650 billion).

What is genetic testing? Simply put, it is a health check of human genes to see if the genes are mutated, whether the unborn baby carries the genetic genes for major rare diseases, or before cancer treatment, to see if the patient carries a specific gene in order to decide on the treatment plan.

In addition, countries such as the United Kingdom and the United States are driven by national policies and are actively investing in gene sequencing. By collecting personal samples and building a human biodatabase, they hope to find the relationship between specific genes and diseases, making gene sequencing a stable and large market.

With the advancement of gene sequencing technology, the price of a gene sequencing was US\$100,000 in 2009, but it dropped to US\$1,000 in 2014. The significant reduction in input costs has made large-scale gene sequencing possible. The latest gene sequencing technology is called next-generation sequencing (NGS). Grand View Research, a US business consulting firm specializing in market research, reported that the next-generation sequencing market has considerable development potential, with a market size of approximately US\$2 billion in 2014 and a rapid growth to US\$30 billion in 2022. As for the genetic testing industry market, it is even more explosive. According to the Illumina report analysis, the largest segment of the global genetic testing market is cancer testing, accounting for 50%, followed by scientific research services accounting for 25%, prenatal testing accounting for approximately 10% to 15%, and infectious diseases accounting for 5% to 10%.

Taking into account the policies and development of the precision medicine industry in major countries, in addition to the patient gene database established with government support, different databases are connected and the application of data is strengthened through cooperation with private enterprises to accelerate the development of the industry. In terms of industrial

applications, countries are also conducting in-depth research and development on specific diseases or ethnic groups, concentrating resources on the country's key development directions. Although my country has established a database, it lacks practical industrial applications. In the future, the database should be operated from the perspective of industrial utilization to enhance the value of the database and accelerate the development of the industry. In terms of industrial applications, we can move towards an Asian patient-centered direction and launch new relevant medical guidelines to achieve a leading position in global precision medicine. For example, Taiwan has profound clinical experience and research capabilities in women's cancer, and combined with immunotherapy or Taiwan's optoelectronics strength to develop detection equipment, it can become a unique field of precision medicine industry development in Taiwan and also bring new opportunities and development possibilities.

B. Medical examination

Whether it is obtaining ISO quality certification or formulating inspection management methods, the management of medical testing centers has become a focus of the inspection industry in recent years. The main goal is to enable medical testing centers to achieve standardized, normalized and internationalized quality management. In addition, establishing a complete LIS and HIS system is an important step in fully leveraging the advantages of automated testing equipment. An optimized information management system can ensure the accuracy of test information, avoid human errors in data processing, and quickly return test results. The selection and maintenance of testing instruments and reagents require the establishment of a set of rigorous standards to ensure the accuracy of test data. The management of the testing process requires not only the efforts of medical examiners, but also the cooperation and support of clinical medical staff and instrument manufacturers to ensure that all links can run smoothly. In recent years, hospital operators have switched to single-supplier services for medical testing laboratories in response to health insurance difficulties. In addition to being able to quickly acquire professional skills and resources, continuously improve quality, and increase customer satisfaction, hospitals can also reduce operating costs to

achieve a win-win situation. In addition, under the lump sum payment, based on cost-effectiveness and without violating any law, if the medical business of a certain department of the hospital is entrusted to a professional organization for operation and management, and the partner is responsible for its own profits and losses, the hospital can be guaranteed the best profits and will not be affected by the decline in business volume. For hospital operators, this can greatly reduce operating pressure. Therefore, it is becoming a trend to entrust domestic medical testing services to a single supplier. For example, the Catholic Fu Jen Catholic University Hospital, the seven Tzu Chi hospitals across the province, Hsinchu Hukou Renci Hospital, and Hsinchu Nanmen Hospital are all successful cases.

(3) Equipment rental

As domestic medical institutions become increasingly receptive to asset leasing, the operating scale of leasing companies has also expanded, and the services they provide have become more diversified. As the demand for medical instruments and equipment by medical institutions increases year by year, the medical rental items and peripherals provided by leasing companies are becoming more and more extensive, and the related services are becoming more comprehensive and complete. In order to continuously enhance the market competitiveness of medical equipment leasing and effectively provide customers with the needs, we have started and are committed to continue to develop towards several key goals:

- A. Expand the scale of business and explore new leasing areas, such as assisting grassroots clinics in equipment leasing and leasing business consultation, and providing equipment leasing and other medical equipment professional service manufacturers to provide more diversified and comprehensive leasing services, including project planning services, professional management, professional technical personnel dispatch and assistance management.
- B. The establishment of professional training facilities will improve the quality of professional manpower, strengthen industry cooperation, and provide support and dispatch to various medical institutions at any time to expand the company's niche.
- C. Strengthen professional talent education and training, actively cultivate talents with both medical business management and leasing expertise, and be able to

implement project planning. Form alliances with original manufacturer professional technicians or industry professional technicians to jointly develop the repair market.

- D. Cooperate with medical institutions to provide high-end and high-priced equipment for joint specialized operation. For example, since September 2015, we have been collaborating with the Ophthalmology Department of Min Sheng General Hospital to provide the latest generation of femtosecond cataract and laser correction equipment, so that people in need can obtain faster, safer and more precise medical equipment to treat eye diseases, thereby improving service standards and patient satisfaction. According to statistics, a total of 6,648 cataract surgeries were performed from 2015 to 2024 , of which 1,136 were laser femtosecond cataract surgeries , accounting for 17.09% of the total number of surgeries, benefiting many villagers who sought medical treatment .

(4) Dialysis business

In response to the improvement in the effectiveness of drugs for treating kidney diseases and the effective delay of kidney function decline, the dialysis business has transformed into providing logistical cooperation for dialysis centers, such as equipment leasing and supply of medical consumables.

3. Product competition

(1) Supply of medicinal materials

A. Competitors

Currently, there are only a few peers in the market that engage in joint procurement of medicines. The main reason is that there are not enough medical institution customers to serve as the basis for the scale of joint procurement.

B. Potential entrants

Although large medical institutions such as medical centers are large in scale, most of them are public or incorporated rather than corporate-run, so it is difficult for them to enter the formal commercial transaction market.

C. Supplier

In addition to the advantage of volume bargaining, joint purchasing will also give us the right to choose dominant brand items in the future.

D. Buyer

The purchasing needs are mainly from small and medium-sized medical institutions and pharmacies, and they hope to reduce costs through a joint purchasing platform.

E. Substitute goods

Generally, large-scale distribution logistics companies only supply limited distribution items, which cannot fully meet the needs of medical institutions and pharmacies.

(2) Entrusted health management

A. Health Check

a. Competitors

Although hospitals that operate health check-ups independently set up their own health check-up systems and marketing channels in accordance with regulations, they mostly passively accept customers and are less competitive in terms of product prices and customer service. As for other hospitals that entrust their health check-up business to health check-up contractors, most of them adopt an outsourcing cooperation model. The hospital itself only collects royalties and does not control the content and quality of the health check-up. As a result, outsourced medical examination teams have developed bad habits such as price competition, cutting corners, and walking on the edge of the law. When a hospital is disqualified from conducting physical examinations, these physical examination contractors only need to start over without taking any responsibility, which has a huge impact on the low-price market.

b. Potential entrants

Small hospitals or clinics are limited by equipment, insufficient resources, laws, and qualifications, and can only provide a limited number of services, posing a low competitive threat to our company. As for large hospitals such as medical centers, they are currently actively developing health check-up businesses. With the brand advantages of medical centers, they can gain more recognition from the public.

c. Suppliers

Based on the strategy of continuously expanding bases, current suppliers are

able to provide relevant inspection equipment or services in line with the company's development direction.

d. Buyer

The purchasers of our company's health checkup services are divided into two categories: groups and individuals. The group portion includes foreign workers and local workers. For foreign workers, we use foreign labor agencies as the channel, while for domestic workers, we provide two types of services: on-site medical examinations and mobile medical examinations. As for individual purchasers, our company provides customized health check-up services based on customer needs.

e. Substitute goods

The chances of the health checkup service process provided by our company being replaced by other products are relatively low, but the examination items may be replaced. For example, some advanced imaging examinations (MRI , 64 -slice CT , PET-CT , etc.) may squeeze out the funds for general examinations. However, the investment cost of advanced imaging examinations is relatively high, and the conditions for their introduction are limited, so they cannot yet replace current health check-up services.

B. Medical examination

a. Competitors

The main competitors are third-party laboratories, each of which has unique expertise and develops independently. At present, some suppliers are rapidly gaining market share by leveraging their product agency resources and political and business relations. This is a force that cannot be ignored.

b. Potential entrants

The biotechnology field is currently booming, and other non-medical biological laboratories are actively planning to enter the clinical medical testing market.

c. Suppliers

There are many brands of testing reagents currently available in the market, but there are still some differences in quality, service and price. Our company has many supervisors with both professional and operational management experience who can help customers communicate with suppliers and choose

the best combination of instruments and reagents.

d. Buyer

Direct purchasers of clinical tests include physicians and examinees, and indirect purchasers include examinees who receive health check-up services. Therefore, it is necessary to continuously provide newly developed and effective testing items and services to meet the needs of all purchasers at different levels.

e. Substitute goods

Currently, medical testing is developing in two directions: small-volume and rapid point-of-care testing (POCT) services and low-cost large-batch operations. The chance of testing services being replaced by other alternative products is low, but we must seize the opportunity for change. In addition to mastering both (POCT) services and testing batch operations, we must also develop special and advanced testing technologies (such as trace element detection technology and molecular testing technology).

(3) Equipment rental

Large leasing companies are mostly developed with financial holding companies as their background, using capital lending as their method of operation, and their leasing projects include factory equipment, aviation equipment, general automobiles, etc. However, there are not many professional operators whose main leasing project is medical equipment. Although Orix, Chailease Dihe, and Taiwan Life Insurance are relatively large in scale in the market, the leasing projects of these three operators are complex and they are not specialized in medical equipment leasing, and lack professional medical equipment integration services. Our company's specialist service department integrates various medical equipment manufacturers and connects various medical institutions to form a procurement economy scale model and create bargaining advantages. The company has sound financial operations and good relationships with its banks, which enables it to provide various lease terms and types. In addition, in order to meet the needs of medical institutions, we not only provide instruments and equipment, but also have the support of original service providers and provide the most complete maintenance services to ensure that the medical equipment rented by customers can be used accurately and

normally. In addition, our company can also provide project planning for medical needs of medical institutions, with a professional service team from site design to operational practices to management advice.

(4) Dialysis business

The dialysis business has transformed into a supplier model, including medicines, consumables and equipment. Continue to integrate the upstream and downstream of the dialysis industry chain, provide more competitive products, and expand the scope of cooperation .

(III) Technology and R&D Overview

Our company is engaged in medical logistics services, with its main focus on business and channel expansion. We are not a research and development-oriented company , so we have no research and development plans in the future.

(IV) Long-term and short-term business development plans

1. Short-term plan :

- (1) Strategically forming alliances with medical institutions with large purchasing capacity will enable the pharmaceutical joint purchasing framework to be expanded to a larger scale and the scope of pharmaceutical supply services to be further expanded, thereby meeting customers' needs for more items.
- (2) Cooperate with clinics and pharmacies to establish a pharmaceutical procurement platform, and further obtain procurement authorization based on the platform's pharmaceutical supply.
- (3) Actively develop the health checkup market in the Greater Taipei area.
- (4) Combine external resources to establish a physical examination base in the Hsinchu area.
- (5) Actively strive for outsourcing of health checkup business from central Taiwan hospitals and expand Shenghong's health management service scope to the Greater Taichung market.
- (6) Actively develop the medical and nursing manpower dispatch market in northern Taiwan and develop diversified health promotion activities.
- (7) Plan and build in-hospital physical examination space to serve corporate

employees who need in-hospital health examination services.

- (8) Develop management consulting and single-supplier services for medical laboratories.
- (9) Integrate with original manufacturers of testing instruments, reagents, and consumables to supply customers with competitive high-quality testing products.
- (10) Integrate community medical resources and expand the medical equipment rental service in Taoyuan, Hsinchu, and Miaoli.
- (11) Education and training project labor outsourcing services and other supporting services.
- (12) Strengthen hospital management and recommend key operational directions.
- (13) Assist the development of the system's hemodialysis and peritoneal dialysis businesses.

2. Long-term plan :

- (1) Develop clinical trials in the biotechnology field.
- (2) Actively develop health examination and inspection management consulting and entrusted management services in southern Taiwan.
- (3) Develop precision medical genetic testing to provide customers with personalized precision health check-up services.
- (4) We will recruit more pharmaceutical joint procurement customers to create a more powerful joint procurement platform and provide customers with new value in pharmaceutical supply.
- (5) Operate own-brand pharmaceuticals, medical materials, health products, and cosmeceuticals to develop market niches.
- (6) Expand equipment leasing and joint procurement items, build an information-based second-hand equipment platform, and develop specialized business operations.
- (7) Go west to mainland China and introduce Taiwan's medical management practice experience into the mainland market.
- (8) Enhance the healthy image of the system.
- (9) Each service location should have a centralized procurement or upstream and downstream integration mechanism to reduce costs.

4.2 Market and Production and Sales Overview

1. Market Analysis

1. Sales (provided) regions of the company's main products (services)

Unit: NT\$ thousand

year project	2023		2024	
	Amount	%	Amount	%
Domestic sales	3,834,956	99.01	4,297,675	99.35
Export	38,428	0.99	28,156	0.65
total	3,873,384	100	4,325,831	100

2. Market share

- (1) The Pharmaceutical Distribution Division currently provides services to the Greater Taoyuan, Hsinchu, Miaoli and Greater Taipei areas. Its customer base is mainly composed of regional hospitals, district hospitals, primary care clinics and pharmacies. Its annual total sales are approximately NT\$1.54 billion. According to statistics from Taiwan's biotechnology industry operating status table, the total value of pharmaceuticals and medical devices in 2022 was NT\$290 billion, accounting for 0.53 % of Taiwan's total market .
- (2) The total turnover of the health checkup market in Taiwan is estimated to be NT\$4.6 billion. The total turnover of medical health checkup management or entrusted operation services provided by our company is approximately NT\$620 million, accounting for approximately 13.5 % of the health checkup market in Taiwan .
- (3) Although there is a trend among Taiwan's medical institutions to gradually switch to leasing when planning and installing medical equipment, there are still many medical institutions that purchase directly or obtain financing from banks. Currently, the medical equipment leasing market is concentrated in four major leasing companies: ORIX, Chailease, Chengye and Taiwan Life Insurance. Our company has successfully expanded the cooperation model of dialysis equipment project leasing in 2014. In 2015, the number of beds was expanded to 17% of the original scale. In 2017, the number of beds was expanded to 25% of the original scale. In 2019, it is expected to expand by another 24% on the

original basis, continuously improving the supply of equipment and medical consumables. In March 2021, the number of beds was further expanded by 3% to provide more equipment rental and support management services.

- (4) According to the statistics of the Ministry of Health and Welfare's Statistics Department in 2016 on the number of outpatients and emergency patients due to nephritis, nephrotic syndrome, and renal failure in each county and city, Taoyuan City had 50,459 outpatients and emergency patients, a mid-year population of 2,124,339, and an average visit rate of 23.75 (per thousand), ranking 14th among counties and cities in Taiwan. In addition, the medical expenses spent by the National Health Insurance on renal failure have always been the highest among all diseases. The trend of the number of patients and the growth of medical expenses have never changed over the years. According to the 2017 Kidney Disease Annual Report, the current prevalence of end-stage renal disease in Taiwan is 3,317 people per million, with an incidence of 311 people.

3. Future market supply and demand and growth

(1) Supply of medicinal materials

The main customer base of pharmaceutical joint procurement services is small and medium-sized medical institutions and pharmacies. The current health insurance environment forces the entire pharmaceutical supply industry to undergo structural changes. Through the joint procurement structure, not only can the quality of supply be stably ensured, but small and medium-sized medical institutions and pharmacies can also obtain lower procurement costs. Looking at the domestic pharmaceutical service industry, there is no model like our company that can provide medical institutions and other customers with a complete product supply and satisfy warehousing and storage management services. Currently, there are very few pharmaceutical companies in the market that can meet the needs of medical institutions for single-point purchase of full-item supplies. Our company, with its existing joint procurement advantages, pharmaceutical expertise, procurement advantages and diversified new services, is actively seizing market share, so that customers can establish loyalty and dependence on the products and services provided by our company as early as

possible. Even if more competitors join the market in the future, it will be difficult for them to break into this complete service network. The value of the joint pharmaceutical procurement service lies in the establishment of product and service channels, which will help the company develop new products and various services in the future.

(2) Health management

With the improvement of knowledge level and the development of medical information, "health management" has become mainstream. The number of people who pay attention to health check-ups is increasing rapidly. The health check-up market in Taiwan continues to grow every year. Currently, there is a huge business opportunity of approximately NT\$ 20 billion a year. Various types of medical institutions and health check-up centers have also spotted this market and started to launch a variety of health check-up services. Recently, some chain health check-up centers have expanded their business to mainland China, which has not only stimulated the other side's attention to health management, but also successfully captured the market and achieved good results. But overall, larger health check-up business opportunities will surely emerge in the future. This phenomenon has also attracted the attention of many technology industries or consortiums, which have turned to invest in health check-up businesses, demonstrating their strong ambition to seize the health management and care market.

(3) Equipment rental

As the population ages, humans are more dependent on medical care, and medical institutions' demand for equipment will continue to increase. In particular, the development of AI artificial intelligence will increase the interaction and dependence of doctors and patients on medical equipment. Major medical brands are developing AI - assisted medical and interpretation technologies to make medical judgments more accurate and rapid. The advantages of equipment leasing include tax management, financial planning, avoiding equipment obsolescence, accelerating equipment replacement and maintaining professional advantages, which are all foreseeable benefits. In recent years, more and more hospitals, clinics or home care institutions have chosen to cooperate with medical equipment leasing companies instead of direct purchases or bank financing to increase the utilization and circulation rate of

medical equipment, making the medical equipment leasing market have development potential. Cooperating with the company to expand its logistics channels can also create more leasing opportunities. The health care industry has shifted from being centered on curing diseases to being centered on people's health. The deep integration of big data and artificial intelligence into all aspects of the development of the pharmaceutical industry has become a battleground. At present, there is a general and continuous shortage of medical personnel around the world, and the use of equipment (such as wearable health monitoring equipment, etc.) and technology-assisted medical care is also a future trend. The company continues to develop and integrate the big health ecosystem model, strengthen upstream and downstream integrated support and comprehensive progress, and seek greater development breakthroughs.

4. Competitive Niche

"Providing innovative medical integration services" is Shenghong's operating model. It is the first to create a medical logistics service integration platform. With rich medical experience and pharmaceutical professional capabilities, it introduces flexible corporate management, effectively integrates existing channels, and actively develops potential markets to create the best profits and value. In addition to providing professional health check-up and medical testing management consulting and entrusted operation services, we also use joint procurement, information integration, and channel management methods to provide optimal cost management to meet clients' demand for drugs, medical materials, instruments and equipment and quality management, hoping to become the leading brand in the national medical service channel.

In terms of the supply of medicinal materials, we use existing medical institutions and chain drugstores as the basis for joint procurement, expand pharmaceutical chain channels outward, and use excellent supply chain operations management, procurement cost advantages, and appropriate market integration mechanisms to form sufficient conditions for integrated joint procurement, create a new model of profit sharing, and establish our own brand products to further increase the company's profits. In addition, the joint procurement platform has the first-mover advantage. Once a joint procurement cooperation model is established with customers, customers must bear considerable switching costs when switching to

other competitors in the future. Therefore, a complete joint procurement platform also has the advantage of strengthening customer loyalty and dependence.

In the management consulting and single supplier services for health examinations and medical tests, we have developed mature medical testing technologies and professional management methods with rich experience, successfully coached the execution units of medical institutions, expanded business and improved service quality. In addition to winning multiple quality certifications, we have also won the recognition and trust of our customers. In terms of medical and nursing manpower support, we use the medical and nursing manpower of the medical system as a strong backup, and attach equal importance to quality. We not only have a rich and comprehensive talent pool, but also continuously improve the quality of talents through professional training, providing clients with the highest quality medical professional dispatch and management services.

In terms of equipment leasing, we use professional medical management, medical equipment background and medical engineering expertise as the best resources and advantages for purchasing medical instruments and equipment. In addition, we integrate instruments and equipment to achieve optimal utilization, avoid waste in purchasing medical equipment, and provide added value of subsequent repair and maintenance services, which becomes a favorable condition for expanding joint procurement channels. We then use professional services to integrate medical equipment rental and professional manpower dispatch to carry out specialized operations; not only will we manage the logistics services of medical institutions well, but we can also participate in assisting the operation of medical institutions and increase the company's revenue.

In terms of hospital management, we use the medical management, medical and nursing manpower of the medical system as a strong backing, and attach equal importance to quality. We not only have a rich and comprehensive talent pool, but also continuously improve the quality of talents through professional training, providing clients with the highest quality medical professional dispatch and management services.

In the dialysis business, we combine the system's strong advantages in pharmaceutical distribution, equipment leasing, information technology and hospital channels to provide dialysis centers with high-quality and safe medical logistics support.

5. Advantages and disadvantages of development prospects and corresponding countermeasures

(1) Favorable factors for development prospects :

- A. The current health insurance policy has put medical institutions under pressure from total health insurance payments and downward adjustments to drug prices, making cost control a top priority. Establishing an integrated joint procurement mechanism to effectively reduce the procurement costs of medical drugs, consumables and instruments and equipment is in line with market demand. In addition, the single-point shopping business philosophy of providing medical institutions with fast and convenient medical integration services will bring the company more stable and huge business income.
- B. Our company has a stable existing distribution channel and loyal customer base, forming a basic scale for joint procurement. In the future, whether in the integration of upstream and downstream or the development of own-brand products , we have laid the foundation for basic customer base and established smooth operation channels. With the advantage of a gradually complete operation network, we can effectively expand our business and create revenue.
- C. Located in the center of northern Taiwan, it is close to Taipei City, where the headquarters of the top 100 companies are concentrated, and to Hsinchu Science Park, where listed technology companies are located, in the south. It has an excellent geographical location for the development of domestic health examinations, inspections and medical manpower dispatching businesses . On the international front, our company is located at the country's gateway, close to Taoyuan International Airport. Whether it is the three links across the Taiwan Straits or international routes in the future, we will have great geographical advantages.

(2) Unfavorable factors and countermeasures for development prospects :

- A. Changes in drug health insurance prices and related subsidy policies affect company profits

Every year, the price of national health insurance drugs is adjusted. The original contract customers will also ask our company to adjust the selling price after the

adjustment to reduce the hospital's losses, which will affect the company's profits.

Countermeasures:

When the National Health Insurance drug prices are adjusted, we will immediately renegotiate the supply prices with suppliers for the items whose prices are adjusted to reduce the impact of the price adjustment. In addition, the impact of the adjustment of NHI drug prices is borne jointly by hospitals and suppliers. Since hospitals usually have weaker bargaining power than our company, especially small and medium-sized hospitals with small market scale, hospitals lack effective bargaining power and will seek joint procurement channels. Therefore, when the NHI drug prices are adjusted, our company will also propose the medical institution pharmacy department escrow service to expand the bidding power.

- B. There are many brands of agents and distributors, and price competition is fierce

Taiwan's biotech industry is well developed. In addition, there are many foreign agent and distributor brands and the pharmaceutical market is mature, which has led to a vicious cycle of price competition for pharmaceutical-related products. In addition, although the scale of joint procurement has gradually expanded, it is also facing pressure from clients to reduce prices.

Countermeasures:

Through market price information, we strive to achieve economies of scale to obtain the lowest supply price. Through upward integration, we can obtain sufficient supply at reasonable prices. We aim to provide customers with good inventory and warehouse management and zero inventory, helping customers reduce their inventory of medicines and medical materials to a minimum and improve their competitiveness.

- C. Changes in national health examination laws and restrictions on health insurance benefits often affect company policies and operations, resulting in reduced profits .

In the pharmaceutical sector, in addition to the pressure of price reduction from the client side, the demand side also faces the possibility of price competition and customer loss due to the entry of potential competitors. On the supply side,

some manufacturers are unwilling to cooperate with the joint procurement platform, and some items may be unwilling to reduce prices or be supplied to the company. As the company's joint procurement platform grows larger, manufacturers' profits may become worse, so some manufacturers may not agree to the company's bargaining conditions.

In terms of health check-ups, due to the total amount of funds controlled by the National Health Insurance, hospitals of all sizes are participating in the competition for self-paid health check-ups, and the competitive operating environment is even more severe. In addition, the exodus of companies and the revision of the medical examination regulations for foreign workers in Taiwan have caused the growth rate of companies and foreign workers' medical examination regulations to slow down.

In terms of medical equipment leasing, there is pressure from clients to reduce leasing interest rates, or there is a backlog of equipment due to expiration of leased equipment or non-renewal, which results in increased costs.

Countermeasures:

In the pharmaceutical sector, we have established a regional integration mechanism to achieve economies of scale through joint procurement, so that the Company can maintain a favorable negotiating position on both the supply and demand sides in order to secure higher profits.

In terms of health check-ups, we expand our customer base and market share through franchising, strategic alliances, or by seeking to merge with external health check-up teams (companies) . We adopt a quantity-based pricing approach to respond to changes in government health check-up regulations. At the same time, we assist large companies in jointly setting up medical clinics and recruiting sufficient professional nursing staff. We also establish an employee stock subscription and training system, build a health check-up management talent pool, and further consolidate the corporate health check-up footprint.

In the field of medical equipment leasing, we focus on the professional needs of customers for medical equipment and strengthen medical and engineering professional services, which not only reduces customers' operating costs but also provides professional evaluations. We also continue to plan and build an

e-commerce platform for medical equipment to evaluate the leasing and sales of second-hand equipment, improve circulation rates, and reduce inventory backlogs. In addition, by acquiring dealers or agents, the company can obtain exclusive rights and technologies for the sales and maintenance of original equipment and expand its market share.

D. Potential competitors enter the market

After listing on the OTC market, the Company's business model has become more transparent, which may easily lead to potential competitors imitating and entering the market, thus creating competition for the Company's operations.

Countermeasures:

Actively seize the joint procurement market share, give full play to the advantages of being a pioneer, strengthen connections and services with clients, become an important partner of the hospital, form entry barriers for competitors, increase the entry threshold for competitors and customer conversion costs.

Important uses and production processes of main products

Main Products	Important uses
Medicinal Materials Supply	Joint procurement of pharmaceuticals, warehousing and logistics management, professional consulting services, health care product agency distribution
Entrusted health management	Management consulting and entrusted operation of medical testing laboratories and medical health examinations, and workplace health management and planning.
Equipment rental	Medical equipment leasing, joint procurement of medical equipment, medical engineering professional services, and specialized business cooperation services

*Our company is not a manufacturing company, so there are no production-related issues.

(III) Supply status of main raw materials

Main raw materials	Main Suppliers	Availability
Medicinal Materials	Yu Lee Co., Ltd., Taiwan Dakshita Co., Ltd., Jiu Yu Enterprise Co., Ltd., Yongxin Pharmaceutical Co., Ltd., Jikang International Co., Ltd., Yuanjian Optical Co., Ltd., Xindong Biotech Co., Ltd., Taiwan Toyo Pharmaceutical Co., Ltd., Youhua Biotech Pharmaceutical Co., Ltd., Jordan Biotech Co., Ltd.	good

(IV) Explanation of significant changes in gross profit margins of major products or departments in the most recent two years

Unit: %			
Main products \ year	Gross profit margin in 2012	Gross profit margin in 2013	Increase or decrease
Supply of medicines, medical materials and scientific materials	13.01	12.38	-4.84%
Health and Medical Management	42.13	41.30	-1.97%
Equipment rental service	27.05	0.92	-96.60%
Description of major changes	Equipment and house rental: mainly due to the decrease in house rental income		

(V) List of major purchasing and sales customers

Names of suppliers who accounted for more than 10% of the total purchases in any of the last two years, purchase amounts, proportions and reasons for changes

Unit: NT\$ thousand

pr oj ec t	2023				2024				As of the previous quarter of 2025			
	name	Amount	Percenta ge of net purchase s for the whole year [%]	proje ct	name	Amount	Percenta ge of net purchase s for the whole year [%]	proje ct	name	Amount	Percenta ge of net purchase s for the whole year [%]	proje ct
1	Yu Lee	642,467	25.03	none	Yu Lee	831,236	27.17	none	Yu Lee	200,752	27.10	non e
2	other	1,924,032	74.97		other	2,227,679	72.83		othe r	540,103	72.90	
	Net purch ase amou nt	2,566,499	100.00		Net purch ase amou nt	3,058,915	100.00		Net purch ase amou nt	740,855	100.00	

Reasons for increase or decrease: Due to the growth of pharmaceutical and health care product sales business, the relative purchase amount also increased.

2. Names of customers who have accounted for more than 10% of total sales in any of the last two years , sales amount, proportion and reasons for change:

Unit: NT\$ thousand

pr oj ec t	2023				2024				As of the previous quarter of 2025			
	name	Amount	Percent age of net sales for the year [%]	Relat ionsh ip with the Issue r	name	Amount	Percent age of net sales for the year [%]	Relat ionsh ip with the Issue r	name	Amount	Percent age of net sales for the year [%]	Relat ionsh ip with the Issue r
1	Min Shin g Gene ral Hos pital	1,624,514	41.94	Its head is the same perso n as the pare nt comp any's chair man	Min Shin g Gene ral Hos pital	1,655,672	38.27	Its head is the same perso n as the pare nt comp any's chair man	Min Shin g Gene ral Hos pital	397,672	37.82	Its hea d is the chair man of the board of direc tors of

												the com pany
2	othe r	2,248,870	58.06		other	2,670,159	61.73		other	653,906	62.18	
	Net sale s	3,873,384	100		Net sales	4,325,831	100		Net sales	1,051,578	100.00	

Reasons for increase or decrease: The sales of pharmaceutical and health care products in 2024 grew compared to 2023.

4.3 Information about employees

(I) Information on employees in the last two years and up to the date of publication of the annual report

year		2023	2024	End of the year March 31 , 2025
staff Num ber of peop le	Number of employees at the beginning of the period	145	141	147
	Number of people leaving this period	33	28	12
	Number of new employees	29	34	42
	total	1 41	147	177
Average age		43.58	44.19	44.45
Average years of service		6 . 06	6.23	5.31
stud y cale ndar point cloth Com pare Rate	PhD	1.4%	3.4%	2.8%
	master	12.8%	14.3%	14.1%
	College	80.8%	76.9%	72.4%
	high school	3.6%	4.0%	9.6%
	Below high school	1.4%	1.4%	1.1%

(II) Employees obtaining certificates and licenses

job title	Employee code	Certificate Name	Licensing authority	Acquisition date
Assistant Manager	A 003976	1.CIA International Auditor Certificate 2. Internal Auditor Certificate	1. IIA American Auditing Institute 2. Internal Audit Association of the Republic of China	1.095/05 2.096/05/22
manager	A000362	1. Class A labor safety technician certificate 2. Class B safety and health technician certificate	1. Executive Yuan Labor Affairs Committee 2. Executive Yuan Labor Affairs Committee	1.093/07/18 2.086/12/21
manager	A000851	1. Class B waste treatment technician 2. Operators of high-pressure gas specific equipment 3. Type 1 pressure vessel operator 4. Supervisor of oxygen-deficient operations . 5. Fire prevention manager	1. Environmental Protection Agency Environmental Protection Officer Training Institute 2. Taiwan Industrial and Commercial Safety and Health Association 3. Taiwan Provincial Industrial and Mining Safety and Health Technicians Association 4. Taiwan Provincial Industrial and Commercial Safety and Health Association 5. Fire Education Academic Research Foundation	1.092/03/11 2.090/06/15 3.090/01/18 4.091/03/29 5.098/07/09
manager	P000018	1. ISO 15189 Medical Laboratory Review Training certificate	1. National Certification Foundation	1.100/06/15
Team Leader	P001452	1. ISO 15189 Medical Laboratory Supervisor Training Training Certificate	1. National Certification Foundation	1.105/12/18
Team Leader	P00167 8	1. ISO 15189 Medical Laboratory Supervisor Training certificate	1. National Certification Foundation	1.105/12/18
Specialist	P000763	1. ISO 15189 Medical Laboratory Supervisor Training certificate	1. National Certification Foundation	1.099/07/19
Higher Education	A002878	1. Certification of ESG Sustainability Manager (CESGA)	1.Taiwan Management Association	1.113/03
Specialist	A000724	1. Information Security Engineer-Primary Competency Assessment	1. Industrial talent capability assessment by the Ministry of Economic Affairs	1.112/12/31

Manager	A002883	1. Information Security Engineer-Primary Competency Assessment	1. Industrial talent capability assessment by the Ministry of Economic Affairs	1.112/12/31
engineer	A004261	1. Information Security Engineer-Primary Competency Assessment 2. Class B computer software application 3. Certified Ethical Hacker 4. ITE-Information Security Management Professional	1. Industrial talent capability assessment by the Ministry of Economic Affairs 2. Ministry of Labor 3. EC-Council 4. Computer Skills Foundation	1.112/07/31 2.107/04/11 3.111/06/24 4.112/06/06

(III) Employee Code of Conduct and Reward and Punishment Measures

1. Employee Service Code

In order to establish systems, improve organization and management, our company formulates employee work rules in accordance with the Labor Standards Act and relevant government regulations.

All personnel management regulations or personnel operation regulations shall be handled in accordance with the employee work rules. The service code is summarized as follows:

- (1) Employees shall comply with government laws and company regulations, obey the reasonable supervision of their supervisors, pay attention to work safety, cherish the company's reputation, demonstrate team spirit, and work hard to perform their duties.
- (2) Employees should behave appropriately, be loyal and responsible, and have honest conduct. One must not use his or her position to engage in corruption, accept gifts, or seek benefits for others or oneself. When handling official business, the principle of honesty and integrity must be strictly followed, and no actions that damage the company's rights and interests should be taken.
- (3) Employees shall not disclose information related to the company's business, technology, salary, customer information, etc., and shall not use the company's name to conduct any external affairs without approval.
- (4) Employees who manage the money, assets, documents, etc. of the company or its affiliated companies must register them clearly and complete the procedures. If there is any loss, the company may request compensation in accordance with the law.

2. Employee Reward and Punishment Measures

In order to regulate employee rewards and punishments, establish fair and reasonable reward and punishment standards to motivate employees and strengthen group discipline, the company has formulated the "Employee Reward and Punishment Methods". This includes the proposal, review, decision-making and related operations of reward and punishment cases. Reward and punishment cases are reported by supervisors to the general manager for approval, and then transferred to the personnel department for follow-up work.

(1) The Company's rewards are divided into three levels:

Reward: A bonus of 500 yuan will be awarded, and a reward and punishment order will be issued.

Minor Merit: Award a bonus of 1,500 yuan and issue a reward and punishment order.

Great Merit: A bonus of 3,000 yuan will be awarded, and a reward and punishment order will be issued.

(2) The Company's penalties are divided into four levels:

Admonition: A fine of 500 yuan and the issuance of a reward and punishment order.

Minor offense: A fine of RMB 1,500 and the issuance of a reward or punishment order.

Serious offense: A fine of RMB 3,000 and the issuance of a reward or punishment order.

Dismissal: To terminate an employee's job and remove him from his position.

4.4 Environmental Protection Expenditure Information

- (1) The total amount of losses (including compensation) and penalties incurred by the company due to environmental pollution in the most recent year and up to the date of publication of the annual report, and disclosure of its future response measures and possible expenditures: None.
- (II) Future response measures and possible expenditures: This situation has not yet occurred .
- (III) Protection measures for the working environment and personal safety of employees:

In order to improve the health of our employees and maintain workplace safety, our company conducts regular employee physical examinations every year in accordance with the relevant provisions of the "Occupational Safety and Health Law" and the "Labor Health Protection Rules", which go beyond the regulations. In addition, in order to protect the workplace safety of employees, prevent sexual harassment in the workplace, and maintain gender equality and personal dignity, the Company has established sexual harassment prevention measures, complaints and disciplinary procedures in accordance with gender equality work regulations. In addition to the above, our company purchases labor and health insurance and arranges group insurance for employees in accordance with labor-related laws to ensure workplace safety for colleagues and protect the rights and interests of employed employees.

1. Workplace safety:

- (1) Sexual harassment prevention and control work: The company has a complaint committee and relevant methods to conduct investigations and penalties.
- (2) Provide necessary health and first aid facilities, strive to reduce hazards to employee safety and health, and prevent occupational hazards.
- (3) Drinking water equipment that meets drinking water standards shall be installed in the workplace and shall be inspected, cleaned and maintained every quarter.
- (4) The environmental hygiene and cleaning management of the workplace shall be entrusted to a professional cleaning company to carry out cleaning and disinfection at least once every quarter to ensure the maintenance of the hygienic quality of the working environment.
- (5) The workplace conducts working environment monitoring (such as carbon dioxide, noise, etc.) twice a year to ensure the safety and health of employees.

- (6) Implement a comprehensive smoking ban in accordance with the Tobacco Control Act.
- (7) Workplace safety is entrusted to a professional security company to conduct daily patrols and install cameras to ensure the personal safety of employees.
- (8) In order to protect the safety of our employees, in addition to purchasing labor and health insurance in accordance with the law, we also provide insurance programs such as business trip travel insurance.
- (9) In accordance with the "Labor Health Protection Rules", special medical staff are deployed to handle labor health management, occupational disease prevention, health promotion and other labor health protection matters, and occupational safety nurses are arranged to provide on-site services twice a month.

2. Fire safety:

- (1) A complete fire protection system shall be installed in accordance with laws and regulations, including alarm system, fire protection system, escape system, etc.
- (2) The fire protection equipment in our building is commissioned to a qualified professional testing consulting company to conduct system unit function testing every month.
- (3) Promotional activities and professional courses are held at least once a year to enable colleagues to understand escape routes and become proficient in the use of facilities, etc.

3. Health management:

- (1) We arrange employee health checks every year to ensure that our colleagues are in good health.
- (2) The company has a first aid kit and medicines.
- (3) The company cooperates with hospitals every year to provide employees with influenza vaccinations.
- (4) Cooperate with hospitals to encourage employees to participate in health lectures and first aid training held by hospitals, so as to establish health awareness from a daily basis and prevent accidents.

4.5 Labor-Capital Relations

- (1) The Company's employee welfare measures, continuing education and training, retirement system and implementation status, as well as labor-management agreements and employee rights protection measures.

1. Employee welfare measures:

- (1) Pursue labor insurance and health insurance for employees in accordance with the Labor Insurance Act and the National Health Insurance Act, and allocate labor pensions in accordance with the law.
- (2) Establish an employee welfare committee to provide benefits including marriage, childbirth, funeral subsidies, scholarships, hospitalization condolence money, birthday gifts, employee travel, year-end parties, celebration activities, three festival gifts , clubs, books, newspapers and magazines, etc.
- (3) After being calculated by the Human Resources Department and approved by the responsible supervisor, the employee's salary will be remitted to the employee's account via bank transfer on the payday of each month.
- (4) Performance bonus: The business unit shall submit the performance bonus calculation method, which shall be implemented after approval.
- (5) Year-end bonus: The year-end bonus is allocated based on the company's annual operating conditions. The payment method and related contents are handled in accordance with the year-end bonus application submitted for that year.

2. Further study and training measures:

- (1) Education and training of new employees :

On the day new employees report to work, the human resources department will be responsible for explaining the personnel regulations and company profile, and each department will then be responsible for introducing their supervisors and colleagues, work environment, work processes, and job descriptions .

- (2) On-the-job employee education and training :

In order to implement lifelong learning, promote the growth of colleagues' professional knowledge, skills and humanistic qualities, thereby improving service quality and performance and driving the overall development of the company, the "Employee Continuing Education and Training Measures" have been specially formulated. Continuing education training is divided into "on-the-job education" and "advanced education". "On-the-job education" includes internal on-the-job training, professional courses, special lectures, etc. "Continuing education" includes personal study or participation in external seminars, conferences, annual meetings, courses, etc.

2024 Annual Employee Education and Training Statistics

department	job title	Name	Course Dates	Hours	Course Title	Course Organizer
Accounting Office	Specialist	Xiao Peiling	1130422	3	2024 Corporate Income Tax and Comprehensive Income Tax Return Practice Seminar	Northern District National Taxation Bureau of the Ministry of Finance
Human Resources Office	manager	Li Xiaoping	1130516	4	How to reserve sustainable combat power and embrace talents	Asian Chinese Health Industry Human Resources Management Society
Administration Department	Deputy General Manager	Cai Yufang	1130619	3	Breach of trust by directors and supervisors and special breach of trust crime Facts of establishment	Securities and Futures Market Development Foundation of the Republic of China
Human Resources Office	manager	Li Xiaoping	1130621	2.5	ESG&DEI Talent Sustainability Action Guide	104 School of Human Resources
Accounting Office	Assistant Manager	Deng Yurong	1130627~0628	12	Continuing Education Course for Accounting Supervisors of Issuers, Securities Dealers and Stock Exchanges	Accounting Research and Development Foundation foundation
Human Resources Office	Clerk	Xiao Guiling	1130702	5	Taoyuan City 2024 Labor Rights Law Promotion Conference	Taoyuan City Government Labor Bureau
Audit Office	Assistant Manager	Leaf cultivation	1130723	3.5	2024 Annual Sustainable Information Management Internal Control System Promotion Conference	OTC Securities Exchange
Human Resources Office	Manager	Zhang Zhenjun	1130910	7	Recruitment/Performance/Retirement Interview Skills	China Industrial and Commercial Research Institute
Human Resources Office	manager	Li Xiaoping	1130912	3	Seminar on the Development Trend and Current Situation of Employee Benefit Trusts	Trust Industry Association of the Republic of China
Human Resources Office	manager	Li Xiaoping	1130921	6	Talent Nine-square Grid Data + Storyboard Application Practice	HR Weekend Community Co., Ltd.
Accounting Office	Specialist	Xiao Peiling	1130925	6	Latest "Annual Report Preparation" related to ESG sustainability policies and laws and net zero carbon emissions on financial statements practical analysis	Accounting Research and Development Foundation
Administration Department	Deputy General Manager	Cai Yufang	1131004	6	Learn the core of corporate governance and compliance from court cases	Accounting Research and Development Foundation
Human Resources Office	Clerk	Xiao Guiling	1131009	6	Labor inspections and corporate countermeasures and prevention practices - Labor incident law response measures	China Industrial and Commercial Research Institute
Human Resources Office	Manager	Zhang Zhenjun	1131021	7	Layoffs and dismissals and resignation management practices - Proper and legal execution to avoid negative impact risks	China Industrial and Commercial Research Institute

Administration Department	Deputy General Manager	Cai Yufang	1131026	3	Legal responsibilities and case analysis related to company "dispute over management rights"	Accounting Research and Development Foundation
Audit Office	Assistant Manager	Leaf cultivation	1131030	6	Promoting corporate sustainable development through risk management	Accounting Research and Development Foundation
Human Resources Office	manager	Li Xiaoping	1131108	7	Performance management system: establishment, improvement and tracking	China Industrial and Commercial Research Institute
Accounting Office	Associate	Huang Yamei	1131205~1206	12	Analysis of the latest financial accounting laws and regulations and the development trend of standards, strategic thinking and practice of "group enterprise restructuring" IFRS perpetual disclosure standards, legal liability and practical case analysis of "non-routine transactions"	Accounting Research and Development Foundation
Regulatory Office	High Commissioner	Lin Lifan	1131121	3	Relevant laws and regulations that boards of directors should pay attention to under the ESG trend	Securities and Futures Market Development Foundation of the Republic of China
Audit Office	Assistant Manager	Leaf cultivation	1131210	6	The latest "Annual Report/Sustainability Information/Financial Report Preparation" related laws and regulations analysis and internal control management practices	Accounting Research and Development Foundation
Accounting Office	Specialist	Xiao Peiling	1131219	3	2024! Conference on Promoting the Adoption of International Financial Reporting Standards in my country	Accounting Research and Development Foundation

3. The company's retirement, pension, layoff and resignation system :

(1) Retirement, layoffs, occupational accident benefits, and pensions :

In order to regulate employee retirement, layoffs, occupational accident compensation, and pensions, the Company has formulated the "Employee Retirement, Layoff, and Occupational Accident Compensation Regulations". All matters related to employee retirement, layoffs, occupational accident subsidies, and compensation, such as identification, application, and payment, are spelled out in the regulations. The summary is as follows:

A. Retirement:

Employees of our company who meet any of the following conditions may

voluntarily retire.

Continuously worked for the company or its affiliated companies for more than 25 years.

Those who have worked for the Company or its affiliated companies for more than 15 consecutive years and are 55 years of age or older.

Those who have worked for the Company or its affiliated companies for more than 10 consecutive years and are 60 years of age or older.

The Company has established a Labor Retirement Reserve Supervisory Committee and formulated the Labor Retirement Reserve Supervisory Committee's organizational charter. Representatives are elected from among the old system employees to serve as committee members to manage the old system retirement funds. In accordance with Article 56 of the Labor Standards Act, 2% -15% of the total monthly salary of old system employees is set aside as a retirement reserve fund. The pension payment shall be made from the retirement reserve account set aside by the company, and the shortfall shall be made up by the company.

The Labor Retirement Reserve Fund Supervisory Committee holds meetings quarterly to review the retirement reserve fund allocation and balance, review the retirement fund applications of old-system employees, and obtain information on employees who have chosen the old retirement system. In addition, for new employees, in accordance with the Labor Pension Regulations, 6% of the labor retirement grade will be contributed to the employee's personal pension account at the Labor Insurance Bureau every month; for those who voluntarily contribute to their pensions, the voluntary contribution rate will be deducted from the employee's salary and transferred to the employee's personal pension account at the Labor Insurance Bureau.

B. Layoffs:

If the Company encounters any of the circumstances specified in Article 11 of the Labor Standards Act, it may terminate the labor contract with the employee by giving advance notice and pay severance pay in accordance with the law. Those who are laid off must provide advance notice in accordance with Article 16 of the Labor Standards Act. When a company lays off an employee, it should list the name, gender, age, address, telephone number, job, reason for

layoff, and whether or not job counseling is required of the laid-off employee 10 days before the employee leaves the company, and report the list to the competent authority and public employment service agency for notification.

C. Occupational accident benefits:

When an employee becomes disabled, injured, becomes ill, or dies due to an occupational accident, the company will provide compensation in accordance with the Labor Standards Act. However, if the company has already paid compensation for the same accident in accordance with the Labor Insurance Act and other laws and regulations, such compensation may be offset. When an employee is injured or suffers from an occupational disease, the company will compensate for the necessary medical expenses. The types of occupational diseases and the scope of medical treatment shall be in accordance with the relevant provisions of the Labor Insurance Act.

D. Compensation:

If an employee of our company dies of illness, accident, danger encountered in the performance of duties or death caused by illness during his/her employment, the company will pay a pension.

(2) Resignation system:

In order to enable employees to resign under reasonable and legal circumstances and ensure smooth business handover, we have formulated the "Employee Resignation Management Measures". The resignation of all full-time or part-time employees of the Company shall be managed in accordance with these regulations. Employees should submit resignation applications in accordance with regulations and complete relevant resignation procedures .

4. Collective Agreement :

The Company promotes labor-management harmony and improves labor welfare through employee welfare committees and labor-management meetings. Both of the above organizations elect labor representatives through employee elections to propose, coordinate, communicate and supervise labor-management related issues on behalf of employees, including but not limited to labor-management relations, working conditions, labor welfare, workplace sexual harassment and bullying, employee diversity and equality issues. Employees are

ex-officio members and have the right to raise the above issues to the labor committee for discussion and negotiation.

In accordance with the "Labor-Management Meeting Implementation Regulations" and Article 83 of the Labor Standards Act, relevant regulations are formulated to hold labor-management meetings regularly. Meetings are held quarterly, four times a year.

In accordance with Article 5 of the Employee Welfare Fund Regulations, public institutions and employees jointly contribute to the employee welfare fund and establish an employee welfare committee. The employee welfare committee meets once a quarter and four times a year.

The company, with representatives from both labor and management, will discuss and properly handle matters through meetings, and track progress and results at the next labor-management or employee welfare meeting.

Cooperate with the government's labor law amendments, implement various labor leave management spirits, and remind employees of the importance of balancing work and vacation.

5. Measures to protect employees' rights and interests:

In order to protect the rights and interests of employees, the Company has clearly stipulated relevant measures for employee benefits in accordance with the law, including various subsidy measures and a mechanism for distributing bonuses during the three festivals. A Labor Retirement Reserve Fund Supervisory Committee will be established to be responsible for the preparation, allocation, custody, use and related legal and regulatory matters of the retirement fund. In order to deal with possible sexual harassment between employees and safeguard gender equality and personal dignity at work, we have formulated "Sexual Harassment Prevention Measures, Complaints and Disciplinary Measures" in accordance with the Gender Equality Work Regulations .


- (2) A description of the losses incurred by the Company due to labor-management disputes in the most recent two years and up to the date of publication of the prospectus, and the estimated amounts and response measures that may occur currently and in the future. If no reasonable estimate is available, the facts that cannot be reasonably estimated shall be explained: The Company has

established a complete communication channel and is committed to creating a good and harmonious labor-management relationship. To date, it has not suffered significant losses due to labor-management disputes. In the future, we will continue to improve communication and coordination between labor and management so that all employees can grow in a safe and enjoyable working environment.

4.6 Information and communication security management

1. Information Security Risk Management Framework

In order to strengthen the security and management of information operations, the company has set up a cross-departmental Information Security Committee to formulate information security management policies, promote "Information Operation Methods", coordinate cross-departmental information processing procedures, review the company's information security policies and implementation results, and regularly report the company's information security governance overview to the board of directors. The organizational structure of the Information Security Committee is as follows:



(II) Information and communications security policy

"Implement information security, reduce information security risks, increase customer trust, and improve operational performance"

In order to strengthen information security management so that the management system can operate effectively and ensure the confidentiality, integrity and availability of the information assets under management, specific policies and regulations are used to provide security management for the continuous operation of the company's business, achieve the purpose of sustainable operation, and comply with the requirements of relevant laws and regulations .


The company is actively introducing and establishing a complete information security management system (ISMS) , establishing a cross-unit information security organization, ensuring the availability of business continuity, implementing information security risk assessment mechanisms, improving the effectiveness of information security management, and implementing an information security internal audit system to ensure the effectiveness of information security management implementation, assisting the group's business continuity and sustainable operation. Business activities must comply with policies and laws and regulations. Through continuous planning-execution-audit-action, the system is ensured to operate effectively, and activities are documented or recorded in the system. All accidents or abnormalities should be evaluated and confirmed in accordance with procedures.

(III) Specific management plans and resources invested in information and communications security management

Information security management measures implemented by our company

Type	Illustrate	Related Assignments
Permission Management	Management of system accounts and permissions	Information Request Form
Access Management	Access to internal and external data, mail transmission, and filtering control	Internal/external access control measures Control of data leakage channels Operation behavior track record
External defense	Network security, anti-virus software, outsourcing and third-party vendors	Network security maintenance, network point installation Legal copyright, anti-virus software installation Sign a confidentiality agreement
System Repair	System usage status and disconnection measures	Maintenance notification system
Database Management	Database backup	Back up data regularly Offsite backup

Our company's information system emergency response plan is as follows. The reporting and handling of information security incidents shall comply with the specifications of this procedure.



(IV) 2024 of Implementation

1. Since the establishment of the "Information Security Committee" in September 2019, the company has held regular Information Security Committee meetings every quarter, and held a total of 4 meetings in 2024 . (3/7 , 6/6 , 9/5 , 12/12) .
2. In 2024, we implemented important information security issues and events, including equipment failure drills, social engineering drills, information security education and training, permission account verification, illegal software verification, information security risk assessment, etc.
3. The Information Security Committee passed a resolution in 2023 and officially introduced ISO 27001:2022 in 2024. The internal audit was completed in October 2024 and a management and audit meeting was held on November 15 of the same year .
4. In accordance with the regulations of the Financial Supervisory Commission, we have assigned an information security supervisor and an information security officer in 2023, and obtained a completion certificate in 2024, meeting the requirements of the competent authority.
5. The implementation status of information security was reported at the 5th meeting of the 8th Board of Directors on December 21, 2024 .
- 6 . List the losses, possible impacts and response measures incurred due to major information and communications security incidents in the most recent year and up to the date of publication of the annual report. If it is impossible to reasonably estimate, the fact that it is impossible to reasonably estimate should be explained: There is no such situation.

4.7 Important Contracts

Nature of the contract	party	Contract start and end date		Main content	Restrictions
		rise	until		
Outsourcing service contract	Taiwan Semiconductor Manufacturing Co., Ltd. Limited Company	113/01/01	117/12/31	Health Center Business Services	none
Medical Service Contract	Min Shing General Hospital	111/01/01	120/12/31	Physical examination service	none
Medical Service Contract	Min Shing General Hospital	111/01/01	120/12/31	Inspection business services	none
Medical Service Contract	Longtan Minsheng Hospital	111/01/01	120/12/31	Inspection business services	none
Medical Service Contract	Longtan Minsheng Hospital	111/01/01	120/12/31	Physical examination service	none
Medical Service Contract	Dayuan Minsheng Hospital	111/01/01	120/12/31	Inspection business services	none
Medical Service Contract	Smart Medical Clinic	112/03/15	120/12/31	Inspection business services	none
Medical Service Contract	Ren Gong Memorial Hospital	113/01/01	117/12/31	Physical examination service	none
Yonggeng Health Checkup Support Cooperation Agreement	Catholic Kenshin Medical Foundation Yonghe Kenshin Hospital	112/06/15	115/06/14	Physical examination service	none
Yonggeng High Prosecutor's Office Center Cooperation Operation Case	Catholic Kenshin Medical Foundation Yonghe Kenshin Hospital	112/06/15	115/06/14	Physical examination service	none
National Taiwan University Medical School Hospital Property Purchase Contract	National Taiwan University Hospital	112/05/01	114/04/30 Can be expanded for 1 year	Purchase Case Number: 【Case No. UD11E20A】 Name of the bidding item: Biochemical immunoassay reagents (with instruments)	none

Nature of the contract	party	Contract start and end date		Main content	Restrictions
		rise	until		
Documents and Agreement					
Equipment procurement contract	Bio-Tech Co., Ltd.	113/01/10		Wireless Central Physiological Signal Monitoring System	none
Equipment procurement contract	Huafeng Technology Co., Ltd.	113/05/07		1. Digital color ultrasound scanner 2. Digital color ultrasound scanner (including vascular system software)	none
Equipment procurement contract	Yikang Biotech Co., Ltd.	113/05/29		1. Electrocardiograph 2. Lung function machine	none
Equipment procurement contract	Yuan You Industrial Co., Ltd.	113/06/24		Electronic nasopharyngeal endoscope host system, nasopharyngeal endoscope and electronic colonoscope	none
Equipment procurement contract	Cheng Chung Enterprise Co., Ltd.	113/06/28		Fully automatic tablet packaging machine	none
Equipment procurement contract	Yuan You Industrial Co., Ltd.	113/09/13		Electronic gastroscope and electronic colonoscope	none
Equipment procurement contract	Juzheng Technology Co., Ltd.	113/09/25		Centrifugal Pump System	none
Equipment procurement contract	Huixing Co., Ltd.	113/11/15		3D Upgrade High Definition Image System Kit	none
Equipment procurement contract	Chengqi Medical System Co., Ltd.	113/11/21		Portable cardiac ultrasound scanner	
Equipment procurement contract	Yuan You Industrial Co., Ltd.	113/12/12		Electrocautery machine and plasma hemostasis device	none
Equipment procurement contract	Huihemei Instrument Co., Ltd.	113/12/17		Hydrogen Peroxide Low Temperature Plasma Sterilizer	none

Nature of the contract	party	Contract start and end date		Main content	Restrictions
		rise	until		
Medical Equipment Lease Contract	Min Shing General Hospital	113/01/01	115/12/31	Computerized tomography scanner	none
Medical Equipment Lease Contract	Smart Medical Clinic	113/01/01	115/12/31	Red rope suspension workstation and floor stand, etc., totaling 2 items	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/02/01	115/01/31	3D, 4K imaging system	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/03/01	116/02/28	X-ray machine	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/03/01	116/02/28	Ophthalmic photocoagulation laser irradiator	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/04/01	116/03/31	Desktop centrifuge	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/08/01	116/07/31	Cardiopulmonary function tester	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/08/01	116/07/31	Central physiological signal monitoring system (including wireless single-lead electrocardiograph/20set)	none
Medical Equipment Lease Contract	Precision Health Co., Ltd.	113/10/01	116/09/30	Electronic blood pressure machine (without cart)	none
Medical Equipment Lease Contract	Min Shing General Hospital	113/11/01	116/10/31	Electronic nasopharyngeal endoscope host system group	none
Medical Equipment Lease Contract	Longtan Minsheng Hospital	113/12/01	116/11/30	Fully automatic tablet packaging machine	none

5. Review and Analysis of Financial Status and Financial Performance and Risk Issues

5.1 Financial Status

Unit: NT\$ thousand

project \ year	2023	2024	difference	
			Amount	%
C u r r e n t A s s e t s	3,239,624	3,392,392	152,768	4.72%
Financial assets at fair value through profit or loss - non-c u r r e n t	19,684	27,853	8,169	41.50%
Financial assets at fair value through other comprehensive income - n o n - c u r r e n t	814,972	770,686	(44,286)	(5.43%)
Financial assets at fair value through other comprehensive income - n o n - c u r r e n t	44,500	43,334	(1,166)	(2.62%)
Investments using the equity m e t h o d	76,578	76,056	(522)	(0.68%)
Property, plant and e q u i p m e n t	1,676,551	1,490,229	(186,322)	(11.11%)
Right-of-use assets	407,790	350,060	(57,730)	(14.16 %)
Investment real estate	338,194	111,884	(226,310)	(66.92%)
I n t a n g i b l e a s s e t s	337,124	322,120	(15,004)	(4.45%)
O t h e r a s s e t s	490,521	517,103	26,582	5.42%
T o t a l a s s e t s	7,445,538	7,101,717	(343,821)	(4.62%)
C u r r e n t l i a b i l i t i e s	1,964,972	1,859,999	(104,973)	(5.34%)
Non-current liabilities	1,525,107	1,260,652	(264,455)	(17.34%)
T o t a l l i a b i l i t i e s	3,490,079	3,120,651	(369,428)	(10.59%)
Equity attributable to owners	3,487,936	3,556,895	68,959	1.98%

of the parent company				
S h a r e c a p i t a l	1,260,443	1,310,861	50,418	4.00%
C a p i t a l r e s e r v e	1,155,834	1,150,037	(5,797)	(0.50%)
R e t a i n e d E a r n i n g s	949,006	1,048,993	99,987	10.54%
O t h e r b e n e f i t s	122,653	47,004	(75,649)	(61.68%)
N o n - c o n t r o l l i n g i n t e r e s t s	467,523	424,171	(43,352)	(9.27%)
T o t a l E q u i t y	3,955,459	3,981,066	25,607	0.65%
<p>Explanation of the reasons for the increase or decrease between the two periods: The increase or decrease ratio reaches 20% and the amount exceeds NT\$10 million</p> <ol style="list-style-type: none"> 1. Decrease in investment properties: Mainly due to the sale of Dayuan investment properties in this period. 2. Decrease in other equity: Mainly due to decrease in unrealized gains and losses on financial assets measured at fair value through its comprehensive income statement. 				

Source: Financial report audited and certified by accountants

5.2 Operating Results

(I) Comparative analysis of operating results:

Unit: NT\$ thousand

project \ year	2023	2024	Increase (decrease) amount	Change ratio%
Operating income	3,873,384	4,325,831	452,447	11.68%
Operating profit	726,377	714,404	(11,973)	(1.65%)
Operating profit or loss	119,099	178,489	59,390	49.87%
Non-operating income and expenses	(10,115)	(4,579)	5,536	(54.73%)
Net profit before tax	108,984	173,910	64,926	59.57%
Net profit of continuing operations for the current period	55,265	122,398	67,133	121.47%
Loss of discontinued business units	0	0	0	0%
Net profit (loss) for the period	55,265	122,398	67,133	121.47%
Other comprehensive income for the period (net of tax)	114,003	(76,034)	(190,037)	(166.70%)
Total comprehensive profit or loss for the period	169,268	46,364	(122,904)	(72.61%)
Earnings per share	0.99	1.53	0.54	54.73%
<p>Analysis of increase or decrease: The increase or decrease ratio reaches 20% and the amount exceeds NT\$10 million</p> <ol style="list-style-type: none"> Operating profit or loss, net profit before tax and net profit for the current period increased: mainly due to the increase in gains from disposal of investment properties, which led to an increase in profit compared with the same period. The decrease in other comprehensive income and loss and total comprehensive income for the current period was mainly due to the decrease in unrealized 				

valuation gains arising from the fair value measurement of financial assets-non-current investees measured at fair value through other comprehensive income in 2024.

Source: Financial report audited and certified by accountants

- (II) Expected sales volume and its basis, possible impact on the company's future financial operations and response plans

The company's sales forecast for 2024 is estimated based on factors such as market demand and industry development trends. In addition, the company will continue to develop new markets, constantly improve service quality, satisfy customers and maintain good cooperative relationships with suppliers.

5.3 Cash Flow

1. Analysis and explanation of cash flow changes in recent years:

Unit: NT\$ thousand

project	2023	2024	Increase (decrease) ratio (%)
Cash flow ratio (%)	13.07	14.34	9.72%
Cash flow adequacy ratio (%)	78.72	72.80	(7.52%)
Cash reinvestment ratio (%)	3.71	3.90	5.12%
Description of increase/decrease ratio changes: Cash flow ratio and cash reinvestment ratio: Due to the increase in profits in 2024, the cash inflow from operating activities increased compared with the same period, and the cash flow ratio increased .			

2. Cash liquidity analysis for the next year:

Unit: NT\$ thousand

Cash at beginning of period Balance	Estimated full-year net cash flow from operating activities	Expected full year Cash Inflow/Outflow	Estimated cash surplus (shortage) amount	Estimated cash shortfall Remedies	
				Investment Plan	Financing Plan
959,415	114,500	(126,500)	947,415	not applicable	not applicable
<p>(1) Analysis of cash flow changes in the next year:</p> <p>① Operating activities: It is estimated that the profit situation in 2025 will continue to grow steadily, showing net cash inflow.</p> <p>② Investment activities: The Company will incur capital expenditures such as purchasing equipment and securities to support business development, resulting in cash outflows.</p> <p>③ Financing activities: The Company will incur cash outflows this year due to repayment of some long-term and short-term loans.</p> <p>(2) Estimated remedial measures for cash shortage and liquidity analysis: Not applicable.</p>					

5.4 Impact of major capital expenditures on financial operations in the most recent year : None

5.5 Recent investment policies, major reasons for profit or loss, improvement plans, and investment plans for the coming year

1. Reinvestment policy: To meet business and operational needs, we are committed to building an ecosystem for the digital transformation of the medical industry and health care, providing integrated medical logistics services, coordinating with the company's long-term development strategy, and prudently evaluating various investment plans .

2. Main reasons for profit or loss and improvement plan:

2024.12.31; Unit: NT\$ thousand

Reinvestment Company	Shareholding ratio	Recognize the investee company's profit and loss for the most recent year	Profit or loss main reason	improve plan
Mytrex Health Technologies, Inc.	61.46	(50,628)	Market demand for mask filter materials declines	Carry out strategic transformation, utilize the group's brand and channel resources, and actively seek strategic partners
Share Hope Medicine Co., Ltd. (Hong Kong)	100	(1,343)	Adjustment of management and sales costs	Diversified income sources
Chungyuan Medical Management Co., Ltd.	100	147	Cost structure optimization	Continue to expand business
Medzoneasia Co., Ltd.	100	(42,131)	Adjustment of organizational management policies	Streamline management costs and plan to merge with parent company Shenghong Pharmaceutical in 2015
Pregetic Medical Health Co., Ltd.	38.19	(25,206)	Repositioning of organization and business direction	Adjust business policies and continue to develop new customers
Shengshi Digital Health Co., Ltd.	100	(95)	Adjustment of management and sales costs	Optimize cost structure

Note 1 : The investment returns for the most recent year only reflect the investment gains and losses of our company.

Note 2: Investment plan for the next year: None .

Note 3: Bohui Biotech Co., Ltd. applied for dissolution in 2024.

Note 4 : In response to the adjustment of the group's business policy, the Company dissolved Shengtai Food Technology Co., Ltd. and Huiyun Microfluidics Co., Ltd. in 2024 .

5.6 Risks

1. Risk factors:

1. The impact of interest rate, exchange rate changes, and inflation on the company's profits and losses and future response measures:

- (1) The impact of interest rate changes on the company's profit and loss and future response measures

The Company's interest expenses in 2024 and 2023 were NT\$58,342,000 and NT\$53,665,000, respectively, accounting for 1.35% and 1.39% of the revenue of the respective years. These expenses were mainly due to interest expenses incurred on loans from various financial institutions. As these expenses accounted for a very small proportion of the operating revenue, changes in interest rates had no significant impact on the Company.

The Company will keep an eye on interest rate changes and strive for more favorable interest rates with its banks to reduce interest costs.

- (2) The impact of exchange rate changes on the company's revenue and profits:

Our company's business model is mainly domestic sales-oriented, and most of our purchases and sales are conducted in New Taiwan dollars, so exchange rate changes have no significant impact on the company's profits and losses.

- (3) Impact of inflation:

The Company's products are not basic consumer goods and are not immediately sensitive to inflation. However, the Company will continue to pay close attention to economic developments and respond appropriately.

2. The policies, main reasons for profits or losses and future response measures for high-risk, high-leverage investments, loaning funds to others, endorsement and guarantee, and derivative transactions:

The Company adheres to the principle of prudent operation and focuses on its core business. In recent years and up to the date of publication of the prospectus, the Company has not engaged in high-risk, high-leverage investments, loaning funds to others, or derivative commodity transactions.

The Company has established "Procedures for Acquisition or Disposal of

Assets", "Procedures for Lending Funds to Others" and "Procedures for Endorsement and Guarantee", which have been approved by the shareholders' meeting. The Company's endorsement guarantee has been processed in accordance with the prescribed procedures. As of the date of publication of the prospectus, the endorsement guarantee amount is NT\$229,880,000.

3. Future R&D plans and estimated R&D expenses:

Our company is engaged in medical logistics services, with its main focus on business and channel expansion. We are not a research and development-oriented company. Our company focuses on cultivating professional talents and innovating operating models, and invests in related expenses.

4. The impact of major domestic and international policy and legal changes on the company's financial business and the corresponding measures:

The Company's operating policies are all handled in accordance with laws and regulations, and the Company pays close attention to important domestic and international policy and legal changes at any time. When necessary, it consults relevant experts and takes appropriate response measures. As of the date of publication of the prospectus, the Company has not been affected by any major domestic and international policy and legal changes that have had a significant impact on its financial operations.

5. Impact of technological and industrial changes on the company's financial business and corresponding measures:

As of the date of publication of the Prospectus, the Company has not experienced any material impact on its financial operations due to technological and industrial changes in the most recent year.

6. The impact of corporate image changes on corporate crisis management and response measures:

The company continues to provide integrated medical logistics management and other services and has a good corporate image and corporate reputation. Since its establishment, the company has been committed to maintaining its corporate image and complying with laws and regulations. So far, no incidents have occurred that would affect its corporate image. If there are any events that affect the corporate image in the future, the crisis management team composed of the company's first-level managers will hold meetings at any time to respond

to sudden crises.

7. Expected benefits, possible risks and countermeasures of mergers and acquisitions: The Company currently has no plans for mergers and acquisitions.
8. Expected benefits, possible risks and countermeasures of factory expansion: The Company currently has no plans to expand its factory.
9. Risks and countermeasures faced by concentrated purchase or sales:

(1) Description of purchase status:

In order to prevent the risk of concentrated purchases, the company maintains stable and market-adaptive supply agreements with several suppliers at the same time. In addition to ensuring the quality and quantity of the supply sources, it can also enhance the integrity and competitiveness of the supply chain.

(2) Sales status description:

In order to avoid the risk of sales concentration on major customers, the Company will continue to develop customer base and expand sales channels in the future with high-quality products in addition to the existing stable basic customers with whom it has close cooperation, so as to maintain a stable sales target.

10. Impact, risks and response measures of large-scale transfer or replacement of shares by directors, supervisors or major shareholders holding more than 10% of the shares on the company: There is no such situation.
11. Impact of the change of management rights on the company, risks and countermeasures: The management of the Company is focused on the operation of the company, with the assistance and support of directors and supervisors. There is no risk that the change of management rights may cause to the company.
12. Other important risks and countermeasures: None

(II) Litigation or non-litigation events:

1. The company shall disclose the facts in dispute, the subject amount, the commencement date of the litigation, the main parties involved in the litigation, and the current status of the litigation, non-litigation, or administrative disputes

that have been decided or are currently under investigation in the most recent two years and as of the date of publication of the prospectus, if the results of which may have a significant impact on shareholders' equity or securities prices: none.

2. The company's directors, supervisors, general manager, de facto responsible persons, major shareholders with a shareholding ratio of more than 10%, and affiliated companies, any litigation, non-litigation, or administrative disputes that have been decided or are currently in the process of being decided in the past two years and as of the date of publication of the prospectus, the results of which may have a significant impact on the company's shareholder rights or securities prices: None .

3. The company's directors, supervisors, managers and major shareholders holding more than 10% of the shares have any of the following circumstances specified in Article 157 of the Securities and Exchange Act in the past two years and up to the date of publication of the prospectus, and the company's current handling of the situation: None

(3) If the company's directors, supervisors, managers, and major shareholders holding more than 10% of the shares have experienced financial difficulties or lost credit in the most recent two years and up to the date of publication of the prospectus, the impact on the company's financial status shall be listed: None.

(IV) Other important matters: None.


5.7 Other important matters : None .

6. Special matters to be recorded

6.1 Relevant information of related enterprises in the most recent year:

(I) Merger business report of related enterprises

1. Organization chart of related enterprises:



2. Basic information of related companies

2024.12.31

Company Name	Date of establishment	address	Paid-in capital	Main business or production projects
Mytrex Health Technologies, Inc. (formerly known as Mytrex Co., Ltd.)	79.08.06	19F , No. 107 , Minsheng Road, Wulingli, Taoyuan District, Taoyuan City	365.36 million	Manufacturing and processing of nonwoven fabrics and sales of medical and sanitary materials
Share Hope Medicine Co., Ltd. (Hong Kong)	101.10.25	Room 511, 5 /F, Silvercord Tower 1, 30 Canton Road, Tsim Sha Tsui, Kowloon	44.83 million	Investment Management Industry
Chungyuan Medical Management Co., Ltd (formerly known as Shenghong Management Consulting Co., Ltd.)	94.07.12	19F , No. 168 , Jingguo Road, Taoyuan District, Taoyuan City	10 million	Management Consulting
Medzoneasia Co., Ltd. (formerly known as Shengyun E-commerce Co., Ltd.)	106.05.19	2F , No. 31 , Lane 17 , Ziqiang North Road, Guishan District, Taoyuan City	187.54 million	Health management services and hotel industry

Company Name	Date of establishment	address	Paid-in capital	Main business or production projects
Pregetic Medical Health Co., Ltd.	106.12.26	19F , No. 168 , Jingguo Road, Taoyuan District, Taoyuan City	329.92 million	Health management services
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	108.07.02	9F - 5 , No. 294, Section 1 , Dunhua South Road, Da'an District, Taipei City	1 million	Management Consulting
Mytrex USA Co. (Original Name: TSVC Co.)	105.07.08	916 LIDO LANE FOSTER CITY , CA 94404	26.46 million	Health care support services
Mytrex Industries, Inc	110.11.05	No. 545 , Section 2, Hezhen North Road, Neidingli, Zhongli District, Taoyuan City	60 million	Manufacturing and processing of nonwoven fabrics and sales of medical and sanitary materials
Sheng Yo Rehabilitative Technologies, Inc.	111.02.14	1F , No. 209 , Section 2, Lin'an Road, North District, Tainan City	29 million	Health management services
YES Health Co., Ltd.	104.02.05	2F , No. 31 , Lane 17 , Ziqiang North Road, Guishan District, Taoyuan City	60.35 million	Drug wholesale and pharmacy management consulting
TECHGROUP Integrate Design Co., Ltd.	83.09.17	7F , No. 53 , Minquan Road, Yonghe District, New Taipei City	12 million	Medical information software services
Digimed Co., Ltd.	109.05.20	6F - 1 , No. 103 , Section 2, Nanchang Road, Zhongzheng District, Taipei City	10 million	Information software services
Hung-Han Medical Health Co., Ltd.	108.05.03	2F , No. 22, Section 2 , Kaifeng Street, Wanhua District, Taipei City	34.2 million	Health management services
Harvard Health Inc. (formerly known as Fuyi Health Management Consultants Co., Ltd.)	105.08.08	12F , No. 250, Section 1, Neihsu Road, Neihsu District, Taipei City	120 million	Health management consulting industry
Macro Global Corporation	80.06.10	18F - 3 , No. 303 , Zhongming South Road, West District, Taichung City	64.6 million	Drug wholesale and trading
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	103.09.17	Room 506 , 5th Floor , Building 7 , No. 1 Jinfang Road, Chaoyang District, Beijing	5.12 million	Hospital management consulting services
Minsheng (Tianjin) Investment Management Co., Ltd	102.03.05	No. 12, Jingjin Highway (west side) , Hexiwu Town, Wuqing District, Tianjin	11.88 million	Investment Management Industry

3. Information on shareholders who are presumed to have a controlling and subordinate relationship: Not applicable.

4. The industries covered by the overall business of the related enterprises: pharmaceutical procurement, equipment leasing, non-woven fabric manufacturing and processing, management consulting,

Health management and information software services , etc.

5. Information on directors, supervisors and general managers of related companies:

2024.12.31				
Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding Proportion
Mytrex Health Technologies, Inc.(formerly known as Mytrex Co., Ltd.)	director	Sharehope Medicine Co., Ltd. Representative: Yang Hongren	22,453,719	61.46%
		Sharehope Medicine Co., Ltd. Representative: Liu Qingwen	22,453,719	61.46%
		Sharehope Medicine Co., Ltd. Representative: Xie Jiannan	22,453,719	61.46%
		Sharehope Medicine Co., Ltd. Representative: Yang Kunzhang	22,453,719	61.46%
		Yang Zheng Investment Co., Ltd. Representative: Zhang Changrong	177,814	0.49%
		Yang Zheng Investment Co., Ltd. Representative: Yang Wenren	177,814	0.49%
	Independent Director	You Qizhang	0	0.00%
		Zhang Hengyu	0	0.00%
		Wu Mengchu	0	0.00%
Share Hope Medicine Co., Ltd. (Hong Kong)	director	Sharehope Medicine Co., Ltd. Representative: Yang Hongren	1,500,000	100.00%
Chungyuan Medical Management Co., Ltd (formerly known as Shenghong Management Consulting Co., Ltd.)	director	Sharehope Medicine Co., Ltd. Representative: Liu Qingwen	1,000,000	100.00%
		Sharehope Medicine Co., Ltd. Representative: Wu Mingxun	1,000,000	100.00%
		Sharehope Medicine Co., Ltd. Representative: Huang Yamei	1,000,000	100.00%
	Supervisor	Sharehope Medicine Co., Ltd. Representative: Cai Yufang	1,000,000	100.00%
Medzoneasia Co., Ltd. (formerly known as Shengyun E-commerce Co., Ltd.)	director	Sharehope Medicine Co., Ltd. Representative: Yang Hongren	17,254,300	100.00%
		Sharehope Medicine Co., Ltd. Representative: Liu Qingwen	17,254,300	100.00%
		Sharehope Medicine Co., Ltd. Representative: Chen Pengxuan	17,254,300	100.00%
		Sharehope Medicine Co., Ltd. Representative: Chen Zhuwen	17,254,300	100.00%
		Wei Ciyi	0	0.00%
	Supervisor	Cai Yufang	0	0.00%

Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding Proportion
Pregetic Medical Health Co., Ltd.	director	Sharehope Medicine Co., Ltd. Representative: Yang Hongren	12,600,632	38.19%
		Sharehope Medicine Co., Ltd. Representative: Zhang Sigang	12,600,632	38.19%
		Fubon Health Management Consultants Co., Ltd. Representative: Wang Hongjun	7,796,875	23.63%
		Fubon Health Management Consultants Co., Ltd. Representative: Zheng Da	7,796,875	23.63%
		China Development II Biomedical Venture Capital Limited Partnership	8,880,445	26.92%
	Supervisor	Ye Jingwen	50,000	0.15%
		Cai Zhiming	0	0.00%
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	director	Xu Shiming	0	0.00%
		Yang Hongren	0	0.00%
		Yang Shunjun	0	0.00%
		He Weiguang	0	0.00%
		Hong Tae-woong	0	0.00%
	Supervisor	Wu Xinyi	0	0.00%
Mytrex USA Co. (Original Name: TSVC Co.)	none	none	N/A	N/A
Mytrex Industries, Inc	director	Mytrex Health Technologies, Inc. Representative: Yang Kunzhang	6,000,000	100.00%
		Mytrex Health Technologies, Inc. Representative: Yang Wenren	6,000,000	100.00%
		Mytrex Health Technologies, Inc. Representative: Lu Meizhen	6,000,000	100.00%
Sheng Yo Rehabilitative Technologies, Inc.	director	Yang Hongren	219,000	2.38%
		Hong Quancheng	0	0.00%
		Yang Kunzhang	219,000	2.38%
	Supervisor	Li Yiqing	4,381,000	47.62%
YES Health Co., Ltd.	director	Mytrex Health Technologies, Inc. Representative: Yang Hongren	6,034,951	100.00%
		Mytrex Health Technologies, Inc. Representative: Chen Pengxuan	6,034,951	100.00%
		Mytrex Health Technologies, Inc. Representative: He Weiguang	6,034,951	100.00%
		Mytrex Health Technologies, Inc. Representative: Wang Bosen	6,034,951	100.00%
		Mytrex Health Technologies, Inc. Representative: Yang Kunzhang	6,034,951	100.00%

Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding
				Proportion
	Supervisor	Mytrex Health Technologies, Inc. Representative: Liu Qingwen	6,034,951	100.00%
TECHGROUP Integrate Design Co., Ltd.	director	Medzoneasia Co., Ltd. Representative: He Weiguang	612	51.00%
		Medzoneasia Co., Ltd. Representative: Liu Qingwen	612	51.00%
		Medzoneasia Co., Ltd. Representative: Yang Hongren	612	51.00%
		Medzoneasia Co., Ltd. Representative: Chen Pengxuan	612	51.00%
		Chen Liuchang	187	15.58%
		Tao Zhenrong	212	17.67%
		Yang Hongcheng	189	15.75%
	Supervisor	Chen Zhuwen	0	0.00%
Digimed Co., Ltd.	director	Yang Hongren	100,000	10.00%
		Medzoneasia Co., Ltd.	600,000	60.00%
		YES Health Co., Ltd.	200,000	20.00%
		He Weiguang	100,000	10.00%
	Supervisor	Lin Hongwen	0	0.00%
Hung-Han Medical Health Co., Ltd.	director	Pregetic Medical Health Co., Ltd. Representative: Yang Hongren	3,420,000	100.00%
	Supervisor	Pregetic Medical Health Co., Ltd. Representative: Fu Lanying	3,420,000	100.00%
Harvard Health Inc. (Original name: Fortune Healthcare Management Consultants Co., Ltd.)	director	Pregetic Medical Health Co., Ltd. Representative: Yang Hongren	12,000,000	100.00%
		Pregetic Medical Health Co., Ltd. Representative: Liu Qingwen	12,000,000	100.00%
		Pregetic Medical Health Co., Ltd. Representative: Yang Shunjun	12,000,000	100.00%
	Supervisor	Pregetic Medical Health Co., Ltd. Representative: Fu Lanying	12,000,000	100.00%
Macro Global Corporation (formerly known as Makolong Co., Ltd.)	director	Hung-Han Medical Health Co., Ltd. Representative: Yang Hongren	6,450,000	99.85%
		Hung-Han Medical Health Co., Ltd. Representative: Liu Qingwen	6,450,000	99.85%
		Honghan Health Enterprise Co., Ltd. Representative: Li Hongyi	6,450,000	99.85%
		Hung-Han Medical Health Co., Ltd. Representative: Chen Pengxuan	6,450,000	99.85%
		Hung-Han Medical Health Co., Ltd. Representative: Shen Jiaxing	6,450,000	99.85%
	Supervisor	Hung-Han Medical Health Co., Ltd. Representative: Fu Lanying	6,450,000	99.85%

Company Name	job title	Name or representative	Shareholding	
			Number of shares (shares)	Shareholding Proportion
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	none	none	N/A	N/A
Minsheng (Tianjin) Investment Management Co., Ltd	none	none	N/A	N/A

6. Overview of related business operations

(1) Financial status and operating results of each affiliated enterprise:

December 31, 2024 ; Unit: NT\$ thousand

Company Name	Capital	assets Total Value	Liabilities lump sum	net worth	Business income	Business Benefit	Profit and loss for the period (After tax)	Earnings per share (Yuan) (after tax)
Chungyuan Medical Management Co., Ltd	10,000	11,820	20	11,800	0	(67)	146	0.15
Mytrex Health Technologies, Inc.	365,356	610,787	10,613	600,174	0	(11,729)	(82,375)	(2.25)
Share Hope Medicine Co., Ltd. (Hong Kong)	44,831	20,208	0	20,208	0	(869)	(1,343)	-
Minsheng (Tianjin) Investment Management Co., Ltd	11,885	2,333	215	2,118	0	(2,839)	(556)	-
Minsheng Asia Pacific (Beijing) Enterprise Management Co., Ltd.	5,124	6,684	258	6,426	0	(709)	(590)	-
Pregetix Medical Health Co., Ltd.	329,919	437,769	211,913	225,856	52,297	(6,525)	(64,817)	(2.25)
Medzoneasia Co., Ltd.	187,543	203,120	135,279	67,841	28,771	(38,197)	(42,249)	(2.25)
Shengshi Digital Health Co., Ltd. (formerly known as Shengshi Technology Co., Ltd.)	1,000	6 92	3	689	0	(99)	(95)	(0.95)
Mytrex Industries, Inc	60,000	1 89,671	35,524	154,147	163,158	(14,727)	(56,408)	(9.40)
Mytrex USA Co.	26,456	14,645	0	14,645	0	(240)	(116)	(0.04)

Company Name	Capital	assets Total Value	Liabilities lump sum	net worth	Business income	Business Benefit	Profit and loss for the period (After tax)	Earnings per share (Yuan) (after tax)
Sheng Yo Rehabilitative Technologies, Inc.	29,000	45,641	31,309	14,332	2,947	(3,236)	(4,663)	(1.61)
TECHGROUP Integrate Design Co., Ltd.	12,000	46,682	25,357	21,325	66,959	8,359	6,825	5,688
Macro Global Corporation	64,600	147,391	79,756	67,635	177,532	6,941	2,984	0.46
YES Health Co., Ltd.	60,350	603,722	448,969	154,753	1,592,608	(21,471)	(7,671)	(1.27)
Digimed Co., Ltd.	10,000	4,382	526	3,856	5,571	(3,813)	(3,802)	(3.80)
Hung-Han Medical Health Co., Ltd.	34,200	119,944	101,308	18,636	15,527	(9,731)	(16,470)	(4.82)
Harvard Health Inc. (formerly known as: Fuyi Health Co., Ltd.)	120,000	310,239	223,135	87,104	40,869	(28,155)	(32,546)	(2.71)

Note 1 : Affiliated companies are foreign companies and the relevant figures are expressed in New Taiwan dollars as of the date of this table.

Note 2 : Fangding Information Co., Ltd. has a par value of 10,000 yuan per share and has issued 1,200 common shares .

(2) Consolidated financial statements of related companies and CPA review reports: see the Public Information Observatory website

https://mops.twse.com.tw/mops/#/web/t57sb01_q1

(3) Relationship report: None.

6.2 Status of private placement of securities in the most recent year and up to the publication date of the annual report: None.

6.3 Other necessary supplementary explanations:

(I) Continuously follow up on OTC listing commitments

The Company promises that any policy adjustments on pricing and cooperation models for drug sales and health check-up business with Minsheng Hospital System must be approved by the Company's Board of Directors, and independent directors must be present to express their opinions and report to the Over-the-Counter Securities Exchange for record and enter important information into the Public Information Observation Center.

7. In the most recent year and as of the date of publication of the annual report, whether any of the matters specified in Article 36 of the Securities and Exchange Act has occurredthreeMatters stipulated in the second paragraph of this item that have a significant impact on shareholders' equity or securities prices: None

Shenghong Pharmaceutical Co., Ltd.



Chairman: Hung-Jen Yan



2024 ANNUAL REPORT



MISSIONCARE FB

